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Chapter 1 
Introduction to Ampullary Adenocarcinoma 
 
1.1 Anatomy of biliary system 
The biliary system is consists of the organs and ducts (bile ducts, gallbladder, and 
associated structures) that are involved in the production and transportation of bile 
from the site of production in the liver through the pancreas into the duodenum. 
These organs are all connected by an intricate ductal system allowing the passage of 
bile. This begins within the liver where hepatic ducts converge to form the common 
hepatic duct that in turn combines with the cystic duct from the gallbladder to give 
rise to the common bile duct (CBD). The ampulla of Vater (or major ampulla) is the 
name given to the confluence and terminal conduit of the distal CBD and main 
pancreatic duct, first described in 1720 by the German anatomist Abraham Vater 
(1684-1751).  
It is a relatively firm and nodular structure that is conically shaped and surrounded 
by muscle fibres of the Sphincter of Oddi (SOD) that are anchored in the duodenal 
muscularis propria. The ampulla drains pancreatic juice and bile into the second part 
of the duodenum (approximately 8 cm from the gastric pylorus) via the major 
duodenal papilla.   
From the duodenal lumen the major papilla appears slightly elevated with a nipple 
like appearance, measuring approximately 1 cm in length; however, much variation 
does exist with mucosal folds often covering the papilla.  
In the majority of patients, lying 2 cm proximal to the Ampulla of Vater lies the minor 
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ampulla which connects an accessory pancreatic duct to the duodenum. This duct is 
commonly known as the Duct of Santorini.  The minor ampulla is typically very small 
in size and is often of limited functionality. 
 
 
Figure 1.1 Diagram of relationship of ampulla to other biliary structures 
Image courtesy of MediVisuals Inc 
 
The Ampulla of Vater is also a key anatomical landmark from a blood supply 
perspective as it denotes the change from coeliac trunk arterial circulation of the 
foregut to the superior mesentery artery (SMA) supply of the midgut.  The blood 
supply of the biliary system is derived from a combination of these arteries and their 
branches with significant anatomical variation seen.   
The specific arterial blood supply to the pancreatic head and ampulla comes from 
the inferior pancreaticoduodenal artery which arises from the SMA.  The venous 
drainage of this region is from a network of small veins which converge together and 
join the superior mesenteric vein. This then converges together with the splenic vein 
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to form the portal vein which enters the liver.  
 
1.2 Pathology of the Ampulla of Vater  
The ampulla can give rise to a surprising number and variety of different neoplasms 
due to the presence of several types of epithelia within.  The commonest form of 
ampullary neoplasm is adenocarcinoma and its precursor adenoma(1) although 
some neuroendocrine tumours and gangliocytic paraganglioma can also affect this 
region.  
Review of the Surveillance, Epidemiology, and End Results (SEER) Program of the 
National Cancer Institute also indicated adenocarcinoma is the most frequently 
identified histology for ampullary cancer. Adenocarcinoma (not otherwise specified 
[NOS]) was reported in 65% of cases. Carcinoma (NOS) was reported in 8.1%; 
adenocarcinoma arising from adenoma (adenocarcinoma in villous adenoma, in 
tubulovillous adenoma, in adenomatous polyp and villous adenocarcinoma) was 
third most common in 7.5%. Other pathologic diagnoses reported included papillary 
adenocarcinoma (5.6%), mucinous adenocarcinoma (4.7%), and signet ring cell 
carcinoma (2%)(2).   
 
1.2.1 Neuroendocrine Tumours 
These tumours can be grossly divided by their differentiation, namely well or poorly 
differentiated.  Poorly differentiated NET’s of the Ampulla of Vater are extremely 
rare(3, 4).  There are two distinct histological types called small cell carcinoma(5) and 
large cell neuroendocrine carcinoma(6) and both are distinguished from well 
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differentiated NET’s by marked necrosis, a high mitotic rate  and a high Ki-67 index 
(>20%, and often >50%)(1) resulting in a highly aggressive nature. With Ki-67 being a 
cellular marker strictly associated with cell proliferation it is widely used in 
pathological investigation as a proliferation marker to determine how aggressive a 
tumour is.  In this regard, most patients present with nodal metastases and recur 
early with a high mortality. 
The well differentiated NET’s have previously been known as carcinoid tumours(7, 8) 
and unlike their poorly differentiated counterparts demonstrate a low mitotic rate 
and Ki-67 index (<20%, usually <5%) with infrequent necrosis seen(1).  Most of these 
tumours are small and are usually identified within the submucosal or muscularis 
layers of the ampulla.  They are associated with several hereditary conditions such as 
multiple endocrine neoplasia 1 (MEN-1) and neurofibromatosis type 1(9) with 
tumours arising in these patients sometimes possessing specific morphological 
features such as gastrinomas or glandular duodenal NET’s. 
The immunohistochemistry analysis of these tumours demonstrates high expression 
of the neuroendocrine markers chromogranin and synaptophysin with most 
expressing keratin also(9).  A small NET found within the ampulla is unlikely to 
harbor nodal spread; however, the tumour can occasionally prove to be more 
advanced that initially thought with the likelihood of spread increasing as primary 
tumour size increases. Patients with nodal disease or liver metastases are difficult to 
cure although the natural history of the disease is protracted and survival for many 
years in this situation is common. 
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1.2.2 Gangliocytic Paraganglioma 
This tumour type is pathologically distinct from others arising at the ampulla and is 
predominantly limited to this region.  This rare tumour behaves in a benign manner 
and contains multiple different cell types that have lost cellular regulation.  Like 
glandular duodenal NET’s they are located in the submucosa and are associated with 
neurofibromatosis type 1(10).  The three cell types with different proportions 
involved in tumour evolution are epitheloid, spindle-cell and ganglion(9). The exact 
origin of the tumour remains unclear due to its possession of both NET and 
schwannian components(11)  Although regarded as a benign tumour cases of 
regional lymph node metastases have been reported. 
 
1.2.3 Adenoma and Adenocarcinoma 
1.2.3.1 Adenomas 
Ampullary adenomas can be subdivided into two overlapping categories; namely 
intestinal type adenomas that arise from the duodenal surface of the ampulla, are 
almost identical to colonic adenomas microscopically and are associated with 
familial adenomatous polyposis (FAP) syndrome(1); and intraampullary tubular 
neoplasms (IAPN) that arise from within the ampulla(12).  The progression of 
periampullary adenomas to adenocarcinoma in FAP patient is between 4% and 
12%(13). 
The intestinal type adenomas progress slowly from premalignant lesions and follow 
a carcinomatous sequence to develop invasive potential as previously described by 
Fischer et al (14). This adenoma to adenocarcinoma sequence, having been well 
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described previously in colorectal cancer,  describes the stepwise progression from a 
normal to dysplastic epithelium to carcinoma associated with the accumulation of 
multiple mutational genetic alterations resulting in oncogene activation and tumour 
suppressor gene inactivation(15, 16).  The transformation of an adenoma to in-situ 
or invasive carcinoma is in the region of 25-85%(17) and neoplastic transformation 
occurs more commonly near the ampulla than any other site in the small intestine.    
In patients diagnosed with FAP the ampulla and periampullary duodenum are the 
commonest locations for extracolonic adenomas(1) and they are usually 
accompanied by multiple other adenomas within the duodenum, sometimes 
creating a carpet like appearance. In most other settings they are usually solitary. 
The microscopic appearances of this intestinal type adenoma show 
pseudostratification of elongated nuclei with addition cytological atypia depending 
on the degree of dysplasia.  In cases of high-grade dysplasia additional nuclear 
atypia, complex cribiform glands are evident and epithelial polarity is lost(1). 
The IAPN’s are commonly intraampullary lesions that develop into exophytic masses 
within the ampulla.  They microscopically demonstrate complex papillary 
architecture lined by cuboidal cells with round, atypical nuclei that lack the 
pseudostratification seen in their intestinal-type counterparts(1, 12). The majority of 
these lesions have high-grade dysplasia present and some show a mixture of 
intestinal and pancreaticobiliary features(12).  The prognosis of these lesions is 
regarded as very good with rare episodes of recurrence recorded. 
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1.2.3.2 Adenocarcinoma 
Ampullary adenocarcinomas are regarded as those that originate distal to the CBD 
and pancreatic duct convergence within the ampullary complex and are the 
commonest malignancies of the ampulla.  Similar to the adenomas and papillary 
neoplasms from which they arise, adenocarcinomas are more common in the 
ampulla than any other site of the small bowel(1). 
There are three main macroscopic appearances of an ampullary adenocarcinoma, 
ulcerative, intramural and extramural, which are polypoidal and protrude through 
the ampullary orifice into the duodenum(18).  Malignancies can arise from either the 
ampullary epithelium or from the epithelium covering the distal biliary or pancreatic 
ducts.   
 
Figure 1.2 a) Gross appearance of ampullary adenocarcinoma; b) microscopic appearances of an 
ampullary adenocarcinoma (x64 magnification) (19) 
 
Invasive disease develops as ampullary epithelial cells incur increasing genetic 
mutations causing oncogene activation and deactivation of tumour suppressor 
genes.    A KRAS gene mutation, resulting in loss of normal cell signaling and 
continuous proliferation, is a common abnormality identified and has been seen in 
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approximately 20% of ampullary tumours(20).  However, this figure is significantly 
less than that seen in pancreatic ductal adenocarcinoma where activating mutations 
in KRAS are seen in greater than 90% of tumours(21).  Owing to the heterogeneity in 
behavior of these tumours, their histological and molecular characteristics have 
been scrutinized in an attempt to prognostically stratify them effectively(2, 22-24) 
 
1.2.3.3 Subtypes 
Adenocarcinoma of the ampulla of Vater may be classified by morphological 
appearance, with Kimura and co-workers first describing intestinal and 
pancreaticobiliary subtypes based on morphological and immunohistochemical (IHC) 
features(25).  The intestinal phenotype originates from the epithelial cell layer 
overlying the ampulla whereas the pancreaticobiliary type evolves from the 
ampullary confluence, distal pancreatic duct or distal CBD endothelium(25-29).   
 
 
Figure 1.3 a) Adenocarcinoma of the intestinal type, resembling that of a colonic tubular carcinoma; 
b) adenocarcinoma of the pancreaticobiliary type (both x 200 magnification) (27) 
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Tumours of pancreaticobiliary phenotype are typically more aggressive than those of 
intestinal origin and are often accompanied with lymph node involvement(25) and 
are associated with higher T stage, advanced UICC/AJCC stage and perineural 
invasion(30).  In this regard, patients whose tumours are of an intestinal phenotype 
have a more favourable prognosis than those of the pancreaticobiliary 
phenotype(29, 31-34). 
 
1.2.3.4 Evaluation of Protein markers in AA using immunohistochemistry (IHC) 
Multiple investigators have attempted to further enhance the histological sub-
classification described above and several immunohistochemical markers have been 
identified as being specific in adenocarcinoma of the ampulla such as mucin 
1(MUC1), mucin 2 (MUC2), cytokeratin 7 (CK7), cytokeratin 20 (CK20), and caudal 
type homeobox 2 (CDX2)(14, 20, 29, 34-36).  The intestinal phenotype tends to stain 
for MUC2, CK20 and CDX2 with the pancreaticobiliary phenotype typically positive 
for MUC1 and CK7; hence when the former markers are positive this correlates 
towards better overall survival and the opposite is true for the latter markers.  MUC1 
is a transmembrane glycoprotein that that is expressed in 66-98%(37) of PDACs and 
cholangiocarcinomas whereas early intestinal differentiation involves CDX2 and is 
commonly strongly positive in duodenal or intestinal tumours but infrequently in 
PDAC(5%)(38-41). 
A more recent study from Chang(31) in 2013 combined tumour histology, MUC1 and 
CDX2 to classify patients having undergone resection of ampullary tumours.  They 
defined their pancreaticobiliary histomolecular phenotype as a tumour displaying 
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pancreaticobiliary histology whilst staining negative for CDX2 and for MUC1. Any 
tumour not meeting the criteria was classed as an intestinal histomolecular 
phenotype.  Their findings demonstrated that pancreaticobiliary phenotype and 
lymph node positivity were independent factors of poor prognosis in three separate 
validation cohorts.   
A further study aimed at validating these results in a large patient population in the 
United States and once again demonstrated the pancreaticobiliary histomolecular 
phenotype to be an independent factor of poor prognosis with HR 2.26 (95%CI 2.40 
– 3.65; p=0.0009)(42). By routinely defining the histomolecular phenotypes that are 
associated with improved overall outcome will help to facilitate clinical decision 
making in the future. 
Furthermore, recent genomic research has identified that some ampullary tumours 
display characteristics of intestinal tumours such as microsatellite instability, 
inactivation of the tumour suppressor gene ELF3 by a high frequency of mutations 
and disruption of the WNT signaling pathway; however, not homogenous for tumour 
type or subtype.  As greater than 50% of patients demonstrated a WNT pathway 
mutation, they hypothesise that their findings may impact treatment choice and 
pave the way for genomic targeted therapies in the future with WNT pathway 
targeted therapies currently in development(43). 
Despite identification of biomarkers that help to categorize the two distinct subtypes 
of AA, there has been little progress or evolution in the discovery of other markers 
that aid in the assessment of tumour aggressiveness or spread and overall survival.  
On review of the literature there has been a few publications that have suggested 
 26 
that specific markers correlate towards a poorer survival but in the most part have 
failed to identify any trends to specific clinicopathological factors or survival 
significance whatsoever.  An overview of the current literature is displayed in Table 
1.1.  The studies evaluating IHC markers in AA are generally limited in terms of 
power and with a failure to consistently control for clinicopathological factors and 
therefore a need exists for an evaluation of these markers in a mature data set with 
compete follow and robust histopathological reporting.   
Following completion of this work, a meta-analysis of the KRAS biomarker as a 
prognostic indicator in ampullary cancer was published in 2016(44) and is the only of 
its kind within the literature.  The five included papers are detailed in Table 1.1.  
Their analysis involved 388 patients for overall survival and found that there was no 
correlation with KRAS mutation.  However, two studies were eligible for disease-free 
survival (175 patients) and they concluded that there was significant association 
between mutation and shorter disease-free survival (HR 2.74, 95%CI: 1.52-4.92 p=0. 
0008).
Table 1.1 Overview of biomarker analysis in AA from current available literature since 2001 
Biomarker Papers Year Author Findings 
MMP7 1 2015 Kumari et al(45) Correlates with reduced survival 
EGFR 1 2015 Xia et al(46) Over expression correlates with reduced survival 
IGF-1R 1 2015 Xia et al(46) IGFR correlates to PB subtype 
ERCC1 1 2015 Kawabata et al(47) No survival correlation 
hENT1 2 2015 
2008 
Kawabata et al(47) 
Santini et al(48) 
No survival correlation 
Over expression correlates with reduced survival 
DPD 1 2015 Kawabata et al(47) Expression Independent prognostic factor for survival 
Kras 5 
 
2016 
2015 
2014 
2012 
1997 
Kwon et al(49) 
Valsangkar et al(50) 
Mikhitarian et al(51) 
Schultz et al(52) 
Howe et al(53) 
No overall survival correlation, correlations to reduced disease free survival 
No overall survival correlation 
No overall survival correlation 
No overall survival correlation, correlations to reduced disease free survival 
No overall survival correlation 
 HER2 
(c-erbB-2) 
2 2015 
2001 
Ata et al(54) 
Ajiki et al(55) 
No survival correlation 
No survival correlation 
Nestin 1 2015 Shan et al(56) Over expression promotes invasiveness 
P53 3 2014 
2004 
2001 
 
Guo et al(57) 
Zhou et al(29) 
Ajiki et al(55) 
No survival correlation 
No survival correlation 
No survival correlation 
P21 1 2014 Guo et al(57) No prognostic value 
Cyclin D1 1 2014 Guo et al(57) Expression correlates with reduced survival 
Bcl2 1 2014 Guo et al(57) No survival correlation 
E-cadherin 1 2014 Sung et al(58) Expression correlates to cell grade & TNM stage 
B-catenin 1 2014 Sung et al(58) Expression correlates to cell grade, TNM stage & lymphatic/perineural invasion 
S100A4 1 2014 Sung et al(58) Expression correlates to TNM stage and lymphatic invasion 
CK7 6 2013 
2013 
2015 
2010 
2004 
2004 
Bronsert et al(59) 
Morini et al(60) 
Yun et al(61) 
Haddad et al(34) 
Le Pessot et al(62) 
Zhou et al(29) 
High CK7 and low CDX2 predicts PB subtype and poor survival 
No survival correlation 
Expression with CK20 loss independent factor of poor survival 
High expression in pancreaticobiliary subtype 
Prognostic value in terms of subtyping 
No survival correlation 
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Biomarker 
 
 
 
Papers 
 
 
 
Year 
 
 
 
Author 
 
 
 
Findings 
 
 
 CK20 7 2013 
2013 
2015 
2010 
2010 
2004 
2004 
Bronsert et al(59) 
Morini et al(60) 
Yun et al(61) 
Kawabata et al(63) 
Haddad et al(34) 
Le Pessot et al(62) 
Zhou et al(29) 
High expression in intestinal subtype 
Expression independent factor of improved prognosis 
Loss with CK7 expression independent factor of poor survival 
Subtypes based on this and Muc1 correlate with survival 
High expression in intestinal subtype 
Prognostic value in terms of subtyping 
No survival correlation 
CDX2 2 2013 
2010 
Bronsert et al(59) 
Haddad et al(34) 
High CK7 and low CDX2 predicts PB subtype and poor survival 
Muc1, Muc2, CDX2 allow most accurate subtyping 
Caspase3 1 2013 Xue et al(64) Assoc differentiation only 
Livin 1 2013 Xue et al(64) Correlates with differentiation, LN metastases and reduced survival 
Ki67 2 2013 
2004 
Xue et al(64) 
Zhou et al(29) 
Assoc differentiation only 
No survival correlation 
TERT 1 2012 Sakabe et al(65) No survival correlation 
Telomerase 1 2012 Sakabe et al(65) Expression independent prognostic factor for survival 
CD44 1 2012 Piscuoglio et al(66) No survival correlation 
CD166 1 2012 Piscuoglio et al(66) No survival correlation 
CD133 1 2012 Piscuoglio et al(66) No survival correlation 
EpCam 2 2012 
2008 
Piscuoglio et al(66) 
Feng et al(67) 
Loss in aggressive tumour, correlated with survival 
Over expression correlates with poor survival 
Muc1 4 2011 
2010 
2010 
2004 
Wang et al(68) 
Kawabata et al(63) 
Haddad et al(34) 
Zhou et al(29) 
No survival correlation 
Subtypes based on this and CK20 correlate with survival 
Muc1, Muc2, CDX2 allow most accurate subtyping 
No survival correlation 
Muc2 3 2011 
2010 
2004 
Wang et al(68) 
Haddad et al(34) 
Zhou et al(29) 
No survival correlation 
Muc1, Muc2, CDX2 allow most accurate subtyping 
No survival correlation 
Muc5AC 3 2011 
2010 
2004 
Wang et al(68) 
Haddad et al(34) 
Zhou et al(29) 
No survival correlation 
No survival correlation 
No survival correlation 
Muc6 2 2011 
2010 
Wang et al(68) 
Haddad et al(34) 
No survival correlation 
No survival correlation 
CEA 1 2012 Kim et al(30) Expression Independent prognostic factor for recurrence 
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Biomarker 
 
 
 
Papers 
 
 
 
Year 
 
 
 
Author 
 
Findings 
 
Osteopontin 2 2011 
2010 
Zhao et al(69) 
Hsu et al(70) 
No survival correlation 
Expression predicts recurrence 
Osteonectin 1 2007 Bloomston et al(71) Expression correlated with nodal disease and poor survival 
KL-6 Mucin 1 2005 Tang et al(72) Expression correlates to LN mets, local invasion and poor prognosis 
PCNA 1 2001 Ajiki et al(55) Over expression correlates with poor survival 
TS 
 
 
1 
 
 
2001 
 
 
Ajiki et al(73) 
 
 
No survival correlation 
 
 
COX2 2 2006 
2005 
Perrone et al(74) 
Santini et al(75) 
Expression associated with intestinal subtype 
Over expression correlates with improved survival 
1.3 Epidemiology of ampullary adenocarcinoma 
Ampullary adenocarcinoma is rare with an incidence of approximately four to six 
new cases per million population (76).  Between 1973 and 2005, 5,625 new cases of 
ampullary cancer were recorded in the Surveillance, Epidemiology, and End Results 
(SEER) Program of the National Cancer Institute.  Ampullary cancer now accounts for 
approximately 0.5% of all gastrointestinal tract malignancies with the incidence 
having increased since 1973 at an annual percentage rate of 0.9%.  Prior to the 
recently reported increase, the quoted incidence for ampullary carcinoma was 0.2% 
of all gastrointestinal malignancies and 6% of all periampullary tumors (77).   It has 
been suggested that men are more frequently affected than women and is also more 
commonly seen in Caucasians than Afro-americans (2). The incidence of ampullary 
malignancy increases with advancing age, particularly over 50 years with mean age 
at diagnosis 65 years(2). The occurrence of ampullary adenocarcinoma is typically 
random; however, in patients with hereditary conditions, most notably familial 
adenomatous polyposis (FAP) syndrome the risk of periampullary cancer is increased 
by 100-200% (78).  Following panproctocolectomy, the ampulla is the commonest 
site for malignant lesions in FAP patients(14). 
 
1.4 Clinical Features and Presentation 
Patient features of ampullary adenocarcinoma are generally the same as the more 
recognized pancreatic ductal adenocarcinoma (PDAC) although tends to present 
earlier in its natural history. This is due to their proximity to the CBD and means 
fewer patients are seen with disseminated disease at presentation(79) and as such 
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are associated with a more favourable prognosis following surgical resection with a 
5-year survival approaching 65% having been previously described(19, 80, 81). 
At early stages of the disease process ampullary adenocarcinomas are often 
asymptomatic and found incidentally during endoscopic or radiological 
investigations for other reasons. It has been previously reported that up to 50% are 
diagnosed in this manner(82).  Later, the most common symptom is jaundice seen in 
80% of patients(83) and is associated with itch, pale, greasy stools and dark urine 
due to intrinsic biliary obstruction causing conjugated hyperbilirubinaemia.   
Recurrent episodes of acute pancreatitis can occur if pancreatic duct obstruction is 
present. Other more general symptoms suggestive of malignancy such as weight 
loss, nausea and vomiting, abdominal or back pain; early satiety, anorexia and 
vomiting can all be present. 
Clinical examination may be unremarkable but again, in larger, more advanced 
lesions jaundice may be accompanied with a distended palpable gallbladder 
(Courvoisier sign) in keeping with CBD obstruction or hepatomegaly. Right 
hypochondrial or epigastric masses may suggest advanced local disease and palpable 
lymphadenopathy or ascites may suggest disseminated metastases.  
 
1.5 Investigative Options  
After a thorough history and examination has raised suspicion of a biliary tree 
abnormality the assessing clinician will then request routine blood tests. It is 
important to accurately stage tumours pre-operatively to avoid exploring inoperable 
tumours.  There are many investigative modalities that are utilized in the 
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confirmation of an ampullary tumour with conventional ultrasound (US), computed 
tomography (CT), magnetic resonance imaging (MRI), endoscopy, endoscopic 
ultrasound (EUS), endoscopic retrograde Cholangiopancreatography (ERCP) and 
positron emission tomography (PET) having all been utilized in diagnosis and 
subsequent tumour staging. The following is a brief overview of the frequently 
utilized investigations. 
 
1.5.1 Blood Tests 
As with many cancers, a patient with ampullary adenocarcinoma may have non-
specific laboratory blood tests which point towards potential causes but are not 
diagnostic.  Liver function tests (LFT’s) are a group of biochemical blood tests that 
provide information about the condition of a patients liver. The bilirubin, alkaline 
phosphatase (ALP) and  glutamyl transferase (GT) show preferential abnormal 
elevation in the presence of cholestasis or biliary obstruction whereas alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) are elevated in cases 
of hepatocellular damage. The prothrombin time and albumin are associated with 
liver synthetic function.  In the presence of a large ampullary tumour causing 
jaundice the patient is likely to have an obstructive picture to their LFT’s with 
disproportionately elevated ALP and GT compared to the transaminases with raised 
bilirubin.  
There are serological markers that have been as adjuncts to conventional 
investigation to aid in a diagnosis of ampullary cancer.  The most commonly used is 
carbohydrate antigen 19-9 (CA 19-9) and when elevated may help guide the 
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diagnosis towards an ampullary adenocarcinoma, although 37% of patients with an 
adenocarcinoma have been found to have a normal CA 19-9(19).   
It has been reported that pre-operative elevated CA 19-9 levels are associated with 
poor survival following AA resection(83-85).  The main issue with this marker is that 
it is extremely non-specific and is expressed in many gastrointestinal malignancies as 
well as benign conditions including liver cirrhosis and pancreatitis(86).  
Carcinoembryonic antigen (CEA) has also been measured in various centres; 
however when compared to CA 19-9 it failed to demonstrate any prognostic power 
(85).  However, more recent studies of greater power have reported that elevated 
pre-operative CEA is a significant indicator of a poor prognosis(30, 87, 88). Again, this 
marker can be elevated for other reasons, the most common being cholangitis and is 
therefore non-specific. 
There are currently no serological markers that reliably detect early stage ampullary 
adenocarcinoma or in fact any other biliary based cancer that could form the basis of 
a screening test which would potentially improve survival from earlier diagnosis and 
treatment. 
 
1.5.2 Ultrasound 
Ultrasound is often the initial investigation for patients with ampullary 
adenocarcinoma. This is because it is readily available and a radiation free test; 
however, is limited in its use for the detection of ampullary lesions due to difficulty 
in identifying small focal lesions from ultrasonic images.  This modality is highly 
operator dependant and it has been proposed from several studies within the past 
 34 
15 years that it is diagnostic in 12-27% of cases (89-91). Where ultrasound is more 
useful is in the detection of more generic findings in keeping with CBD obstruction 
such as intra and extrahepatic biliary dilitation, enlarged CBD diameter and a 
distended gallbladder indicating the need for further investigation. It can also readily 
identify gallstones as an alternative diagnosis and liver metastases or peritoneal 
ascites as an indicator of disease stage. 
 
1.5.3 Computed Tomography (CT) 
The use of CT scanning in the diagnosis and staging of ampullary adenocarcinoma is 
widespread due scanners being easily accessible, non-invasive, quick to perform and 
non operator dependant all of which makes it the first line investigation for staging 
patients with obstructive jaundice(92). It also allows for the quick detection of 
disseminated disease and its use in staging should therefore be routine(93).  A triple 
phase ‘Pancreatic Protocol’ scan should be undertaken with both oral and 
intravenous contrast during both arterial and portal-venous enhancement stages.  
Examples of key images obtained following CT are displayed below with Figure 1.4a 
demonstrating ‘double duct’ sign with both CBD and PD dilatation due to external 
compression in an axial plane and Figure 1.4b showing an ampullary mass lying 
within the second part of the duodenum, again in the axial plane. 
The last 15 years has seen an increase in detection rates due to technological 
improvements in CT imaging quality such as higher resolution and reduced slice 
thickness(89, 91).  However, accurate TNM staging remains challenging and 
generally tumours are understaged (89, 90, 93, 94) with the main pitfall being the 
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precise assessment of lymph node metastases, particularly out with the loco-
regional zone.  From recent studies, accurate primary tumour staging by CT scanning 
has demonstrated a sensitivity between 82% to 90% and specificity between 66% to 
87% whereas lymph node staging has a reported low sensitivity of 0% to 40% in the 
literature(92).  A meta-analysis from Tseng et al(95) reviewed the diagnostic accuracy 
of CT scanning in assessing extra-regional lymphadenopathy in peri-ampullary cancer 
with only 25% of histopathologically proven lymph node metastases having been 
correctly diagnosed on CT. Conversely, a further 14% of patients were incorrectly 
labeled as having metastases according to CT imaging.  
  
Figure 1.4a Non contrast axial CT demonstrating dilatation of CBD (arrows) and pancreatic duct 
(arrowheads)(96) 
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Figure 1.4b Axial CT image demonstrating a solid ampullary mass lying within the duodenum (Image 
courtesy of Dr Bruno Muzio radiopaedia.org rID:19429) 
 
1.5.4 Endoscopic Biopsy 
A tissue diagnosis is vital to enable informed treatment decisions therefore biopsy of 
all ampullary lesions is mandatory. The visual appearance at endoscopy often allows 
differentiation between a benign and malignant process where ulceration, irregular 
margins, firmness, spontaneous haemorrhage and necrosis are all suggestive of 
adenocarcinoma(97-99).   Granular or villiform exophytic lesions are most commonly 
seen and are usually benign(100); whereas smooth elevated lesions have a greater 
risk for invasive disease(101).  There is no agreed correlation between increasing 
lesion size and predicted malignancy with many papers publishing conflicting 
findings (19, 79, 102).  Forceps biopsy accuracy has also shown marked 
heterogeneity and range from 47% to 95% (97, 103). 
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1.5.5 Endoscopic Ultrasound (EUS) 
EUS has been utilised in the staging of periampullary tumours since its inception by 
DiMagno et al in 1980(104).  The use of a specialised endoscope with an ultrasonic 
transducer at the tip when positioned within the duodenum allows for detailed 
assessment of the periampullary region and biliary tree. It is highly operator 
dependent but useful in identifying intraductal extension and provides the ability to 
undertake ultrasound guided fine needle aspiration (FNA) and more recently fine 
needle biopsy (FNB) via the endoscopic lumen of suspicious lesions for histological 
diagnosis. This not only includes primary lesions around the ampulla and also loco-
regional lymph nodes to aid in disease staging.  Currently the American Society for 
Gastrointestinal Endoscopy guideline recommends using EUS on a case by case basis 
in the work-up of ampullary lesions due to a paucity of high powered evidence(105).   
A small study of 35 patients found the diagnostic accuracy of endoscopic FNA to be 
in excess of 90%(106).  The main advantages of this modality is that it negates fat 
and gas lying between a traditional US probe and the lesion allowing for better 
images although due to its invasive nature is not without complications, 
predominantly haemorrhage(1.3-4%)(107, 108) and pancreatitis(0-2%)(109-111) . 
EUS has an excellent tumour detection rate with sensitivity above 90%(92) whilst 
also providing precise assessment of local and distant invasion with T and N staging 
accuracy having been documented between 63-82% and 60-81% respectively(112).  
The accuracy of identifying loco-regional lymph node metastases is comparable to 
that of CT(113). The overall positive predictive value for detecting primary tumour 
has been reported as 93%(92). 
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This modality is currently evolving further with the introduction of intraductal 
ultrasound (IDUS) where the ultrasound transducer is placed within the bile ducts for 
assessment. With this technique being in its infancy there is a paucity of information 
regarding its use at present; however, there are encouraging results with its use in 
accurately determining duodenal submucosal invasion(114, 115) and hence 
identifying advanced tumours that would benefit from surgical excision. 
1.5.6 Endoscopic Retrograde Cholangiopancreatography (ERCP) 
ERCP is an endoscopic technique that allows for direct visualization of the ampulla, 
CBD and pancreatic duct using a side viewing endoscope. It also has the ability to 
obtain cytological and histological specimens with brushings and allows for the 
deployment of biliary stents when clinically appropriate.  The classical appearance 
suggestive of an ampullary or pancreatic head tumour at ERCP (‘double duct’ sign) is 
evident when both CBD and pancreatic ducts are dilated (Figure 1.5) 
 
Figure 1.5 ERCP film demonstrating double duct sign(116)  
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Pre-operative biliary stenting for jaundice patients with resectable peri-ampullary 
disease is controversial with a recent systematic review from 2014 by Lai et al(117) 
showing no benefit of pre-operative drainage in surgical outcome(118).  Instead 
there were concerns regarding post drainage complications and an increase in 
positive intra-operative bile cultures and subsequent infective complication rate post 
resection(117).   This is reinforced in the GUT guidelines on pancreatic and ampullary 
cancer management from 2005 that state it is reasonable to obtain internal biliary 
drainage only if definitive surgery has to be delayed by more than 10 days.  The 
guideline also state that self-expanding metal stents should not be placed in this 
situation as surgical resection is made more challenging due to the tissue reaction 
provoked by these stents(119).  
However, this statement is now regarded as incorrect with plastic stents no longer 
being recommended for use.  The evidence base for this stems from the multicentre, 
randomised trial by van der Gaag et al who assigned 202 patients with cancer of the 
pancreatic head and obstructive jaundice with a bilirubin level of 40 to 250mol/l to 
either early surgery or preoperative biliary drainage. They found the rate of serious 
complications was higher (74% versus 39%; p<0.001) in patients undergoing routine 
pre-operative plastic biliary stenting compared to those proceeding straight to 
resection(120).  Furthermore, 46% of patients having preoperative biliary drainage 
experienced a complication and patients who had undergone pre-op drainage had 
more surgery related complications than those having not (47% versus 37%; p=0.14) 
resulting in a longer hospital stay and more readmissions(120). 
Further work by this group compared pre-operative biliary stenting with metal stents 
in patients with a resectable tumour who could not undergo early surgery for 
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logistical reasons against the previous cohort stented with plastic stents.  They found 
that biliary drainage related complications (24% versus 46%) and stent related 
complications (6% versus 31%) were both less in the metal stent group whilst there 
was no difference in complication rate following their definitive surgical 
procedure(121). 
They concluded that early PD without pre-operative biliary drainage remains the 
treatment of choice but metal stents should be preferred over plastic stents in the 
occasion pre-operative stenting is indicated(121). 
 
1.5.7 Positron Emission Tomography (PET) & Magnetic Resonance Imaging (MRI) 
MRI has the benefit over CT in that it does not expose the patient to ionising 
radiation whilst PET scanning is a newer imaging technique that works on the basis 
that malignant cells absorb and metabolise a radio-labeled glucose analogue 
administered intravenously quicker than normal tissue allowing for 
identification(122).   
Currently both modalities have a limited role in the diagnosis of ampullary tumours 
and are predominantly used as adjuncts to the previously described investigations in 
select cases, often to clarify the presence of disseminated disease. A small study by 
Sugita et al demonstrated an accuracy of 96% for MRI in detecting tumour invasion 
from autopsy specimens(123).  A further study by Kim et al evaluated MR imaging of 
29 patients with pathologically proven ampullary carcinomas and found that 62% 
had a discrete nodular mass, a positive double duct sign in 52% and only bile duct 
dilatation seen in the remaining 48% of patients(124). 
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A study on the staging of biliary cancer that compared PET and CT accuracy found no 
significant difference in the detection of loco-regional lymph node metastases with 
overall accuracy of 69%.  PET did however detect 100% (4/4 patients) of distant 
lymph node metastases(125). 
 
1.6 Treatment Options 
1.6.1 Pancreaticoduodenectomy 
Having been first described by the Italian surgeon Alessandro Codivilla in 1898(126), 
the first periampullary cancer resection was performed in 1909 by Walther 
Kausch(127) and subsequently improved on by Allen Whipple in 1935(128) from 
whom the procedure often takes its name. 
Currently, following a diagnosis of ampullary adenocarcinoma the gold standard and 
mainstay of treatment remains radical surgical resection by either conventional 
pancreaticoduodenectomy (PD) or by the pylorus-preserving (PPPD) method with 
the latter becomingly increasingly utilized in Europe. The perceived benefits of PPPD 
over PD as concluded in several reviews and meta-analyses are reduced operative 
time and blood loss although there was no significant difference in gastric emptying 
seen(129-131).  However, this did not translate into reduced morbidity or mortality, 
reduced complication rates or long-term survival.  There also remains debate that 
the relative reduced dissection in PPPD is adequate from an oncological 
perspective(129).  There has also been discussion over the years with regards to 
whether standard or extended lymphadenectomy should be performed at the time 
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of resection although a randomized trial has demonstrated no significant difference 
in long-term survival (56% versus 60%)(132).  
Both methods are major surgical procedures and involve the en-bloc removal of the 
pancreatic head, duodenum, proximal jejunum, CBD, gallbladder, local lymph nodes 
and the gastric antrum depending on method. As the gastroduodenal artery (GDA) 
supplies the duodenum and the pancreas as it runs through its head both organs 
require to be resected should the GDA be ligated.  A full description of the surgical 
technique used at the West of Scotland Pancreatic Unit at Glasgow Royal Infirmary is 
described later in Chapter 3. 
The decision to proceed to surgery should be evaluated thoroughly as the procedure 
possesses a highly significant risk profile.  Despite the improvements in surgical 
instruments, technique and post-operative care reducing the 30 day mortality to 2-
5% the procedure remains high risk with significant complications and morbidity 
seen in approximately 20-50% of patients(112).  Complications and subsequent 
morbidity are particularly common in patients with AA, due to adverse surgical 
conditions intraoperatively, namely a ‘soft’ pancreas with normal parenchyma and a 
bile duct of small caliber, increasing the anastomosis difficulty.  The commonest 
complications include post-operative pancreatic fistula (POPF), bleeding, 
anastomotic leak, intra-abdominal collection and delayed gastric emptying. Notably 
a significant reduction in morbidity and mortality has occurred with the 
centralization of PD to high volume tertiary referral hospitals(133, 134). 
The International Study Group on Pancreatic Fistula (ISGPF) classification defined a 
POPF as a failure of healing of a pancreaticoenteric anastomosis or a parenchymal 
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leak not directly related to an anastomosis with three different grades of POPF 
defined according to the clinical impact on the patient's hospital course(135). The 
classification is seen in Table 1.2 below. 
   
Pancreatic Fistula GRADE A GRADE B GRADE C 
Clinical conditions Well Often well Ill appearing/bad 
Specific treatment 
(antibiotics,TPN,somatostatin) 
No No/yes Yes 
US/CT (if obtained) Neg Neg/Pos Pos 
Pesistent drainage at 3 wksa No Usually yes Yes 
Reoperation No No Yes 
Death related to POPF No No Possibly yes 
Signs of infection No Yes Yes 
Sepsis No No Yes 
Readmission No Yes/no Yes/no 
aWith or without a drain in situ 
Table 1.2 ISGPF classification and grading of POPF 
 
PD resection for AA is of much higher risk for the development of POPF than that 
encountered during resection of a PDAC and is attributable to the intra-operative 
conditions encountered in the presence of an AA.  The presence of a pancreatic duct 
under 3mm; soft pancreatic parenchyma; ampullary, duodenal or cystic pathology 
and intra-operative blood loss of more than 1000ml have been described as 
predictive factors for POPF following PD(136).  At multivariate analysis, a PD for AA 
pathology possessed an HR of 2.98 (95%CI 1.36 – 6.54 p<0.001) against PDAC or 
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pancreatitis for POPF.  Similarly, a soft pancreas gland, regularly seen in AA surgery, 
demonstrated a HR of 5.02 (95%CI 1.97 – 12.81 p=0.007) for POPF compared to firm 
gland texture at time of PD(137). 
 
1.6.2 Surgical Ampullectomy (SA) 
Halsted performed the first transduodenal resection of the ampulla in 1899(138) and 
currently there are two recognised approaches in this regard by either laparoscopy 
or open surgery.  The procedure itself requires a duodenotomy and then full 
thickness excision of the ampulla with subsequent local lymph node dissection. 
Initial results regarding this procedure were promising, with 30 day mortality of 
<1%(139) and morbidity much lower than PD(79); however, high positive resection 
margin (R1) rates of 60%(140) and disease recurrence approaching 80-100% has 
been reported following excision of malignant lesions (140-144).  
These issues have restricted SA to benign lesions and with the diagnostic uncertainty 
of forceps biopsy in determining invasive disease alongside the improvements in EA, 
both in refining diagnosis and management, its role has become limited with few 
indications.  When comparing local surgical and endoscopic options, morbidity was 
significantly higher in the surgical arm at 42% versus 18%.  There was also a longer 
hospital stay associated with local surgical excision although no significant difference 
in recurrence was seen suggesting that EA should be the primary method of local 
excision(145) in the correct clinical setting. 
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1.6.3 Endoscopic Management 
1.6.3.1 Endoscopic Ampullectomy (EA) 
Endoscopic ampullectomy with curative intent was first described in 1993 (146).  In 
the recent past there has been an increasing role for this technique as an effective 
alternative to surgical resection for certain ampullary lesions and is associated with 
good outcomes(147, 148).  The procedure is undertaken using a side-viewing 
endoscope to visual the ampulla within the duodenum. The tumour mass is then 
regularly raised from the deep tissues using saline injections with or without 
adrenaline to create a plane for resection similar to the technique used in 
endoscopic mucosal resection for colonic polyps.  The lesion is then snared and 
excised with diathermy assistance.  The failure of a lesion to rise from the 
surrounding mucosa is associated with malignancy(149, 150).   A detailed description 
of our EA technique is described in chapter 4.   
It is a less invasive procedure with minimal trauma that reduces overall morbidity 
and mortality compared to PD although it remains controversial as to whether 
ampullary adenocarcinoma can be optimally managed in this manner.  A 
lymphadenectomy is not performed using this technique and therefore accurate pre-
procedural staging is essential(151) although the performance of CT in this area 
remains poor as described earlier.  EA is not without risk and the commonest 
complications associated are pancreatitis, bleeding, cholangitis and perforation at a 
frequency of 27.9%(152).  It is however, an attractive option for patients unfit for 
radical resection or those with low-grade disease, as it does not expose them to the 
risk of major abdominal surgery.  
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Not only be EA be used as an effective definitive treatment option but also it serves  
as a vital component in the diagnostic work-up of patients with ampullary lesions 
whereby large specimens, following snare excision, can provide refined diagnostic 
pathological grading of each lesion in addition of biopsy specimens.  
The accuracy of traditional forceps biopsy has been questioned due to several 
factors. Firstly, variability in interpreting histological specimens by pathologists and 
secondly, small forceps biopsies may not evaluate the degree of dysplastic change 
within an ampullary lesion correctly and thirdly the presence of a potentially missed 
foci of invasive adenocarcinoma within global dysplastic change must be considered. 
Previous studies have shown a false-negative rate of 17%-40% for forceps biopsy in 
the detection of infiltrating carcinomas(153-155) and Bellizzi et al(156) recently 
reported a diagnostic agreement of only 64% when comparing biopsy samples to the 
eventual resected specimen.  
 
1.6.3.2 Ablative Therapy 
Endoscopic management options are not limited to ampullectomy with ablative 
therapies such as argon plasma coagulation (APC), laser and bipolar cautery 
commonly used in patients whose ampullary lesion is not safely resectable by snare 
excision or in surveillance procedures following excision to destroy any residual 
tissue that may be left.  APC is the most frequently utilised technique for this 
purpose(97).  Recently radiofrequncy ablation (RFA) has began to play a role as an 
ablative therapy in this area; particularly in cases with the presence of intraductal 
extension.  A recent retrospective multicentre study evaluated the use of RFA in 
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ampullary neoplasms with intraductal extension with a total of 14 patients being 
evaluated.  With a median of one RFA catheter session complete intraductal ablation 
was achieved in 91.6% of patients at a median follow-up period of 16 months(157).  
Another small case series of four patients from Suarez et al(158) found similar 
results with three patients(75%) achieving complete eradication of the intraductal 
adenoma extension.  The main adverse risk of this procedure is stricture formation 
that may require subsequent stenting(157-159). 
The increased use of these techniques has been demonstrated to provide both 
significantly lower morbidity and mortality in selected patients with Ceppa et al(145) 
reporting 0% and 18% associated mortality and morbidity. 
 
Figure 1.6 a-c) Endoscopic appearances at time of ampullectomy; d) follow-up surveillance 
 
1.6.4 Adjuvant Therapy  
1.6.4.1 Chemoradiotherapy 
There is currently no standardised guideline for the use of adjuvant chemotherapy in 
the treatment of ampullary adenocarcinoma(25, 160-163).  Previous randomized 
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controlled trials (RCTs)(164-166) and institutional cohort studies(167, 168) have 
failed to demonstrate a survival benefit for chemotherapy.   
The ESPAC-3 trial(169) is the only prospective RCT evaluating the effects of adjuvant 
chemotherapy on survival in resected peri-ampullary cancer. The trial was a three 
group, randomised, open-label phase 3 study with 434 patients included with 
patients receiving either 5-fluorouracil or gemcitabine in the two adjuvant 
chemotherapy arms or observation only in the third arm.  In the primary analysis, 
there was no survival benefit seen for 5-fluorouracil or gemcitabine compared to the 
observation group (45.7 months vs. 38.9 months vs. 35.2 months P=0.23)(169).  On 
secondary analysis, when adjusting for prognostic variables the HR for 
chemotherapy compared with observation was 0.75 (95% CI: 0.57-0.98; P=0. 03).  On 
subgroup analysis, there was no significant benefit for intestinal or pancreaticobiliary 
phenotypes although the subgroup of patients undergoing R0 resection 
demonstrated improved overall survival with adjuvant chemotherapy(169).   
When considering adjuvant chemoradiotherapy in resectable ampullary cancer two 
large series from the Mayo clinic reported that there may be a survival benefit seen 
in node positive patients following surgery(168, 170). The latter study from 2011 by 
Narang et al, consisting of 186 included patients undergoing 5-fluorouracil based 
chemoradiation, demonstrated a mean overall survival of 32.1 months versus 15.7 
months (5 yr OS: 27.5% vs. 5.9%; RR=C.47, P=0.004)(168).  
Kim et al reported their series of 118 patients, 41 of whom received adjuvant 
chemoradiation therapy with 5-fluorouracil and total radiation dose up to 40 Gy. 
Their results revealed improved locoregional relapse-free survival, and possibly also 
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an overall survival advantage, although statistical significance was not 
achieved(167). Similarly, Willett and colleagues reported their experience with 
adjuvant radiotherapy, with or without concurrent 5-fluorouracil for high-risk 
tumours.  Compared to surgery alone, the radiotherapy group demonstrated a trend 
toward better locoregional control; however, no advantage in survival was 
seen(171).  However, the only prospective, randomized study into the benefits of 
chemoradiation in ampullary adenocarcinoma by Klinkenbijl et al failed to 
demonstrate any survival benefit(164).  
Despite the lack of evidence, theoretically those patients with an intestinal subtype 
tumour may benefit from fluorourocil based chemotherapy regimes whereas 
pancreaticobiliary subtypes may derive improved survival from treatment with 
gemcitabine based regimes(172). Further research is required in this area before any 
definite conclusions can be made. 
 
1.6.4.2 Pathological staging of AA 
The majority of patients are staged pathologically after examination of the resected 
specimen and associated lymph nodes following surgery.  The classification is 
predominantly based upon the extent of local disease with T and N stage indicative 
of this.   The status of resection margins is not included in the conventional staging 
system applied today.  An R0 resection is defined as one with grossly and 
microscopically negative margins, R1 possess grossly negative but microscopically 
positive margins and R2 margins have gross tumour evident.  Although not included 
in conventional staging, the extent of resection is of great significance prognostically. 
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1.6.4.3 Guidelines AJCC 7th Edition  
The most recent staging guidelines were published in the American Joint Committee 
on Cancer staging manual 7th edition and are unchanged from the previous edition.  
They are similar to those implemented in PDAC with T1 disease being confined to 
the ampulla or sphincter of Oddi and T4 disease involving structures out with the 
pancreas.  The nodal and metastasis classification is generic to all other 
gastrointestinal malignancies.  The classification is shown in Table 1.3.     
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AJCC 7th Edition Guidelines on Ampullary Cancer Staging 
  
Tx 
Primary tumour cannot be assessed 
T0 
No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour limited to ampulla of Vater or sphincter of Oddi 
T2 Tumour invades duodenal wall 
T3 Tumour invades pancreas 
T4 
Tumour invades peripancreatic soft tissues or adjacent organs/ structures 
  
Nx 
Regional lymph nodes cannot be assessed 
N0 
No regional lymph nodes involved 
N1 Regional lymph node metastases 
  
M0 
No distant metastases 
M1 
Distant metastases 
 Approximate  
5 year survival 
 
Stage 0 Tis N0 M0 >90% 
Stage 1A T1 N0 M0 >75% 
Stage 1B T2 N0 M0 ~60% 
Stage 2A T3 N0 M0 ~50% 
Stage 2B T1-3 N1 M0 ~35% 
Stage 3 T4 Any N M0 25% 
Stage 4 Any T Any N M1 <10% 
Table 1.3 AJCC 7th Edition Guidelines for Ampullary Adenocarcinoma staging(173) 
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1.7 Overall Survival of Periampullary tumours 
Despite a partially shared embryological origin tumours of the biliary tree possess 
marked variation in overall survival(174).  Overall, ampullary adenocarcinoma is 
regarded to have a poorer prognosis than duodenal tumours but better than both 
cholangiocarcinoma and PDACs with 5-year survival rates of 37-68% having been 
reported(19, 140, 151).  A large study from Tol et al reaffirmed this with survival 
rates of 13.9% for PDAC, 27.3% for cholangiocarcinoma, 44.4% for AA and 73.0% for 
duodenal adenocarcinoma (DA) by tumour location documented at 5 years following 
PD respectively(175).  Approximately 76.5% to 89.4% of ampullary adenocarcinomas 
are suitable for resection with curative intent(88, 176) which is significantly higher 
than PDAC and due to their relatively early presentation.   
 
1.7.1 Prognostic factors for Ampullary adenocarcinoma 
1.7.1.1 Pathological factors 
When considering the TNM staging classification, advancing tumour stage, positive 
resection margins and most strongly lymph node involvement have all been shown 
to worsen prognosis and survival.  Some other pathological factors such as the 
presence of lymphovascular and perineural invasion, despite not being a part of 
routine staging, are associated with poorer overall outcome(33, 83, 177) and all will 
be further evaluated in the next chapter. 
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1.7.1.2 Serum Markers 
An elevation in pre-operative CA 19-9 levels and associated with poorer survival 
following surgical resection (83-85, 178).  High serum levels of CEA pre-surgery have 
also been implemented as a factor of poor prognosis in several studies(30, 87, 88) 
and identified as an independent factor after multivariate analysis in one study(87).  
In terms of subtype, it has been suggested that CEA levels predict recurrence in the 
intestinal based tumours(30).  The study by Todoroki found that both CEA and CA 
19-9 correlated with distant recurrence following an R0 resection with CEA being 
associated with liver and distant nodal disease and CA 19-9 with lung 
metastases(88).  
A poor prognosis following surgical resection is also true of elevated total bilirubin 
and patients undergoing pre-operative biliary drainage(83) with the latter likely due 
to be related to the physiological effects of high serum bilirubin and more advanced 
disease rather than the drainage procedure itself. 
 
1.7.1.3 Molecular factors 
As mentioned previously, Kimura et al first described further subdivision of biliary 
based adenocarcinomas into two distinct phenotypes, pancreaticobiliary and 
intestinal, with the latter having demonstrated a significant survival benefit in the 
majority of studies(30, 31, 83, 179).  The two IHC markers MUC1 and CDX2 are 
closely related to and involved in subtype differentiation with high levels of MUC1 
seen regularly in pancreaticobiliary phenotypes and expression of CDX2 almost 
exclusively expressed in intestinal epithelium.  
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1.8 Pattern of Recurrence 
Despite earlier diagnosis and improved surgical technique, tumour recurrence 
following radical resection with curative intent remains problematic with rates of 
28% to 44% reported within the literature(30, 88, 180).  Following radical resection 
by PD the time to recurrence from index surgery ranged from 13 months to 21 
months in studies(30, 88).  The common sites of recurrence are regarded as being 
the liver, aortocaval lymph nodes and lung alongside loco-regional recurrence(88, 
180-182).  In patients with recurrent disease following PD liver metastases were 
reported in 55%, 59% and 67% of cases and distant lymph node disease in 43% and 
54% respectively(30, 88, 182).  There has also been documented recurrent disease 
found within the peritoneum, bones, brain and mesocolon although in small 
numbers. 
 It is uncommon for patients to represent with locoregional failure alone following 
PD with one study reporting no cases of this in all 54 recurred patients(88) and a 
further study finding that 49.3% of patients with recurrent disease had more than 
one site involved(182).  Recurrence is more frequently seen in the patients with 
pancreaticobiliary subtype but no significant difference has been observed between 
histological subtype and the site of recurrence(30).  
The overall pattern of recurrence is different following definitive endoscopic 
ampullectomy compared with PD described above.  When undertaken for LGD or 
HGD adenomata there has been a reported local recurrence of 6% to 33% with no 
evidence of distant disease(97, 146, 152, 183-186).  These lesions in the most part 
are usually benign and amenable to repeat endoscopic treatment.  Those lesions 
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recurring due to intraductal extension were most likely to require surgical 
intervention(186-188). 
There is limited data on recurrence patterns in patients who have been treated by 
EA for an invasive adenocarcinoma as until recently this has been seen as a palliative 
management strategy. A single paper found reported no recurrence in patients with 
Cis or T1 disease who were unfit for definitive surgery at 27 months and 32 months 
respectively(151). 
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 2.0 AIMS AND HYPOTHESIS 
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Chapter 2 
Aims and Hypothesis 
 
2.1 Introduction 
Much is known regarding the molecular pathology and clinicopathological factors 
influencing survival in pancreatic cancer with work previously undertaken in Glasgow 
to understand the molecular pathology pathways of LKB1, p21, p53 and WNT 
signaling in PDAC(43, 189, 190). Focus has now turned to extensive pancreatic 
genomic analysis to provide clarity in the understanding of molecular pathways in 
tumorigenesis(191).  However, in ampullary adenocarcinoma these factors and 
pathways are less well established partly due to a paucity of research on the topic.  
At the inception of this project only limited work with isolated tumour markers has 
been undertaken.   
There have been several studies that have looked at outcome following radical 
surgical resection of AA with no real overall consensus with regards to what are poor 
prognostic indicators and their weighting.  Certainly, like all other gastrointestinal 
malignancies, lymph node involvement and positive resection margins have been 
implicated but how detrimental are their presence to outcome and in relation to 
other routinely evaluated factors?  There has yet to be any systematic reviews or 
meta-analyses undertaken on this subject to the best of knowledge at this time. 
Endoscopic ampullectomy has developed in recent years and has gained an 
increasing role in the diagnosis and management of ampullary adenoma and 
adenocarcinoma.  It has been suggested that EA should be used exclusively in benign 
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disease except in exceptional circumstances due to the in ability to perform 
lymphadenectomy amongst other reasons but how does survival compare between 
definitive EA and PD and is there patient groups who can be adequately treated with 
only EA? 
There has been limited progress in the development and identification of useful 
tissue markers in AA.  Tumour markers such as CA 19-9 and CEA, when elevated pre-
op are thought to be suggestive or a poorer prognosis although have no significant 
value following resection.  The identification of MUC1 and CDX2 and their role in 
subtype differentiation in resected specimens has further allowed for improved 
prediction of survival in an extremely heterogeneous group of patients. However, to 
date, no markers have been identified that show strong correlation towards disease 
progression or invasion which can be applied in the clinical setting.  
 
 
2.2 Hypothesis 
Ampullary adenocarcinoma has a better prognosis than its PDAC counterpart.  
Lymph node involvement, resection margin status and histological subtype are likely 
to be the strongest factors determinant of survival following surgical resection.  
There will be protein markers that, when up regulated are indicative of an 
aggressive, metastatic phenotype that warrants more aggressive treatment. 
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2.3 Aims 
We will test the hypothesis by the following strategies:  
 
1/. Establish an ampullary cancer patient database with basic demographics, 
pathological and survival data and maintain prospectively.  
 
2/. Undertake a systematic review and meta-analysis of the literature to establish 
true clinicopathological predictors of poor prognosis in AA following radical surgical 
resection.  
 
3/. Simultaneously evaluate the created West of Scotland Pancreatic Units database 
of resected AA and compare results to meta-analysis. 
 
4/. Interrogate patients pathway who underwent EA from database and assess its 
role in the diagnosis and management of AA with consideration of survival, 
complications and outcome. 
 
5/ Create tissue micro-arrays using tissue from the ampullary cancer database to 
enable the efficient examination of relevant protein markers using standard 
immunohistochemical techniques.  
 
6/. Using immunohistochemistry, stain with multiple protein markers to establish 
whether a metastatic phenotype or poor survival in these patients with ampullary 
cancer is associated with up regulation of these pathways.  
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3.0 REVIEW AND META-
ANALYSIS OF FACTORS 
INFLUENCING SURVIVAL 
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Chapter 3 
Systematic Review and meta-analysis of clinicopathological 
factors influencing survival in ampullary adenocarcinoma 
 
3.1 Introduction 
Ampullary adenocarcinoma is a rare condition that accounts for 0.2% of all 
gastrointestinal malignancies(77).  It is generally regarded that they have a better 
overall prognosis than some of their biliary counterparts, namely PDAC and 
cholangiocarcinoma, whilst possess a poorer prognosis than DA(19, 175). Part of the 
reason for this may be due to a typically earlier diagnosis than other peri-ampullary 
tumours resulting in an increased frequency of resectable lesions(192).  Having said 
this, up to 50% of AAs recur following surgical resection(193) and it is therefore 
important to identify factors implicated in overall survival so that high-risk patients 
can be identified and treatment strategies tailored accordingly.   
In direct contrast to PDAC, which continues to be widely and extensively researched, 
there is a paucity of published data regarding AA that is further limited by small 
patient cohorts(32, 80, 88, 194-197).  From the current literature there is no 
consensus regarding the most important clinicopathological features determining 
outcome with marked heterogeneity in the significance of routinely reported 
histological features.  A landmark paper published in 2004 by Kimura and co-workers 
first described the two distinct histological subtypes of AA, pancreaticobiliary type 
and intestinal type whilst demonstrating in their cohort that patients with the latter 
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had a much better overall prognosis(27).  These differences suggested two diverse 
underlying disease processes which are now routinely recognised today.   
There have been multiple, mostly small cohort studies published within the 
literature in recent years that document both clinical and pathological factors that 
influence survival in patients with resected AA; however, no systematic reviews or 
meta-analyses exist on this subject.  This chapter aims to combine and appraise the 
relevant literature and clarify the key clinical and histopathological factors 
influencing survival in AA following resection with curative intent. 
 
3.2 Materials and Methods 
3.2.1 Systematic Search Strategy 
The literature search aimed to identify all research manuscripts that assessed the 
clinicopathological factors influencing survival or outcome in ampullary 
adenocarcinoma following formal surgical resection.  A search of the PubMed 
database on the 21st February 2016 used the following search criteria: 
• [ampulla*] AND [survival] OR [ampulla*] AND [outcome] OR [ampulla*] AND 
[prognosis] 
The title and abstract of each citation was then reviewed to identify studies 
reporting on survival in ampullary cancer and the full text of each was obtained.  A 
further search through the identified manuscripts bibliographies was conducted to 
ensure identification of any papers that may have been missed in the primary 
PubMed search.  The search was limited to English language publications and those 
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reporting on human subjects.  The study was performed in accordance with the 
guidelines of preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) 2009(198). 
 
3.2.2 Inclusion and Exclusion Methodological Assessment 
Studies were deemed eligible for inclusion according to the criteria listed below 
(Table 3.1).  As ampullary tumours have been shown to have a different natural 
history to other biliary tract malignancies any studies reporting combined results 
(including PDAC, DA or cholangiocarcinomas) as ‘periampullary tumours ‘ were 
excluded from further review. Conference abstracts, review articles and case series 
of less than 35 patients were also excluded. A study was also removed if it did not 
allow for the extraction or calculation of survival data from its published results. 
Table 3.1 Criteria for inclusion of ampullary adenocarcinoma outcome studies 
1. Prospective or retrospective cohort design with justification for excluded 
cases from 2000 onwards 
2. Patients with AA undergoing surgical resection with curative intent 
3. Statistical analysis using multivariate proportional hazards modeling 
4. Documentation of HRs, 95% CIs and P values 
 
3.2.3 Data Extraction 
The author (C.R.F) reviewed and appraised all manuscripts obtained from the 
PubMed search and extracted the number of ampullary adenocarcinomas studied, 
the methodology and all results documented in each manuscript.  The surgical 
procedure was either PD or PDDD and the data collected included authors’ names, 
 64 
institution, year of publication, number of cases and the clinicopathological factors 
evaluated using univariate and multivariate analysis with overall outcome. The 
multivariate Hazard Ratio (HR) with 95% Confidence Interval (CI) including P value 
was obtained and in manuscripts reporting results without CIs the P value was used 
to estimate the standard error using the Z statistic. 
 
3.2.4 Statistical Analysis 
The clinicopathological factors selected were those routinely reported upon in 
histopathology reviews based upon standardised TNM staging and those evaluated 
in the current scientific literature.  The overall outcome data was presented as a HR 
with a 95% CI.  For factors assessed appropriately in a single study, the HR (including 
95% CI) represents the value reported from that study; whereas when reported in 
multiple studies, a fixed effects summary HR and 95% CI were calculated using the 
generic inverse variance method and the random effects model as per the 
DerSimonian-Laird method.  An observed HR greater than 1 indicated a worse 
outcome for the study group compared to the reference group and would be 
considered as statistically significant when P <0.05 and the 95% CI did not overlap 1.  
All meta-analyses were performed using the REVMAN systematic review and meta-
analysis software package version 5.1 (The Cochrane Collaboration Software Update, 
Oxford, UK). 
 
 
 65 
3.3 Results 
3.3.1 Excluded Studies 
The search of AA outcome literature initially identified 717 articles for consideration 
and the PRISMA diagram (Fig 3.1) summarises the systematic literature search 
undertaken.  An initial 31 manuscripts were immediately excluded as they were not 
related to human subjects and a further 61 were not published in English language. 
There were 65 full text articles deemed appropriate for eligibility following initial 
title and abstract evaluation alongside additional bibliography reviews.  Each full text 
was obtained and the criteria for inclusion were applied to each with 12 studies not 
exclusively reporting on AA; instead the study design allowed for inclusion of other 
periampullary tumours including PDAC, cholangiocarcinoma or DA so were excluded.  
A further six studies did not report on overall survival or outcome.   Of the remaining 
47 cohort studies, all reporting on AA survival post surgical resection, 11 did not 
report HRs or 95% CIs in their results with a further four limiting their analysis to 
univariate log-rank analysis only. Three studies were excluded as they did not meet 
the minimum cohort size leaving 30 high-quality eligible studies. 
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Figure 3.1 PRISMA (preferred reporting items for systematic reviews and meta-analyses) flow chart 
showing methodology for ampullary adenocarcinoma studies 
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3.3.2 Included Studies 
A total of 30 high-quality cohort studies met the eligibility criteria for this systematic 
review by presenting multivariate survival estimates of independent prognostic 
variables affecting survival in ampullary adenocarcinoma.  A list of all the included 
retrospective studies is detailed in Table 3.2.  Overall there were 3290 patients 
included with a mean age of 64 years.  The frequency of positive lymph nodes 
ranged from 15% to 67% (median 43.6%) and negative resection margins from 75% 
to 100% (median 96.8%). Seven studies included only R0 resections. 
The 5-year overall survival following resection ranged from 33% to 68% (median 
52.6%) and the median survival from 31 to 87 months (median 54 months).  Subtype 
classification was undertaken in seven studies only.  17 of the 30 studies reported on 
microscopic invasion with perineural involvement present in 10% to 74.6% (median 
25%) resection specimens. Lymphatic and venous invasion was seen in 14% to 72.1% 
(median 47.7%) and 3% to 47.8% (median 36%) respectively. 
Of the 30 included studies, only 15 provided any data regarding the use of adjuvant 
treatment following surgical resection.  The percentage of patients who undertook 
any form of adjuvant treatment ranged from 6.3% to 67% with an overall median of 
37.9%.  There were 5 studies that specified between the use of chemotherapy and 
radiotherapy or a combination of both with the remainder referring to adjuvant 
treatment only.  There were no P values that showed statistical significance within 
any of the manuscripts when presented in univariate analysis or median overall 
survival.
Table 3.2 Baseline characteristics and clinicopathological features of the 30 included studies 
 
Study 
Year n 
(m/f) 
Age 
(y) 
 
PD 
(n) 
LN +ve (%) R0 
(%) 
 
Subtype 
(Int/Pb) 
 
5yr surv. (%) Median  
surv.  
(months) 
 
PI 
(%) 
LI 
(%) 
 
VI 
(%) 
 Allema et al (194) 1995 67(42/25) 61 67 52 75 50  
Beghelli et al (195) 2002 89(55/34) 59 89 41  56/28  46    
Bettschart et al (180) 2004 88(49/39) 63 70 40 97.2  37.9§ 45.8 12.9   
Bourgoin et al (199) 2015 55(20/35) 66 55 36 98  51 66 27  36 
Brown et al (80) 2005 51(25/26) 69 51 47 100  58     
Carter et al (200) 2008 157(90/67) 64 115 33 86 54/53/11   74.6 72.2*  
Choi et al (201) 2011 78(43/35) 61 70 31.4 95.7  59.9 70 10   
DiGiorgio et al (202) 2005 94(53/41) 65 63 28 100  64.4 54    
Duffy et al (196) 2003 55(34/21) 67 55 41.8 98.2  67.7  21.8 16.4*  
Falconi et al (203) 2008 90 (51/39) 63 90 48 100  61  33.3  47.8 
Hsu et al (182) 2007 127(71/56)  127 40.8 94.3       
Iacono et al (204) 2007 59(42/17) 57 59 37.3   46 31    
Lazaryan et al (177) 2011 72(42/30) 72 72 34 96  61  29 39*  
Morini et al (60) 2013 72(42/30) 65 72 48.6  31/35/6 50 68    
Ohike et al (205) 2010 244(145/99) 65 244 38 95  33  23 64*  
Pomianowska et al (206) 2013 61 67 61 48 75  46  33  36 
Qiao et al (81) 2007 127(71/56) 62 124 35 98.4  43.3     
Robert et al (179) 2014 319(173/146) 65 301 41.7 97.5 106/105/10
8 
56.4  27.9  23.5 
Sakata et al (207) 2007 62(34/28) 62 62 50 96.7  62  14.5 67.7 21 
Schueneman et al (42) 2015 163(96/67) 65 163 55.9  70/93 54.4 87.7 28.6 35.5*  
Sellner et al (208) 1999 34 62 34 15 100       
Sessa et al (32) 2007 53(30/23) 68 53 59.2 80.7 23/30      
Showalter et al (209) 2011 61(38/23) 70 61 67 95  44 50    
Sierzega et al (210) 2009 111(61/50) 59 106 47 100 38/59/14 52 61.8 20 14*  
Sommerville et al (197) 2009 39 61 39 62. 0 97  32 35    
Todoroki et al (88) 2003 66(32/34) 64 59 40. 0 93  52.6   56.4 41.8 
Tol et al (175) 2015 227(138/89) 65 227 43.6 81.1  44.4     
Winter et al (19) 2010 347(199/148) 68 347 54.5 96.1  45  41.4  43.6 
Woo et al (211) 2007 163(84/79) 59 163 31. 0 100  68  15 30 3 
Yokoyama et al (212) 2005 59(35/24) 62 58 53.5 100  61  13.6 67.8 16.9 
M=male; F=female; PD=pancreaticoduodenectomy; PI=perineural invasion; LI=lymphatic invasion; VI=venous invasion.  
§ includes not resected patients.  
* Data as lymphovascular invasion 
3.3.3 Meta-analysis 
Meta-analysis was performed for the following clinicopathological features: 
3.3.3.1 Bilirubin 
Bilirubin was only the serum marker with data available for evaluation. There were 
four studies that reported on elevated serum bilirubin within their multivariate 
survival analysis with two using a value of >50umol/L and one with 75umol/L as cut-
offs. The remaining paper provided no numerical values.  The average bilirubin from 
the 3 studies was 87.5umol/L.  There were three manuscripts to have found elevated 
serum bilirubin levels to be an independent factor of poorer outcome with overall 
HR: 2.14 (95% CI: 1.55 – 2.97; p <0. 00001) (Fig 3.2).  
 
Figure 3.2 Forest plot of the relationship between bilirubin and overall survival 
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3.3.3.2 T stage 
T stage was designated as T1/2 versus T3/4 with a total of 12 manuscripts reporting 
T stage as an independent prognostic factor when classified in this manner. 
Increased T stage was associated with a worse prognosis (HR: 2.68, 95% CI: 2.13 – 
3.38; p <0.00001) (Fig 3.3). 
 
Figure 3.3 Forest plot of the relationship between T stage and overall survival 
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3.3.3.3 Nodal stage 
N stage was measured in a binary fashion as the presence or absence of lymph node 
metastases and was the most frequently assessed independent prognostic factor 
influencing survival with 15 of the studies reporting.  The combined HR for all of the 
studies was 1.75 (95% CI: 1.53 – 1.99; p <0.00001) (Fig 3.4).  
 
Figure 3.4 Forest plot of the relationship between N stage and overall survival 
 
 
There were 3 different studies that further assessed lymph node involvement by 
reporting on the total number of nodes involved using the following categories 0, 1 -
3 and >3, demonstrating a modest prognostic disadvantage in the 1-3 positive nodes 
group (HR: 1.77, 95%CI: 1.00 – 3.13; p=0.05).  In contrast, in the > 3 lymph node 
positive group there was a significantly worse overall survival with HR 8.18 (95% CI: 
4.45 – 15.06; p<0.00001) compared to node negative patients (Fig 3.5). 
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Figure 3.5 Forest plots of the relationship between lymph node number and overall survival 
 
a) 1 – 3 positive LN group 
 
 
b) >3 positive LN group 
 
 
Furthermore, lymph node involvement was also reported as a ratio and found to be 
an independent factor influencing survival in two studies.   The lymph node ratio 
(LNR) is calculated from the number of positive nodes over the total number 
harvested. The HR from both studies calculated as 8.18 (95% CI: 4.45 – 15. 04; p < 0. 
00001) (Fig 3.6). 
 
Figure 3.6 Forest plot of the relationship between LNR and overall survival 
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3.3.3.4 UICC/AJCC Stage 
The American Joint Committee of Cancer (AJCC) 7th edition and Union for 
International Cancer Control (UICC) TNM classification staging systems were 
combined to maximize numbers. There were two studies reporting on UICC stage 
and a further three on AJCC stage following their multivariate analyses with three 
remaining independent predictors of survival.  With an overall disease stage of > III 
the combined overall risk was HR 1.92 (95% CI: 1.18 – 3.13; p=0. 008) (Fig 3.7). 
 
Figure 3.7 Forest plot of the relationship between UICC/AJCC stage and overall survival 
 
 
3.3.3.5 Tumour Grade 
Tumour grade was determined according to the degree of differentiation of the 
adenocarcinoma (well, moderately and poorly differentiated). The well and 
moderate group are then classed as low-grade tumours and the remaining lesions 
with poor differentiation as high grade (WHO classification).  There were six studies 
that fully reported on grade following multivariate analysis with grade remaining 
independently prognostic only in the cohort presented by Iacono et al(204).  The 
overall reported HR 1.75 (95% CI: 1.20 – 2.53; p=0.003) (Fig 3.8). 
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Figure 3.8 Forest plot of the relationship between tumour grade and overall survival 
 
 
3.3.3.6 Resection Margin Status 
Margin status was reported as R0 or R1 in all reviewed articles.  There were data 
regarding margin status following multivariate analysis from five papers with four of 
those documenting almost three times the risk of death with positive microscopic 
resection margins.  This translated to overall HR 2.36 (95% CI: 1.73 – 3.21; 
p<0.00001)(Fig 3.9).  There was no clear consensus as to how margin was defined 
with two studies failing to clearly describe if they defined R1 as microscopic disease 
within 1mm of or at the resection margin(205, 206), two studies used the criteria of 
tumour at the margin(32, 182) and one study utilised within 1mm definition(175). 
Figure 3.9 Forest plot of the relationship between margin status and overall survival 
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3.3.3.7 Ampullary Adenocarcinoma Subtype 
Data on ampullary adenocarcinoma sub-typing according to intestinal or 
pancreaticobiliary phenotypes was only available in seven studies with assessment 
of independent prognostic impact following multivariate analysis reported in five 
studies.  The presence of a pancreaticobiliary subtype was indicative of a poorer 
outcome with HR 1.84 (95%CI: 1.38 – 2.45; p<0.0001) (Fig 3.10). 
Figure 3.10 Forest plot of the relationship between subtype and overall survival 
 
 
3.3.3.8 Perineural invasion 
Perineural invasion was reported upon in eight papers following multivariate analysis 
with marked heterogeneity between analyses as demonstrated in the figure below. 
Overall the presence of perineural invasion was a poor prognostic features 
associated with significantly shortened survival. The overall HR for the combined 
studies was 2.27 (95%CI: 1.72 – 2.99; p<0.00001) (Fig 3.11). 
Figure 3.11 Forest plot of the relationship between perineural invasion and overall survival 
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3.3.3.9 Lymphatic Invasion 
There were six of the 29 eligible studies that reported upon lymphatic invasion 
following multivariate statistical analysis with four remaining statistically significant. 
There was once again marked heterogeneity between studies. The overall HR was 
2.03 (95%CI: 1.43 – 2.87; p<0.0001)(Fig 3.12). 
Figure 3.12 Forest plot of the relationship between lymphatic invasion and overall survival 
 
 
3.3.3.10 Venous invasion 
A single paper identifies venous invasion as an independent prognostic factor for 
survival in patients with ampullary adenocarcinoma with Woo et al reporting HR 
8.63 (95% CI: 2.47 – 30.2; p = 0. 001). 
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3.4 Discussion 
There is a relative paucity of clinical data for patients with ampullary 
adenocarcinoma, likely due to the rarity of the disease compared to PDAC, and often 
limited in the most part to small patient cohorts from retrospective studies.  This 
review of the literature, encompassing 3290 patients from 30 high quality studies, 
provides a comprehensive analysis of radical surgical resection by PD for ampullary 
adenocarcinoma and the clinicopathological prognostic factors that influence overall 
survival. 
Radical resection by PD remains the gold standard of treatment for ampullary 
adenocarcinoma, owing to the high recurrence rates of 80% to 100% seen in local 
transduodenal resection(141, 143, 144) and the relatively unknown long-term 
outcomes for endoscopic ampullectomy.  The marked improvement in the past 
decades of both surgical technique and post-operative care has reduced the 
operative mortality and morbidity of the procedure (213) with operative mortality 
between 0% and 10% readily reported(19, 33, 80, 81, 88, 141, 180, 192-194, 196, 
201-204, 214). The largest study from Winter et al of 435 patients undergoing PD 
(for both adenoma and adenocarcinoma) reported peri-operative mortality of 
2%(19).  Despite these advancements the long-term survival remains poor.  The 
median 5- year overall survival barely surpassed 50% and ranged from 33% to 68% 
despite the vast majority of patients undergoing an R0 resection (median 96.8%).  
The high negative resection margin rate suggests that it is easier to achieve R0 
resections in ampullary cancer than in other periampullary adenocarcinomas with a 
recent systematic review of cholangiocarcinoma reporting a rate of 84%(215) whilst 
for PDAC, rates of 15%, 24% and 27.6%(216-218) have been reported.  It also 
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suggests that resection margin status is not the most powerful contributing factor 
influencing survival as only a small proportion of patients undergo a margin positive 
resection however; with a HR of 2.36 with R1 disease, care must be taken to 
maximise potential for complete excision and utilising intra-operative frozen section 
to ensure microscopic clearance is advised.   
The definition used to describe a R1 status in each of the manuscripts failed to 
demonstrate a consensus and it was not clear as to whether a standardised protocol 
(SP) reporting system was used which raises questions with regards to the accuracy 
of reporting.  Research undertaken by Verbeke et al(217) looked at two comparable 
cohorts of patients undergoing PD resection, the first were reported using a non-
standardised protocol (NSP) and the second a standardised proforma.  They 
demonstrated that the implementation of a SP resulted in a higher R1 rate overall 
and that survival correlated with resection margin status in the SP cohort but not for 
the NSP group (p<0. 001).  They also found that there was a trend towards better 
median and 5-year survival after R0 resection in the SP PDAC subgroup suggesting 
that standardised reporting allows for more accurate specimen analysis(217). 
A review of resection margin involvement and tumour origin by the same group 
demonstrated a wide variation in the published incidence and R1 rates of ampullary 
cancers from 5% to 42% and 0% to 27% respectively, with similar seen in PDAC and 
distal cholangiocarcinoma(219).  These studies suggested that differences in 
pathological assessment rather than surgical practice was the main determining 
factor and histopathological distinction between the three cancer groups is less 
accurate than generally thought.  They concluded that inaccurate distinction 
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between tumours alongside inconsistent resection margin assessment results in 
obfuscation of clinicopathological data and unless pathological examination 
becomes standardised, comparison of results between centres or multicentred trials 
will be of limited value(219). 
From our previous work on resection margin status in PDAC using a SP reporting 
method for each resection specimen, we demonstrated a R1 rate of 74% that was in 
contrast to the majority of the previously reported literature(220).  Despite this high 
R1 rate, the median overall survival time was comparable to those reporting much 
lower rates and therefore is likely a reflection on high-quality reporting rather than 
inadequate surgical technique(220). 
An explanation for the poor prognosis attributed to ampullary adenocarcinoma 
despite small volume localised primary disease is the frequency of lymph node 
metastases (43.6%) at the time of presentation. The frequency of lymph node 
metastases, lymphatic invasion (47.7%), venous invasion (36%) and perineural 
invasion (25%) seen in resected specimens was significantly less than observed in 
PDAC.   
Lymph node metastases has been strongly associated with poor outcome in AA, a 
finding reaffirmed in this review with 19 of 30 studies indicating that nodal 
involvement was an independent prognostic factor associated with reduced survival. 
Five studies further analysed lymph node involvement through assessment of 
number of involved lymph nodes and LNR (175, 197, 203, 207, 210) and confirmed 
that increasing metastatic burden significantly worsens survival and outcome.  
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 The total number of lymph nodes harvested has also been reviewed previously.  The 
paper from Partelli et al(221) retrospectively reviewed 127 patients undergoing PD 
for ampullary adenocarcinoma and concluded that removal of 12 or more lymph 
nodes was associated with improved survival in both N0 and N1 patients.  The 
reason for this may be potentially related to more extensive lymphadenectomy and 
therefore better staging. 
These data demonstrate that the pancreaticobiliary phenotype is associated with a 
significantly reduction in overall survival when compared to those patients with an 
intestinal phenotype tumour (HR 1.84, 95%CI: 1.38 – 2.45; p<0.0001). Unfortunately, 
subtype was only commented on in seven studies. This has potential implications for 
all ‘periampullary cancers’ (PDAC, AA, duodenal & distal cholangiocarcinoma 
combined) with all tumours with a pancreaticobiliary phenotype having a poorer 
prognosis(33, 59, 222).  Potentially this histological feature determines outcome 
more so than anatomical tumour location, and poses the question as to whether 
phenotypic characterisation is a more important prognostic stratifier for 
pancreaticobiliary malignancies. Subsequently this may become an important 
component of standardized reporting for pancreaticobiliary malignancies.   
There was significant heterogeneity seen in both perineural and lymphatic invasion 
in this meta-analysis. On further review of the papers demostating significance on 
multi-variate analysis there were several factors identified that may account for this. 
Generally, the studies consisted of small numbers  with no clear or fixed 
histopathological process described in many cases. There were only five studies that 
specifically detailed the use of H&E slides for assessment(32, 42, 60, 200, 207).  As 
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there is no recognised adjuvant therapy protocol in ampullary cancer the use of 
chemotherapy was discretionary throughout the studies. It was also noted that the 
inclusion criteria to multivariate analysis varied between some studies with p values 
not being uniform (<0.01 to 0.15)(32, 42, 201).  The surgical technique varied slightly 
in two studies where a specific extending lymphadenectomy was performed with 
particular attention made to the superior mesenteric nodes which may result to 
altered outcomes(207, 212). 
 
3.5 Strengths and Limitations 
At the time of writing this thesis, to the best of knowledge, this is the only systematic 
review and meta-analysis of ampullary adenocarcinoma within the literature.  There 
are a limited number of manuscripts topical to AA compared to other more common 
pancreaticobiliary malignancies; however, by selecting only the larger cohort studies 
for inclusion and limiting their publication to within the past 20 years it has been 
attempted to only report on the most relevant and powered studies. 
A limitation of this review is the retrospective nature of all the included studies that 
may have allowed for the introduction of bias whilst the prognostic significance of 
some factors could be questioned due to the limited data available for analysis.  
Unfortunately this is a global problem shared amongst all the ampullary 
adenocarcinoma literature and is related to the rarity of this clinicopathological 
disease entity.    
Another significant issue with the included studies is the lack of consensus regarding 
pathological assessment and reporting of resected specimens which must call into 
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question the accuracy of any subsequent survival analyses.  The initial staging 
investigations performed in each study will not be standardised as there is no 
globally recognised preoperative staging criteria, again likely in part due to low 
incidence of AA.   
As described earlier, there have been previous studies and RCTs performed to 
evaluate the effectiveness of adjuvant chemotherapy, however, no significant 
survival benefit has been determined.  With this in mind, there is no standardised 
chemotherapy regime within the selected studies and this will result in a very 
heterogeneous group with regards to having received chemotherapy or not and 
what agent was given. 
 
3.6 Summary 
This systematic review of the clinicopathological factors influencing survival in 3290 
patients with AA undergoing PD with curative intent supports that increased T stage, 
perineural invasion and lymph node involvement, particularly an increasing nodal 
metastatic burden are the strongest predictors of survival in this patient group. The 
influence of resection margin involvement is challenging to address as there has not 
been a standardized definition used throughout the literature. Clearly, the relatively 
small cohort numbers in some of the included studies highlights the challenges of 
studying patients with this disease and subsequently there is a need for future 
studies to be performed using a collaborative, multi-centre approach with 
standardization of pathological and prognostic factor reporting. 
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Chapter 4 
Outcome and Pattern of Recurrence following 
Pancreaticoduodenectomy: a Single Centre Experience 
4.1 Introduction 
Ampullary adenocarcinoma accounts for approximately 0.2% of gastrointestinal 
malignancies yet represents up to 30% of resectable peri-ampullary malignancy(77). 
It is associated with a more favourable prognosis following surgical resection when 
compared with PDAC with 5-year survival times approaching 50%(19, 80, 81). 
Unfortunately, a wide spectrum of outcomes exists following resection by PD. As 
previously evaluated in our meta-analysis of the literature (Chapter 3), pathological 
factors of prognostic value in AA include depth of tumour infiltration(77, 81, 192, 
223), tumour differentiation(224), lymphovascular(19), perineural invasion(225) and 
resection margin status(194).  Lymph node metastases are also an important 
factor(19, 32, 77, 81, 192) with both lymph node ratio (LNR)(203, 226), along with 
lymph node burden(210) associated with poor outcome. Adenocarcinoma of the 
ampulla of Vater may be classified by morphological appearance, with Kimura and 
co-workers initially describing intestinal and pancreaticobiliary subtypes based on 
morphological and IHC features(25).  
Variability exists within the literature regarding the relative importance of these 
factors.  Subsequently, the inability to predict individual outcomes for cancers 
affecting this anatomical location has hampered aspects of clinical decision-making, 
specifically the aggressiveness of therapy, choice of appropriate chemotherapeutic 
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strategies and clinical trial interpretation (24, 223).   
Currently no standardized adjuvant therapy regimens exist for this cohort(25, 160-
163). Randomized controlled trials(164-166) and institutional cohort studies(167, 
168) have failed to definitively demonstrate a survival benefit for adjuvant 
chemotherapy.  Identification of an appropriate high-risk group is therefore likely to 
be important for stratification in future trials. Furthermore, reporting of the site and 
pattern of recurrence following resection with curative intent varies significantly 
within the literature(88, 161), hampered by inadequate follow-up and incomplete 
pathological reporting.  
Our review also highlighted the issue of marked variation in the pathological 
evaluation of tumours with no standardised histopathological reporting tool having 
been utilised raising questions regarding the accuracy of patient outcomes and 
survival being published within the literature.  
 
4.2 Aims 
In this single institution experience of a large cohort of ampullary adenocarcinoma, 
resected according to a standardized surgical strategy, we examined, in the context 
of a robust protocolised pathological method, the relative prognostic importance of 
pathological factors, in particular, resection margin status and morphological 
subtype, and furthermore evaluated the pattern and determinants of disease 
recurrence.   
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4.3 Methods 
Resectional surgery was performed in the West of Scotland Pancreatic Unit, Glasgow 
Royal Infirmary, UK, during a twenty-four year period (January 1990 to May 2014). 
This analysis was limited to patients undergoing either classical (Whipple resection) 
or pylorus-preserving PD for ampullary adenocarcinoma, performed by the same 
team of surgeons. Other lesions (e.g. pancreatic, duodenal or distal bile duct 
adenocarcinomas, mucinous cyst-adenocarcinomas or intraductal papillary mucinous 
neoplasms) were excluded.  
The decision to perform resection was made by a multi-disciplinary team including 
surgeons, oncologists, radiologists and pathologists.  The criteria for resectability 
included: a) CT evidence of localized tumour in the peri-ampullary region; b) no 
evidence of superior mesenteric vein occlusion or significant tumour narrowing; c) 
no overt arterial involvement. (227)  
 
4.4 Operative Procedure 
The following is the standard operative approach conducted by all hepatobiliary 
surgeons within Glasgow Royal Infirmary. An initial roof top abdominal incision is 
made to enter the peritoneal cavity with subsequent retraction aided by an 
Omnitract retractor fitted to the operative table.  The mobilisation phase of PD 
begins as the lesser sac is entered by freeing the greater omentum from both the 
transverse and ascending colon and following this plane to the right. Division of the 
peritoneal reflection and caudal mobilisation of the hepatic flexure of the colon 
exposes Gerota’s fascia overlying the right kidney and the anterior aspect of the 
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pancreas and duodenum. This often exposes the superior mesenteric vein (SMV) at 
the inferior border of the pancreatic neck adjacent to the uncinate process.The 
peritoneum to the lateral aspect of the second part of duodenum is divided to allow 
extended Kocherisation to the left lateral border of the aorta to mobilise the 
pancreatic head which is reflected medially and exposing the vena cava.  
The porta hepatis is then explored and identification of the common hepatic artery is 
made. The dissection is continued distally to identify the right gastric and 
gastroduodenal arteries. The portal vein is also sought at this point.  Depending 
upon technique, the distal stomach or proximal duodenum is then divided followed 
by the proximal jejunum.  The third and fourth parts of the duodenum are then fully 
mobilised with division of the Ligament of Treitz and then reflected underneath the 
superior mesenteric artery and vein exposing the pancreatic body.   
The pancreas is then transected at the level of the portal vein and the pancreatic 
head reflected laterally allowing for separation from the SMV, portal vein and their 
smll tributaries. With medial retraction of the SMV and portal vein confluence, the 
tissue between the pancreatic head  and lateral wall of the SMA is freed with division 
of arterial branches as required. 
The resection phase requires division of the distal stomach or duodenum, jejunum, 
small bowel mesentery, bile duct, pancreas and mesopancreas to allow complete 
excision.  In cases of more advanced disease there may be requirement for portal 
vein, SMV or SMA resection with reconstruction.  The gallbladder is routinely 
removed and the spleen less frequently so. Transection margin frozen section 
analysis are routinely performed in our institution to establish the presence of 
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residual disease, with further pancreatic body resection undertaken until negative 
histopathological status is obtained.  Reconstruction requires a minimum of three 
surgical anastomoses, namely a hepatico-jejunostomy, pancreatico-jejunostomy and 
gastro-jejunostomy; however a further jejuno-jejunosotomy is performed in this 
institution to prevent problems with bile reflux (220).   
 
Figure 4.1a&b) Pancreatic head mobilisation 
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Follow-up comprised a standardized protocol of outpatient reviews. CT scans or 
other appropriate imaging modalities were performed whenever local–regional 
recurrence or distant metastatic disease was suspected; however, it is the case that 
our practice does not routinely perform postoperative imaging while the patient 
remains asymptomatic and not undergoing active treatment. Following recurrent 
disease, the patient was considered for chemotherapy if oncologically naïve or for 
rechallenge if they had received previous adjuvant chemotherapy. Detailed 
recurrence data was available in all except nine patients. 
 
4.5 Pathology assessment 
Ampullary tumours were defined as those unequivocally originating from the 
anatomical structures forming the ampulla of Vater.  The pathology reports from all 
patients undergoing PD or PPPD during the study period for an ampullary tumour 
were undertaken by three senior pathologists (AKF, KO, FD) with both AFK and FD 
having led local standardisation and been co-authors of the British Royal College of 
Pathologists (RCPath) National Ampullary specimen guidelines (2002, 2019)(228). 
The gross and microscopic evaluation of PD resection specimens has been 
performed in this manner since 1996 with resection margins having not been inked 
prior to this time.  
Clinico-pathological cohort data was collated in a prospectively maintained database 
including tumour stage, size, differentiation, perineural, lymphovascular invasion 
and resection margins status. All pathology was reviewed according to Tumour Node 
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Metastasis (TNM) staging in accordance with the UICC/AJCC (7th edition)(229) which 
corresponds to the RCPath guidelines. 
Microscopic assessment and reporting included the maximum tumour diameter, the 
extent of local spread, tumour grade; perineural, venous and lymphatic invasion; and 
lymph node positivity. To my knowledge no extra or novel stains or solutions were 
used in this process other than those for standard reporting. Data for total number 
of resected lymph nodes and number of positive nodes were recorded.  LNR was 
determined by dividing the number harboring metastasis by the total number of 
examined nodes. Tumour grade was categorized into high for poorly differentiated 
tumours and low for moderately and well-differentiated tumours.  
Resection margin involvement (R1) was defined according to the RCPath guidelines 
as the presence of tumour at or in an involved lymph node within 1 mm of a margin 
when assessed by microscopy of haematoxylin and eosin (H&E) stained slides(228).  
On receipt of the specimen, this margin status analysis requires inking of the four 
pancreatic resection margins (pancreatic transection, medial, posterior and anterior 
surface) as described previously(220, 230).  The medial margin is regarded as the 
tissue plane running alongside the lateral borders of the mesenteric vessels and the 
posterior margin comprises the smooth pancreatic surface lying behind the medial 
margin(220, 230) Figure 4.2a&b. This method of reporting was applied uniformly to 
ampullary resections in our institution throughout the study period under the 
supervision of the aforementioned pancreatic pathologists (AKF, FD, KO).  
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Figure 4.2a) Pancreatic resection specimen b) with margin inking 
 
Regarding morphological subtyping a minimum of 4 H&E slides were reviewed for 
each case. All tumours were categorized according to the original criteria(25), later 
revised by Albores-Saavedra and co-workers(231).  Tumours of the intestinal subtype 
had a more cribiform appearance macroscopically with tall/elongated pseudo-
stratified columnar epithelium with elongated nuclei often found at the cytoplasmic 
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border of the nucleus.  Pancreaticobiliary tumours had branching glands 
macroscopically with a simple cuboidal epithelium with no stratification and a single-
layer of nuclei of differing sizes.  Tumours found to have elements of both 
morphology were classified on the predominant features.  
Patients were divided into four groups based on LNR, including those with no lymph 
node metastases (LNR = 0) and three groups with positive lymph nodes as follows: 
LNR = 0.01-0.2; LNR ≥ 0.2-0.4; and LNR > 0.4(23).  Lymph node positive patients were 
additionally evaluated according to the number of involved nodes identified (1 - 3 
and ≥ 4 nodes).  
 
4.6 Statistics 
Categorical variables were compared using the Mantel –Haenszel (χ2) test.  The 
Mann-Whitney U test was used to compare continuous variables following 
confirmation of a normal distribution of values.  The principal outcome measure was 
length of survival as measured from the time of the original surgery.  Length of 
survival following surgery and cause of death were obtained from our prospectively 
maintained database and validated using the NHS Scotland Information Services 
Department (http://www.isdscotland.org).  Kaplan-Meier survival analysis was used 
to analyze the overall survival from the time of surgery.  Patients alive at the time of 
follow-up were censored.  The last follow-up period for patients still alive was June 
2014. To compare the length of survival between curves, a log-rank test was 
performed.  A Cox proportional hazards model was used for multivariate analysis to 
adjust for competing risk factors, and the hazard ratio (HR) with 95% confidence 
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intervals (CIs) was reported as an estimate of the risk of disease-specific death. 
Variables that were found to be significant on univariate analysis at P < 0.10 were 
included in multivariate analysis in a backwards stepwise fashion.  The statistical 
significance for a test was set at a P ≤ 0.05.  All statistical analyses were performed 
using SPSS version 22.0 (IBM Corporation, NY, USA). 
 94 
4.7 Results 
4.7.1 Patient characteristics  
From a total of 564 PDs performed, 127 patients were identified as having had a PD 
for ampullary adenocarcinoma with full clinicopathological follow up available. The 
90-day mortality was 3.9% (5 patients) with these survival data being censored from 
analysis.  
Patient demographics and tumour characteristics are summarized in Table 1. The 
median age was 64.0 years (range 35-80). There were 77 men (60.6%) and 50 
women (39.4%). No vascular resections were required. 39 patients received adjuvant 
chemotherapy (30.7%). At a median follow up of 100.0 months, the median overall 
survival was 35 months (95% CI: 17.8-52.2). At the time of follow-up 51 patients 
(40.2%) remained alive following resection. 62 patients (48.8%) had died of recurrent 
disease. The deaths of 14 (11.0%) patients were not attributable to ampullary 
adenocarcinoma. 
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Table 4.1: Clinicopathological factors and outcome for patients with ampullary adenocarcinoma (n = 
127) 
 Total Cohort Histological Intestinal 
Subtype 
Histological 
Pancreaticobiliary Subtype 
 
Variables 
n = 127 
No. (%) 
 
Median 
OS 
(Months) 
(months) 
 
P value 
Log-
rank 
(Log 
rank) 
n = 69 
No. (%) 
 
Median 
OS 
(Months) 
(months) 
 
P value 
Log-rank 
(Log rank) 
n = 58 
No. (%) 
 
Median 
OS 
(Month
s) 
(months
) 
 
P value  
Log-rank 
(Log rank) 
Sex          
    Male 77 (60.6) 35.0  40 (58.0) 92.0  37 (63.8) 21.0  
    Female 50 (39.4) 32.0 0.927 29 (42.0) 121.0 0.919 21 (36.2) 26.0 0.622 
Age (years)          
    Mean 63.1   61.9   64.5   
    Median 64.0   62.0   66.5   
    Range 35.0 – 80.0   35.0 – 80.0   43.0 – 77.0   
Outcome          
    Follow-up (months) 0.3 – 289.0   0.3 – 289.0   0.4 – 164.0   
    Median follow-up 100.0   104.0   90.5   
    Death AC 62 (48.8)   28 (40.6)   34 (58.6)   
    Death other   14 (11.0)   6 (8.6)   8 (13.7)   
    Death unknown 0 (0)   0 (0.0)   0 (0.0)   
    Alive 51 (40.2)   35 (50.7)   16 (27.6)   
Stage          
    I 28 (22.1) NR  18 (26.1) NR  10 (17.2) NR  
    II 77 (60.6) 29.0  42 (60.9) 50.0  35 (60.3) 20.0  
    III 22 (17.3) 21.0 <0.0001 9 (13.0) 27.0 0.001 13 (22.4) 12.0 0.049 
T Stage          
    T1   10  (7.9)   8 (11.6)   2 (3.4)   
    T2 37 (29.1) NR  22 (31.9) NR  15 (25.9) 26.0  
    T3 58 (45.7)   30 (43.5)   28 (48.3)   
    T4 22 (17.3) 27.0 0.001a 9 (13.0) 35.0 0.009a 13 (22.4) 21.0 0.269a 
N Stage          
    N0 56 (44.1) NR  35 (50.7) NR  21 (36.2) NR  
    N1 71 (55.9) 20.0 <0.0001 34 (50.3) 27.0 0.003 37 (63.8) 14.0 <0.0001 
LNR          
    0 55 (43.3) NR  34 (49.3) NR  21 (36.2) NR  
    0.01 - 0.2 45 (35.4) 27.0  25 (36.2) 92.0  20 (34.5) 15.0  
    ≥ 0.2 - 0.4 20 (15.7) 14.0  7 (10.1) 26.0  13 (22.4) 14.0  
    ≥ 0.4 7 (5.5) 12.0 <0.0001 3 (4.3) 13.0 <0.0001 4 (6.9) 6.0 <0.0001 
Lymph node burden          
    0 52 (43.3) NR  34 (49.3) NR  22 (37.9) NR  
    1 – 3 38 (31.7) 25.0  21 (30.4) 92.0  19 (32.8) 15.0  
    > 4 30 (25.0) 15.0 <0.0001 14 (20.3) 26.0 <0.0001 17 (29.3) 12.0 <0.0001 
Differentiation           
    Well 5 (3.9)   3 (4.3)   2 (3.4)   
    Moderate 87 (68.5) 67.0  54 (78.3) 121.0  33 (56.9) 30.0  
    Poor 35 (27.6) 19.0 0.001b 12 (17.4) 48.0 0.793b 23 (39.7) 12.0 0.001b 
Tumour size          
    ≤ 20mm 72 (56.7) 48.0  38 (55.1) NR  34 (58.6) 30.0  
    > 20mm 55 (43.3) 29.0 0.107 31 (44.9) 55.0 0.380 24 (41.4) 14.0 0.026 
Margins (≤ 1 mm)           
    R0 87 (68.5) 55.0  54 (78.3) NR  33 (56.9) 24.0  
    R1  40 (31.5) 27.0 0.013 15 (21.7) 32.0 0.025 25 (43.1) 15.0 0.724 
Subtype          
    Intestinal 65 (51.2) 121.0        
    Mixed 4 (3.1)         
    Pancreaticobiliary 58 (45.7) 21.0 <0.0001c       
Perineural Invasion          
    Negative 90 (70.9) 67.0  53 (76.8) NR  37 (63.8) 24.0  
    Positive 37 (29.1) 22.0 0.002 16 (23.2) 32.0 0.001 21 (36.2) 21.0 0.855 
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Venous Invasion 
Venous Invasion 
         
    Negative 90 (70.9) 69.0  51 (73.9) NR  39 (67.2) 29.0  
    Positive 37 (29.1) 17.6 <0.0001 18 (26.1) 32.0 0.018 19 (32.8) 12.0 0.002 
Lymphatic invasion          
    Negative 82 (64.6) 92.0  47 (68.1) NR  35 (60.3) 30.0  
    Positive 45 (35.4) 24.0 0.003 22 (31.9) 32.0 0.078 23 (39.7) 15.0 0.033 
Chemotherapy           
    Adjuvant 39 (30.7) 31.0  20 (29.0) NR  19 (32.8) 30.0  
    No Adjuvant 88 (69.3) 44.0 0.597 49 (71.0) 121.0 0.765 39 (67.2) 14.0 0.119 
          a) T1/2 Vs T3/4 for survival analyses based on AJCC TNM Staging System: Ampullary Cancer 7th 
Edition, 2009. b) Differentiation: Well/ Moderate (low grade) Vs Poor (high grade) for survival analyses. 
c) Intestinal and mixed subtype Vs pancreaticobiliary subtype for survival analyses. Comparison 
between intestinal and pancreaticobiliary phenotype (χ2 test) # P < 0.05, ## P < 0.005. NR - Median 
survival time not reached. 
 
4.7.2 Pathological factors  
The median tumour size was 20 mm (range 5-110 mm). Most tumours were low 
grade (72.4%), T stage 3 or 4 (63.0%), node-positive (N1) (55.9%), with negative 
resection margins (68.5%). Perineural, venous and lymphatic invasion was present in 
29.1%, 29.1% and 35.4% respectively. According to tumour morphology: 69 (54.3%) 
were of intestinal and 58 (45.7%) of pancreaticobiliary phenotype. The former were 
more likely to be lower grade (P = 0.005) and have R0 status (P = 0.005) according to 
χ2 test analysis (Table 4.1). Four tumours had a mixed phenotype.  
The overall median number of positive lymph nodes was 1 (range 1-16), while the 
median number in the N1 group was 3 (range 1-16). The median number of nodes 
evaluated was similar over the study period (1990-2002, 17 [Interquartile range 
(IQR) 12-21], vs. 2003-2013, 21 [IQR 17-26], P < 0.0001). A high LNR was associated 
with adverse pathological tumour characteristics including higher stage, higher 
grade, with perineural, venous and lymphatic invasion along with R1 status (P < 
0.05). In contrast, patients with T1 disease had no evidence of lymph node 
metastases, perineural, venous, lymphatic invasion and were all R0 resections (P < 
0.0001). 
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TABLE 4.2. Demographic, operative, pathologic and treatment characteristics by resection margin 
status in 127 patients undergoing resection for ampullary adenocarcinoma  
 
 No. (%) patients 
 R0 Resectiona R1 Resectiona P value 
Total No. of patients 87 (68.5) 40 (31.5)  
Gender    
Female 34 (39.1) 16 (40.0) 0.922 
Male 53 (60.9) 24 (60.0)  
Age (yrs)†    
Median 62.0 68.0 0.015 
Mean 61.6 66.4  
Range 35.0-78.0 49.0-80.0  
Tumour stage    
T1 10 (11.5)   0 (0) <0.0001 
T2 31 (35.6)   6 (15.0)  
T3 38 (43.7) 20 (50.0)  
T4   8 (9.2) 14 (35.0)  
Lymph node status    
N0 48 (55.2)   8 (20.0) <0.0001 
N1 39 (44.8) 32 (80.0)  
Tumour size (mm)b    
Median 18.0 25.0 0.003 
Mean 20.9 
 
 
27.2  
Range 5-55 10-110  
Tumour grade    
Low 62 (71.3) 30 (75.0) 0.662 
High 25 (28.7) 10 (25.0)  
Perineural invasion    
No 69 (79.3) 21 (52.5) 0.002 
Yes 18 (20.7) 19 (47.5)  
Venous invasion    
No  70 (80.5) 20 (50.0) <0.0001 
Yes 17 (19.5) 20 (50.0)  
Lymphatic invasion    
No 60 (69.0) 22 (55.0) 0.126 
Yes 27 (31.0) 18 (45.0)  
Morphological subtype     
Intestinal 54 (62.1) 15 (37.5) 0.010 
Pancreaticobiliary 33 (37.9) 25 (62.5)  
Adjuvant chemotherapy    
No 65 (74.7) 23 (57.5) 0.051 
Yes 22 (25.3) 17 (42.5)  
a) Resection margin positive (R1) if microscopic evidence of tumour ≤ 1 mm from any pancreatic 
margin.  b) Mann-Whitney U test used.  
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Clinicopathological and treatment characteristics were evaluated according to 
resection margin status in Table 4.2. Patients with R1 tumours (31.5%) in addition to 
more frequently demonstrating a pancreaticobiliary phenotype were larger (P = 
0.003), with higher T stage (P < 0.0001), more likely to be lymph node positive (P < 
0.0001), with more frequent perineural (P = 0.002) and venous invasion (P  < 
0.0001). 
 
4.7.3 Clinicopathological variables associated with survival 
For the entire cohort of 127 patients according to univariate analysis, standard 
clinicopathological variables associated with reduced overall survival included higher 
AJCC stage (P < 0.0001), higher T stage (P = 0.001), lymph node status (P < 0.0001), 
high grade (P = 0.001), R1 status (P = 0.013), perineural (P = 0.002), venous (P < 
0.0001), lymphatic invasion (P = 0.003), pancreaticobiliary phenotype (P < 
0.0001)(Table 3.1). Survival at 3yrs, 5yrs and 10 yrs was 49%, 42% and 36% 
respectively. 
Patients with N0 disease had a significantly prolonged survival compared to N1 
patients (median survival not reached [NR] versus 20.0 months, 95%CI: 14.1-29.9, P 
< 0.0001). The N1 group was stratified with those patients with 1-3 positive nodes 
having a prolonged overall survival compared to those with ≥ 4 nodes involved (25.0 
months, 95%CI: 15.5-34.5 versus 15.0 months 95%CI: 8.1-21.9, P < 0.0001). LNR also 
successfully stratified outcome as patients with an LNR of ≥ 0.4 or ≥ 0.2-0.4 had a 
reduced overall survival (12.0 months, 95%CI: 3.6-20.4 versus 14.0 months, 95%CI: 
6.8-21.2 months respectively), compared to patients with an LNR of 0.01-0.2 (27 
months, 95%CI: 18.5-35.5 months P < 0.0001). In the R0 cohort (68.5%), those with 
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no lymph node metastases had a 5 yr overall survival of 66%. While resection margin 
involvement had a negative impact on survival for the T1/T2 stage tumours (R0 [NR] 
vs. R1 [14.0 months, P < 0.0001]) this effect was not evident in higher stage T3/T4 
tumours (P = 0.739). 
According to morphological phenotype the median overall survival following 
resection for patients with an intestinal phenotype tumour was 121.0 months in 
comparison to 21.0 months (95%CI: 11.0-31.0) for the pancreaticobiliary subtype (P 
< 0.0001) (Table 4.1). For the intestinal phenotype: AJCC stage, T stage, lymph node 
status, LNR, lymph node burden, resection margin status, perineural, venous and 
lymphatic invasion were significant predictors of survival (Table 4.1, Fig. 4.3). 
Survival at 3 years, 5 years and 10 years was 63%, 54% and 46% respectively. For the 
pancreaticobiliary phenotype: AJCC stage, lymph node status, LNR, lymph node 
burden, tumour grade, tumour size, venous invasion and lymphatic invasion were 
prognostic factors on univariate analysis (Table 4.1, Fig. 4.4). Survival at 3 years, 5 
years and 10 years was 29%, 26% and 22% respectively.  
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Figure 4.3 Kaplan Meier graphs demonstrating clinicopathological factors influencing survival 
stratified by intestinal phenotype 
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Figure 4.4 Kaplan Meier graphs demonstrating clinicopathological factors influencing survival 
stratified by pancreaticobiliary phenotype 
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While adjuvant chemotherapy failed to impact on survival for the overall cohort, for 
the lymph node-positive patients, chemotherapy (n = 26) improved outcome 
compared to those who did not receive adjuvant therapy (n = 45) (29.0 months, 
95%CI: 16.0-42.0 vs. 14.0 months, 95%CI: 10.0-17.9, P = 0.015). Adjuvant 
chemotherapy failed to impact significantly on survival in either intestinal (P = 0.765) 
or pancreaticobiliary (P = 0.119) subgroups. Limited cohort size prevented evaluation 
of different adjuvant chemotherapy regimens (Gemcitabine vs. 5FU) according to 
morphological subtype.  
Patients with ampullary adenocarcinomas had a prolonged overall survival compared 
to a similarly managed PDAC cohort  (35.0 vs. 18.6 months, P < 0.0001) (Fig. 4.5A) 
(230). However, the overall survival of pancreaticobiliary phenotype patients does 
not significantly differ from the PDAC cohort (21.0 vs. 18.7 months, P = 0.278) (Fig. 
4.5B). 
Figure 4.5 A) Kaplan Meier graph demonstrating AA survival compared to PDAC and B) comparison of 
survival to PDAC when AA stratified by intestinal and pancreaticobiliary phenotypes 
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4.7.4 Multivariate analysis 
Multivariate Cox proportional hazards models were created including univariate 
prognostic factors. For the overall cohort (n = 127) factors independently associated 
with poor outcome included: lymph node involvement (HR = 4.13, 95%CI: 2.30-7.43, 
P < 0.0001), venous invasion (HR = 2.97, 95%CI: 1.78-4.96, P = 0.002), and 
pancreaticobiliary phenotype (HR = 2.47, 95%CI: 1.50-4.08, P = 0.001) (Table 4.3).  
Table 4.3 Predictors of survival following pancreaticoduodenectomy using multivariate Cox regression 
analysis for 127 patients with ampullary adenocarcinoma 
Multivariate  Overall survival 
  HR (95% CI) P value 
Patient Related Factors    
Lymph node status N0/ N1 4.13 (2.30-7.43) < 0.0001 
Morphological Subtype Intestinal/ Pancreaticobiliary 2.47 (1.50-4.08) 0.001 
Venous invasion Absent/ Present 2.97 (1.78-4.96) 0.002 
Tumour stage T1/T2 Vs T3/T4 2.49 (1.40-4.40) 0.203 
Lymphatic invasion Absent/ Present 2.13 (1.30 3.49) 0.297 
Tumour grade Low/ High 0.44 (0.26-0.72) 0.306 
Margin status (1 mm) R0/ R1 1.91 (1.15-3.17) 0.526 
Perineural invasion Absent/ Present 2.15 (1.30-3.56) 0.952 
    
 
Following recalculation of univariate prognostic factors according to histological 
phenotype, for the intestinal phenotype tumours, independent predictors of poor 
overall survival were: lymph node involvement (HR = 3.23, 95%CI: 1.45-7.22, P = 
0.003); high tumour stage (HR = 2.83, 95%CI: 1.24-6.50, P = 0.028); and perineural 
invasion (HR = 3.87, 95%CI: 1.80-8.28, P = 0.002) (Table 4.4). For the 
pancreaticobiliary phenotype tumours, the independent prognostic predictors of 
poor outcome were: lymph node involvement (HR = 4.52, 95%CI: 1.86-10.98, P < 
0.0001) and venous invasion (HR = 2.95, 95%CI: 1.51-5.75, P = 0.005) (Table 4.4). 
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Table 4.4. Predictors of survival following pancreaticoduodenectomy using multivariate Cox 
regression analysis for A) intestinal and B) pancreaticobiliary ampullary adenocarcinoma cohorts  
Multivariate Overall survival  
Intestinal phenotype (n = 65) HR (95% CI) P value 
Perineural invasion Absent/ Present 3.87 (1.80-8.28) 0.002 
Lymph node status N0/ N1 3.23 (1.45-7.22) 0.003 
Tumour stage T1/ T2 Vs T3/ T4 2.83 (1.24-6.50) 0.028 
Venous invasion Absent/ Present 2.67 (1.18-6.02) 0.386 
Lymphatic invasion Absent/ Present 1.96 (0.93-4.17) 0.603 
Margin status (1 mm) R0/ R1 2.50 (1.12-5.59) 0.645 
Pancreaticobiliary phenotype (n = 55)   
Lymph node status N0/ N1 4.52 (1.86-10.98) <0.0001 
Venous invasion Absent/ Present 2.95 (1.51-5.75) 0.005 
Tumour size (mm) < 20/ ≥ 20 2.15 (1.10-4.20) 0.122 
Lymphatic invasion Absent/ Present 2.06 (1.06-3.99) 0.166 
Tumour grade Low/ High 0.32 (0.17-0.63) 0.218 
 
A combination of histological phenotype along with the most powerful independent 
prognostic factor, lymph node status, enabled stratification of the cohort into three 
prognostic groups. First, those patients with an intestinal phenotype (n = 35) and no 
lymph node involvement had an excellent prognosis, with a 5-year survival of 72.0% 
(median survival not yet reached). Second, the group of patients with a 
pancreaticobiliary phenotype and lymph node metastases (n = 37) had a poor 
prognosis, with a 5-year survival of 11.0% and median survival of 15.0 months 
(95%CI: 12.9-17.1 months). Third, the remaining intestinal phenotype patients with 
lymph node metastases or pancreaticobiliary phenotype with no lymph node 
involvement [n = 55]) had an intermediate prognosis, with a 5-year survival of 46.0% 
and median survival of 32.0 months (95%CI: 5.9-66.1 months) (Figure 4.6). 
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Figure 4.6 Kaplan Meier graph comparing survival in the intestinal LN negative group, intestinal LN 
positive & pancreaticobiliary LN negative group and the pancreaticobiliary LN positive group 
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4.7.5 Time variable calculation 
As data was collected over a 24 year period a time variable calculation was 
performed to ensure there was no effect on survival over time. The cohort was 
dichotomised with early patients operated on from 1990 to 2006 and the later 
patients from 2007 to 2014.  
 On univariate analysis for patients with an intestinal phenotype there was no 
significant relationship between the time of resection (early v late) and survival 
(P=0.891). Therefore, time of resection was not added into the multivariate analysis 
for further assessment. 
On univariate analysis for patients with a pancreaticobiliary phenotype there was a 
minimally significant relationship between time of resection and survival (P=0. 075). 
This was therefore included in the multivariate analysis from Table 4.4 but was 
found not to be an independent predictor of overall survival and did not affect 
lymph node status or venous invasion as being independently significant. 
 
4.7.6 Pattern of Recurrence 
From the 62 (48.8%) cancer specific deaths, full disease recurrence data was 
available for 53 patients. A single site of initial recurrence was seen in 36 (67.9%) 
patients with multiple sites affected in the remaining 17 (32.1%) (Table 4.5). 
Metastatic disease involved various sites including 32 (60.4%) patients with any liver 
metastases, 20 (37.7%) liver metastases as the only site, 18 (34%) locoregional 
recurrences, with 12 (22.6%) lung, 5 (9.4%) bone, 4 (7.5%) peritoneal, 2 (3.8%) brain 
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and 5 (9.4%) metastases at other sites including skin and adrenals.  5 (9.4%) patients 
developed liver and locoregional recurrence simultaneously. 
We analyzed the pathological factors that potentially influenced site of recurrence 
(Table 4.5). Liver metastases were associated with the presence of venous (P < 0.05) 
and lymphatic invasion (P < 0.05).  Local recurrence was associated with lymph node 
involvement (P = 0.008). Furthermore local recurrence was more likely as lymph 
node burden (P = 0.023) or LNR increased (P = 0.027). Although bone metastases 
were rare (9.4%), all occurred following a resection for pancreaticobiliary subtype 
tumour (P = 0.03). Resection margin status did not correlate with any pattern of 
recurrence. It was noted that T1 tumours demonstrated no metastatic potential with 
no recurrence seen within this subgroup. 
During the follow-up period 10 (7.9%) patients developed a secondary malignancy 
including 4 (3.1%) breast cancers, 2 (1.6%) NSCLCs, 2 (1.6%) prostate cancers, 1 
(0.8%) follicular lymphoma and 1 (0.8%) oesophageal. 
 
TABLE 4.5 Demographic, operative, pathologic and treatment characteristics by disease recurrence in 53 patients with metastatic disease following resection for ampullary 
adenocarcinoma  
 Metastatic Disease Location n (%) 
 Local Recurrence Liver Metastases 
Lung Metastases  
37 (30.8) 
15 (40.5) 
0.965 
22 (59.5) 
  Lung Metastases 
0.001 
  6 (16.2) 
18 (48.6) 
13 (35.1) 
  7 (18.9) 
Bone Metastases 
30 (81.1) 
25.0 
0.005 
27.4 
10-110 
Peritoneal Disease 
0.731 
10 (27.0) 
20 (54.1) 
0.007 
17 (45.9) 
Total No. of patients 18 (34.0) 32 (60.4) 12 (22.6) 5 (9.4) 4 (7.5) 
Tumour stage      
T1 0 (0.0)                0.372 0 (0.0)               0.645 0 (0.0)               0.072 0 (0.0)              0.451 0 (0.0)              0.190 
T2 5 (27.8) 9 (28.1) 2 (16.6) 2 (40.0) 0 (0.0) 
T3 8 (44.4) 18 (56.3) 5 (41.7) 3 (60.0) 4 (100) 
T4 5 (27.8) 5 (15.6) 5 (41.7) 0 (0.0) 0 (0.0) 
Lymph node status      
N0 0 (0.0)                0.008 6 (18.8)             0.657 2 (16.6)             0.691 1 (20.0)            0.965 2 (50.0)             0.134 
N1 18 (100) 26 (81.2) 10 (83.4) 4 (80.0) 2 (50.0) 
Tumour size (mm)      
<20 8 (44.4)              0.630 17 (53.1)           0.465 6 (50.0)             0.941 5 (100)              0.017 0 (0.0)               0.041 
>20 10 (55.6) 
 
15 (46.9) 6 (50.0) 0 (0.0) 4 (100) 
Tumour grade      
Low 10 (55.6)            0.912 17 (53.1)           0.528 9 (75.0)             0.144 2 (40.0)             0.431 4 (100)             0.069 
High 8 (44.4) 15 (46.9) 3 (25.0) 3 (60.0) 0 (0.0) 
Perineural invasion      
No 10 (55.6)            0.776 18 (56.3)           0.538 6 (50.0)             0.823 3 (60.0)             0.736 1 (25.0)            0.246 
Yes 8 (44.4) 14 (43.7) 6 (50.0) 2 (40.0) 3 (75.0) 
Venous invasion      
No  8 (44.4)              0.089 16 (50.0)           0.050 4 (33.3)            0.029 3 (60.0)             0.986 2 (50.0)             0.659 
Yes 10 (55.6) 16 (50.0) 8 (66.7) 2 (40.0) 2 (50.0) 
Lymphatic invasion      
No 9 (50.0)              0.621 14 (43.7)           0.048 5 (41.7)            0.302 3 (60.0)             0.803 2 (50.0)             0.844 
Yes 9 (50.0) 18 (56.3) 7 (58.3) 2 (40.0) 2 (50.0) 
Morphological subtype       
Intestinal 6 (33.3)              0.210 15 (46.9)           0.774 7 (58.3)            0.302 0 (0.0)               0.033 2 (50.0)            0.844 
Pancreaticobiliary 12 (66.7) 17 (53.1) 5 (41.7) 5 (100) 2 (50.0) 
Adjuvant chemotherapy      
No 12 (66.7)            0.888 20 (62.5)           0.296 7 (58.3)            0.418 3 (60.0)             0.690 4 (100)              0.153 
Yes 6 (33.3) 12 (37.5) 5 (41.7) 2 (40.0) 0 (0.0) 
4.8 Discussion 
Understanding the prognostic influence of clinicopathological factors in a disease 
with a broad range of outcomes such as adenocarcinoma of the ampulla of Vater is 
of considerable importance. Enabling patients to be better selected for surgery, 
justify the allocation of significant adjuvant therapy if aggressive pathology findings 
are present or enable the expectation of good prognosis if sinister features are 
absent is possible. 
We have focused upon the survival of a cohort of 127 patients with resected primary 
ampullary adenocarcinoma treated over three decades at a single institution. A 
relatively consistent surgical approach was accompanied by careful pathological 
review with uniform tumour classification according to the AJCC staging system (7th 
edition)(229)  along with a detailed standardized specimen preparation protocol 
with focus on resection margin status, using evidence of microscopic disease within 
1mm of the resection margin as an R1 specimen. 
The results from our single centre cohort are comparable to those seen from our 
meta-analysis of the reviewed literature.  Our data demonstrated statistically 
significant survival differences in T stage, N stage, margin status, morphological 
subtype, perineural, lymphatic and venous invasion which is in keeping with other 
studies. When further interrogated using cox regression survival analysis all the 
aforementioned HRs were similar except lymph node positivity had a stronger effect 
on survival in our cohort (HR 4.13 versus HR 1.75). This is also true for morphological 
subtype (HR 2.47 versus HR 1.84).  An R1 resection margin demonstrated an 
increased risk in the meta-analysis (HR 1.91 versus HR 2.36) and may be attributable 
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to the heterogenic method of pathological reporting of margin status in the 
literature.  Overall, our results can be validated from an original meta-analysis with 
large patient numbers.  
The current study validates the current AJCC staging system for ampullary 
adenocarcinoma demonstrating sufficient survival discrimination between tumour 
stages. Yet traditional staging criteria do not adequately stratify all patients, as up to 
60% of patients will eventually succumb to recurrent disease, with some subgroups 
identified as having particularly poor prognosis(81, 192). In the present study, 
perineural invasion was not an independent prognostic factor as has been proposed 
previously(225) which is consistent with our meta-analysis as marked heterogeneity 
was apparent following evaluation.  Nodal involvement however, significantly 
reduced overall survival from a 5yr survival of 66% to 22%, one of the largest survival 
differences reported and approximate a large population based study(24). Due to 
the impact of lymph node involvement, some have advocated extended 
lymphadenectomy for PDAC and ampullary adenocarcinoma to improve pathological 
staging and survival, however such extended resections have failed in subsequent 
randomized trials(132). 
As in PDAC(232), N1 patients are not homogenous with regard to outcome therefore 
other prognostic refinements must be considered. We did not identify any evidence 
of lymph node spread in patients with T1 disease regardless of morphological 
subtype. This has important implications for endoscopic ampullectomy, as nodal 
spread may be less common than previously reported. This contrasts with a recent 
single institution assessment of 350 ampullary adenocarcinoma resections that 
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identified a 28% N1 rate in these early stage patients(19). This difference may simply 
be explained by the low frequency of T1 lesions (n = 10) in the present study.  
In the node-positive patients, survival could be stratified by both lymph node burden 
and LNR, with high LNR cases associated with a more aggressive pathological 
phenotype. Importantly, when analysed separately both remained independent 
prognostic factors.  The findings from our cohort are in keeping with those from the 
meta-analysis which found LN positivity to be a factor of poor prognosis; however, a 
LN burden of >3 or a high LNR showed much stronger correlation to poor survival, 
both possessing HRs of 8.18 p<0.00001. 
Recently, the SEER database of 678 resected ampullary cancers was used to 
determine the most appropriate lymph node cut-offs(233).  54% were N0 with a 5-
year survival of 77%, compared to 43% for those with 1-3 nodes and 7% for > 3 
nodes involved. The authors concluded that the total number of positive nodes and 
not LNR was the most powerful prognostic nodal variable(229).  Conversely Falconi 
and co-workers concluded that LNR independently predicted survival(210).   The 
median number of retrieved lymph nodes in our study (n = 19) was greater than in 
the previous studies(203, 210) suggesting high quality lymphadenectomy at our 
institution. It is likely that within future pathological reporting datasets lymph node 
burden along with minimal adequate total lymph node retrieval standards will serve 
to enhance stratification. 
Although IHC evaluation of caudal-related homeobox 2 (CDX2), cytokeratin and 
apomucin expression variation can differentiate intestinal and pancreaticobiliary 
phenotypes and has yielded prognostic information(31, 35, 39, 234, 235) simple 
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histological evaluation is often overlooked(236).  While initial analysis of subtype 
morphology revealed no significant variation in pathological features(200) an 
increased frequency of lymphatic, vascular and perineural invasion was 
demonstrated recently(237).  We identified intestinal type tumours were of lower 
grade and significantly less likely to be R1 resections. Perineural invasion had a 
similar frequency between subtypes, although had prognostic impact only in the 
intestinal subtype. Despite these associations morphological subtyping provided 
strong independent prognostic information and therefore further biological 
explanation is required to account for the variation in outcome.  
Although not all studies have identified histological subtype as prognostic, many 
were under-powered(29, 32, 34, 238) with most recent studies including our meta-
analysis supporting our data(25, 33, 195, 200, 239). Considering the histological 
subtypes separately, multivariate analysis yielded differing results, confirming 
divergent clinicopathological behaviour. In particular T stage, lymph node spread 
and perineural invasion were independent predictors of poor outcome in the 
intestinal subtype compared to lymph node spread and venous invasion in the 
pancreaticobiliary subtype. Our results indicate that more valuable prognostic 
information is obtained from morphological subtyping than provided by tumour 
stage or tumour grade. Certainly standardized reporting of these pathological 
criteria should be incorporated within future standard (UICC/AJCC) staging 
classification.   
The overall survival of intestinal and pancreaticobiliary subtypes shows marked 
heterogeneity (Fig 4.5b) with median overall survival of 121 months versus 21 
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months (p<0.0001). The pancreaticobiliary subtype shows a marked similarity to 
PDAC in the survival curve with no significance in survival seen (21 months versus 
18.7 months p=0.287).  This raises the question as to whether ampullary cancer is in 
fact two separate disease processes and as pancreaticobiliary subtypes show great 
similarity to PDAC they should be treated as such and considered for neoadjuvant 
chemotherapy regimes such as FOLFIRONOX (combination folinic acid, 5-fluorouracil, 
irinotecan and oxaliplatin regarded as first line in PDAC).  Again, the marked variance 
in survival also questions whether subtype and not origin is a more important 
classification tool for biliary cancers. 
These data suggest a high (31.5%) R1 rate, in excess of that previously reported 
throughout the literature (0-25%)(19, 23, 32, 84, 200, 203, 206, 239) and from our 
meta-analysis (median 3.2%, 0-25%).  We believe this reflects our use of a SP 
alongside high-quality pathological specimen examination in accordance with the 
British RCPath guidelines rather than inadequate operative resection with 
representative survival figures seen within this cohort similar to our previous 
findings for PDAC(220).   A prospective evaluation of resection margin involvement 
which employed a similar ≤ 1 mm R1 clearance definition, margin inking and 
standardized specimen examination technique identified a comparable figure of R1 
involvement (27%)(217).   
While patients with R1 resections had tumours with detrimental pathological 
features including lymph node positivity, perineural and vascular invasion, it would 
appear that resection margin involvement is not as powerful a prognostic factor in 
the overall ampullary adenocarcinoma cohort as in PDAC(218). This may be 
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explained by the anterior and posterior circumferential margins being the most 
commonly involved margins owing to the location of ampullary tumours at the 
anatomical crevice between the duodenal wall and the posterior and anterior aspect 
of the pancreatic head. We have previously reported that involvement at these 
‘mobilization’ margins has lesser prognostic significance in PDAC(220). Nevertheless, 
the negative prognostic impact of anterior margin involvement in this cohort 
underlines the importance of rigorous pathological assessment at all circumferential 
and transection margins.  Interestingly, in the intestinal subtype, R1 involvement did 
compromise survival although was not an independent prognostic factor. However, 
R1 status was not a prognostic factor in the pancreaticobiliary subtype cohort.   
At present there is no proven role for adjuvant therapy in ampullary 
adenocarcinoma and as such our cohort did not receive a standardized adjuvant 
regimen nor did morphological subtype alter adjuvant strategy.  The ESPAC-3 
adjuvant therapy trial for periampullary cancer revealed a negative result(169). The 
potential benefit of adjuvant chemotherapy was only demonstrated in multivariate 
analysis when adjusted for other prognostic variables, suggesting that poor-
prognosis tumours were potentially associated with responsiveness.  The studies 
included in our meta-analysis demonstrated a wide variation in use of adjuvant 
chemotherapy between 6.3% and 67% with no clear consensus in use.  Again, there 
was no significant outcomes in any of the included studies. 
The evidence from single-institutional studies supports this, with a recent 
chemoradiation evaluation demonstrating that in N1 patients, survival was 
prolonged(168). Only 31% received adjuvant chemotherapy in the current study, but 
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as shown previously(168) we found adjuvant chemotherapy provided a small but 
significant benefit for the N1 group only, although this may simply reflect selection 
bias. While adjuvant chemotherapy had limited impact according to morphological 
subtype, potentially gemcitabine regimens may be more effective in the 
pancreaticobiliary subtypes with 5FU beneficial to those patients with intestinal 
subtypes.  
This potential heterogenicity in response may make it difficult to detect a statistically 
significant difference in clinical trials of unselected patients. Certainly posthoc 
analysis based on histological subtype alone in the ESPAC3 study did not identify 
differential treatment responsiveness. Unfortunately cohort size did not allow 
stratification by chemotherapy regimen in the present study.   
The predictors for pattern of recurrence vary greatly in the ampullary cancer 
literature. An R1 resection did not affect the pattern of first recurrence. Specifically, 
margin positivity did not result in greater frequency of local or regional recurrences. 
Consistent with the literature, the most common metastatic sites were the liver 
followed by locoregional and lung. Indeed, more than a half of patients with 
recurrence died with the presence of liver metastases. We encountered a higher 
level of lung metastases than reported previously.  Lymph node metastases were 
strongly associated with local recurrence while distant metastases, particularly liver 
and lung, were associated with venous and lymphatic invasion as identified 
previously(88).  Further emphasizing the importance of morphological subtyping, we 
noted for the first time, patients succumbing to bone metastases all had 
pancreaticobiliary subtype tumours.  These data suggest potential for modification 
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of follow-up regimens to account for variation in pattern of recurrence according to 
histological subtype as well as ensuring adequate thoracic imaging to identify 
frequent pulmonary recurrence. 
In view of the recently documented PDAC intestinal variant(33, 231) potentially the 
challenge of differentiating the precise anatomical origin of a periampullary lesion 
may be less important than classification according to histological phenotype for the 
purpose of prognosis and management(219).  
An important result of the present study is the favorable overall outcome associated 
with resected ampullary adenocarcinoma. For N0 patients with clear resection 
margins, 5-year survival was 66%.  The absence of lymph metastases and intestinal 
phenotype identifies patients with an overall survival approaching 70% at 10 years 
suggesting long-term survival may only be possible if an intestinal phenotype is 
identified. These figures are encouraging and highlight the importance of early 
identification of periampullary malignancy, accurate morphological phenotyping 
along with the minimization of morbidity in the post-operative period. The favorable 
prognosis of intestinal tumours may have implications for more aggressive 
endoscopic management of this subgroup.  Furthermore, preoperative MRI scanning 
has potential to differentiate morphological phenotype(240).  Chung et al analysed 
50 ampullary carcinomas with 15 of intestinal phenotype on immunohistochemistry. 
Of these 15, all were nodular, 87% were isointense and 73% demonstrated an oval 
filling defect on standard MR and MRCP imaging. Unfortunately MRI was not 
routinely available for our cohort.  
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Although limited to 127 PD resections, this represents a large cohort of true 
ampullary adenocarcinoma with complete follow-up data. More comprehensive 
analysis will only be achieved via multi-centre studies(239). The quality of 
pathological assessment is highlighted by the high R1 rate (32%) supported by our 
previous PDAC assessment (74%)(220).  While morphological subtype classification 
requires subjective assessment, the frequency matches the prior literature. 
Molecular marker evaluation may yet improve classification reproducibility, 
however, high quality morphological assessment along with careful lymph node 
examination can yield excellent prognostic discrimination. In the future, genomic 
sequence profiling will undoubtedly provide further molecular insight into these 
subtypes. 
 
4.9 Conclusions 
In summary, this validated single centre analysis of resected ampullary 
adenocarcinoma demonstrates that long-term survival can be expected for patients 
with intestinal phenotype and lymph node negative tumours. It questions whether 
pancreaticobiliary subtype tumours should be treated in a similar manner to PDAC 
due to their similar characteristics and survival.  While R1 status is more common 
than previously reported, standard pathological factors must be considered in the 
context of morphological phenotype. Notably, site of recurrence was related to the 
tumour phenotype. These findings lend support to the routine integration of 
phenotype classification in pathological reporting, appropriate stratification of future 
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adjuvant therapy trials and increasingly detailed molecular characterization of 
ampullary adenocarcinoma. 
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Chapter 5  
The role of endoscopic ampullectomy in the diagnosis and 
management of ampullary lesions 
5.1 Introduction 
Ampullary lesions have historically been diagnosed by histological examination of 
biopsy specimens to assess the cellular origin of the lesion and the extent of 
dysplasia.  Before the availability of endoscopic ampullectomy as treatment option, 
the majority of patients diagnosed with an ampullary adenoma underwent surgical 
resection as it was regarded as the sole intervention option without a significant 
recurrence risk.   
Such major surgery was undertaken as it has been demonstrated that ampullary 
adenomas have malignant potential and adenoma to carcinoma progression exists 
within these lesions, similar to that seen in the colon(14).  The transformation of an 
adenoma to in-situ or invasive carcinoma has been reported in the region of 25-
85%(17) Confounding this, the accuracy of diagnostic biopsy specimens have been 
questioned with previous studies having shown false-negative rates of 17% to 40% 
for forceps biopsy in the detection of infiltrating carcinomas(153-155).  For these 
reasons complete removal is mandatory for curative therapy.   The only exception to 
this is the presence of low-grade dysplasia (LGD) within an adenoma in FAP patients, 
where in the absence of symptoms, regular surveillance is often adequate(78). 
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Endoscopic ampullectomy with curative intent was first described in 1993 by 
Binmoeller et al(146).  It is regarded as an important diagnostic tool in the initial 
investigation of patients with an ampullary lesion as it provides larger pathology 
specimens for analysis, therefore improving diagnostic accuracy and refining 
diagnosis.  More recently there has been an increasing role for endoscopic resection 
and it is now preferred over surgical resection for dysplastic adenomata given it is 
recognized as a safe and reliable treatment modality(183) with much-reduced 
morbidity(145). 
The management approach to invasive ampullary adenocarcinoma remains 
controversial with some reports having suggested endoscopic treatment is a viable 
alternative in select ampullary cancer patients(103), particularly if patient 
comorbidity precludes formal surgical exploration and resection which is associated 
with significant morbidity burden.  However, other authors deem the presence of an 
adenocarcinoma to be a criterion for exclusion from endoscopic management(146, 
186, 241).  Despite this, endoscopic ampullectomy is now being considered as 
curative therapy, in place of extensive surgery, for patients with high-grade dysplasia 
(HGD) adenomas, carcinoma in situ or even focal T1 tumours although the literature 
to support such management is lacking and often anecdotal(242).   
Definitive therapeutic indications for use of endoscopic ampullectomy have yet to be 
defined. This relates to the previously described difficulty in accurately determining 
disease grade within an adenomatous lesion; both from low diagnostic accuracy in 
forceps biopsy specimens and understaged lesions on CT(89, 90, 93, 94). 
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The aim of the current study was to evaluate the use of endoscopic ampullectomy in 
dysplastic and malignant ampullary lesions over a fifteen-year period whilst 
considering management pathways, outcomes, complications and overall long-term 
survival in a retrospective cohort of patients at a single centre in an effort to develop 
a a comprehensive treatment algorithm.  
 
5.2 Methods 
A retrospective search of patient records was undertaken and a database of all 
patients referred and treated endoscopically for an ampullary lesion over a 15-year 
period from 1st January 1999 to 1st April 2014 inclusive was collated.  All patients 
were staged and treated either primarily by endoscopic or surgical management or a 
combination of both by the same team of surgeons.  This analysis was limited to 
patients undergoing management for pathologically confirmed ampullary adenoma 
and adenocarcinoma with other lesions (e.g. pancreatic, duodenal or distal bile duct 
adenocarcinomas, mucinous cystadenocarcinomas or intraductal papillary mucinous 
neoplasms (IPMN), and adenosquamous tumours) being excluded. 
A multi-disciplinary team consisting of surgeons, oncologists, radiologists and 
pathologists decided upon which treatment option each patient should receive 
based on initial biopsy findings when available, cross sectional imaging for local and 
metastatic disease, patient fitness and preference.  Assessment of fitness was made 
objectively by reviewing each patient’s co-morbidities. 
 123 
Clinicopathological data regarding the cohort of patients was held within the created 
database that was prospectively maintained.  Patients were identified from both the 
hepatobiliary multidisciplinary meeting, nurse specialist patient files and GRIs 
endoscopic reporting database where coded for an ampullary lesion.  Ampullary 
lesions were defined as those unequivocally arising from the duodenal anatomical 
structures that form the ampulla of Vater.  The lesions were classified as LGD, HGD 
or adenocarcinoma and treatment groups were categorised in a hierarchical manner 
from most definitive to least; PD, surgical bypass, ampullectomy and biopsy +/- 
ablative therapy including biliary stenting procedures. Individuals were then 
allocated to the highest treatment category as per their recorded individual 
treatment pathway. Pre-procedural, procedural and post-procedural data was 
retrieved from both case notes and intranet based patient records in each case.  The 
endoscopic diagnosis, final histology, lesion size, treatment pathway, number of 
endoscopic sessions, surgical intervention if any, complications, follow-up and 
survival for each patient was reviewed and recorded. 
Patients whose lesion was amenable to endoscopic ampullectomy and who did not 
already have a formal pathological diagnosis of invasive adenocarcinoma from 
simple biopsy underwent a “staging” ampullectomy to improve diagnostic yield.  The 
set criteria for ampullectomy Included: 1) that the lesion must be localised, 2) it must 
be exophytic with no ulceration, 3) the base of which could be entirely encompassed 
within a snare. Ablative therapies were utilised in sessile lesions unsuitable for 
ampullectomy or surgical intervention. Biliary stenting was times necessary but did 
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not precluded the subsequent utilization of ablative therapies. A single surgeon 
performed all endoscopic procedures. 
 
5.3 Endoscopic Procedure 
5.3.1 General Considerations 
The procedure itself is an advanced endoscopic therapeutic technique that requires 
an endoscopist with extensive training and experience to perform well.  The aim of 
the procedure should be to perform a complete en-bloc excision of the ampullary 
lesion in question with larger lesions with extra-ampullary extension removed in as 
few pieces as possible.  The depth of excision should be flush to the duodenal wall to 
minimize recurrence from minor ductal extensive within the ampulla.  The ability to 
perform en-bloc excision has the advantage of allowing more accurate histological 
assessment and reduced recurrence(101).  The importance of adequate initial 
excision is paramount as repeat procedures for partially resected lesions encounter 
problems with submucosal fibrosis, both increasing the difficulty and risk of 
complications. 
 
5.3.2 Excision Technique 
Prior to commencing the procedure written consent is obtained following a detailed 
discussion regarding the procedure itself, its associated complications and 
alternatives.  An intravenous cannula is placed preferentially in the right hand for 
ease of access and the patient is then placed in the left lateral position. The patient 
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then receives a dose of intravenous midazolam (3 to 5mg) with or without fentanyl 
(2.5 to 5 mcg) as sedation. A side viewing endoscope is then inserted via the 
oropharynx into the oesophagus and onwards until the duodenum is reached.  The 
ampulla is then located within the second part and the lesion assessed for 
resectability for which the criteria are described above. 
Once the lesion is deemed suitable for excision a stable endoscope position should 
be obtained with the lesion in direct view.  A thin wire snare should then be selected 
to maximize current through the tissue and then opened to encompass the ampulla 
with the snare tip anchored at the ampullary apex.  The snare is then closed 
maximally whilst maintaining contact at the apex to achieve the correct tissue plane.  
The ampulla itself should be relatively mobile compared to the adjacent duodenal 
wall and absence of this raises concerns regarding deep invasion or duodenal 
inclusion within the snare. 
The diathermy current is then applied through the snare to excise the lesion.  If there 
is extra-ampullary extension of the lesion, submucosal injection of saline or 
gelofusine with methylene blue (with or without adrenaline) into the duodenum can 
be used to elevate this component from deeper layers for excision.  Multiple base 
biopsies are then obtained from the site of excision in an effort to identify evidence 
of residual malignant disease.  The patient is then recovered and returned to the 
ward for observation. 
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5.4 Statistical Analysis 
Comparison of categorical variables was done using the χ2 test. The Mann-Whitney U 
test was used to compare continuous variables following confirmation of a normal 
distribution of values. The principal outcome measure was length of survival as 
measured from the time of the original intervention. Length of survival following 
intervention and cause of death were obtained from our prospectively maintained 
database and validated using the NHS Scotland Information Services Department 
(http://www.isdscotland.org). Kaplan-Meier survival analysis was used to analyze 
the overall survival from the time of intervention. Patients alive at the time of 
follow-up were censored. The last follow-up period for patients still alive was April 
2015. To compare the length of survival between curves, a log-rank test was 
performed. Statistical significance was set at a P value of ≤ 0.05. All statistical 
analyses were performed using SPSS version 22.0 (IBM Corporation, NY, USA). 
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5.5 Results 
5.5.1 Patient Characteristics  
A total of 241 patients were identified as having been referred to the West of 
Scotland Pancreatic Unit at Glasgow Royal Infirmary for management of an 
ampullary lesion from January 1999 to April 2014 of which 76 underwent endoscopic 
ampullectomy as part of a diagnostic and management algorithm. The 90-day 
mortality was 1.3% with a minimum follow-up of 12 months. 
The patient demographics, lesion characteristics, procedure specifics and definitive 
management are summarized in Table 5.1 and Figure 5.1. The median age for this 
cohort was 71.0 years (range 38-87 years). There were 42 men (55.3%) and 34 
women (44.7%). There were 59 patients (77.6%) who had undergone prior 
endoscopic biopsy with the remaining 17 (22.4%) progressing straight to endoscopic 
ampullectomy.  At a median follow up of 68.5 months, the median overall survival 
was 83 months (95% CI: 44.6 - 121.4). At the time of follow-up 41 patients (53.9%) 
remained alive following endoscopic ampullectomy. 28 patients (36.8%) had died of 
recurrent ampullary disease. The deaths of 7 (9.2%) patients were attributable to 
other medical co-morbidities. 
 
 
Figure 5.1 Flow chart of definitive endoscopic management outcome for all patients diagnosed with an ampullary lesion between 1999 and 2014 
 
LGD = low grade dysplasia; HGD = high grade dysplasia; EA = endoscopic ampullectomy; APC = argon plasma coagulation
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Table 5.1 Clinicopathological factors of patients undergoing endoscopic ampullectomy (n = 76) 
 Total Cohort Adenocarcinoma Cohort 
 
Variables 
n = 76 
No. (%) 
 
Median 
OS 
(Months) 
 
 
P value Log-
rank 
(Log rank) 
n = 34 
No. (%) 
 
 
 
Median OS 
(Months) 
 
 
P value Log-
rank 
 
Sex      
    Male 42 (55.3) 89  18 (52.9) -  
    Female 34 (44.7) - P=0.290 16 (47.1) 34 P=0.537 
Age (years)       
    Mean 68.6   71.8   
    Median 71.0   74.0   
    Range 38.0 – 87.0   51.0 – 87.0   
Outcome       
    Follow-up (months) 12.0 – 186.0   12.0 – 185.0   
    Median follow-up 68.5   51.5   
    Death AC 28 (36.8)   15 (44.1)   
    Death other              7 (9.2)   4 (11.8)   
    Death unknown 0 (0)   0 (0)   
    Alive 41 (53.9)   15 (44.1)   
Previous Biopsy       
    Yes 59 (77.6) 35  19 (55.9) 34  
    No 17 (22.4) - P=0.069 15 (44.1) 34 P=0.944 
Grade       
    LGD            32 (42.1) NR     
    HGD 10 (13.2) 58     
    Adenocarcinoma 34 (44.7) 34 p<0.0001    
FAP       
    Yes 5 (6.6) -  0 (0) -  
    No 71 (93.4) - P=0.251 34 (100) 34 - 
Tumour Size       
    ≤ 20mm 43 (58.1) -  16 (50.0) 35  
    > 20mm 31 (41.9) 58 P=0.020 16 (50.0) 28 P=0.466 
 Diagnostic Change       
    Upgraded 17 (28.8) -  13 (68.4) -  
    Downgraded 3 (5.1) 20  0 (0)   
    Same 39 (66.1) - P=0.009 6 (31.6) 13 P=0.187 
Resection Margin -ve       
     LGD 29 (90.6%)      
     HGD 9 (90%)      
     Adenocarcinoma 25 (73.5%)      
     Combined 63 (82.9%)      
 Definitive Treatment       
    Endoscopic 64 (84.2) -  22 (64.7) 30  
    Surgical Bypass 3 (8.8) 17  3 (8.8) 17  
    Whipple 9 (26.5) - P=0.042 9 (26.5) - P=0.046 
 Complications       
    Nil 54 (71.1) -  29 (85.3) 35  
    Pancreatitis 10 (13.2) -  0 (0) -  
    Bleeding 8 (10.5) -  4 (11.8) 14  
    Cholangitis 3 (3.9) -  1 (2.9) 34  
    AKI 1 (1.3) - P=0.287 0 (0.0) - P=0.257 
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5.5.2 Pathological Factors 
Of the 76 patients to have undergone endoscopic ampullectomy, a final histological 
diagnosis of LGD was seen in 32 patients (42.1%), HGD in 10 patients (13.2%) and 
invasive adenocarcinoma in 34 patients (44.7%). Five patients (6.6%) had a history of 
Familial Adenomatous Polyposis (FAP).  
 
5.5.2.1 Diagnostic Accuracy 
Endoscopic ampullectomy were performed on biopsy proven adenomas or 
adenocarcinomas in 59 patients (77.6%) with the remaining 17 (22.4%) proceeding 
directly to ampullectomy. The mean tumour size was 17 mm (range 5 – 50 mm).  
According to the original biopsy histopathological diagnosis of LGD or HGD, the 
diagnosis was upgraded in 17 cases (28.8%) and downgraded in three tumours 
(5.1%).  When considering the upgraded cases, 7 (41.2%) were from LGD to 
adenocarcinoma, 6 (35.3%) from HGD to invasive disease and 4 (23.5%) from LGD to 
HGD.  
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Figure 5.2 Pie chart of diagnostic accuracy of forceps biopsy following EA
 
 
No patient underwent repeat ampullectomy for residual lesions as the snare was 
only attempted when the lesion was encompassed in its entirety on first sitting.  
There were 13 (17.1%) of the 76 patients whose histology demonstrated incomplete 
resection with the remaining 63 (82.9%) patients having no evidence of residual 
disease at the diathermy margin. 
 
5.5.2.2 LGD & HGD Group  
An EA procedure was regarded as definitive management in 64 patients (84.2%). All 
the patients with a final diagnosis of either LGD or HGD were treated definitively by 
endoscopic ampullectomy +/- APC and surveillance.  No patients within the HGD 
group proceeded to formal surgical resection as 7 patients were unfit for this and the 
remaining 3 elected for endoscopic management all of which demonstrated good 
results with histological improvement in each case.  There was a single case of 
Unchanged, 66%
Upgraded, 29%
Downgraded, 5%
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disease progression to adenocarcinoma following incomplete initial resection after 
27 months in the medically unfit group indicating a single endoscopic treatment 
failure.  
Figure 5.3 Chart demonstrating breakdown of diagnostic change from biopsy following EA 
 
LGD = low grade dysplasia; HGD = high grade dysplasia; Ca = invasive malignancy 
 
5.5.2.3 Adenocarcinoma Group 
Within the adenocarcinoma group (N = 34), a total of nine patients (26.5%) 
underwent surgical treatment by pancreaticoduodenectomy with a further three 
patients (8.8%) requiring surgical bypass. The remaining 22 patients (64.7%) were 
managed by endoscopic ampullectomy and subsequent surveillance due to 
significant co-morbidity precluding surgery in 13 cases (38.2%), patient preference in 
three (8.8%), complete excision and subsequent normal biopsies in three (8.8%), 
locally advanced disease in two (5.9%) and a single patient (2.9%) who had 
previously undergone an oesophagectomy precluding further duodenal resection.  
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There were six of the 22 endoscopically managed patients with adenocarcinoma still 
alive at the time of follow-up with three demonstrating no evidence of tumour 
recurrence. Of the deaths within this group, four (25%) were not related to 
ampullary adenocarcinoma and therefore of unrelated cause. 
 
5.5.3 Complications 
Post-endoscopy complications were mostly mild in nature and seen in 22 patients 
(28.9%) with acute pancreatitis in 10 (13.2%), bleeding in 8 (10.5%), cholangitis in 3 
(3.9%) and acute kidney injury (AKI) in a single patient (1.3%).  A single patient (1.3%) 
died following EA from a post-procedural myocardial infarction having suffered a 
significant haemorrhage. 
 
5.5.4 Overall Survival following Endoscopic Ampullectomy 
It was not possible to obtain sufficient information and data regarding disease free 
survival to perform meaningful statistical analysis in relation to the EA cohort and 
have therefore used overall survival which is a limitation to the following findings. 
Patients whose disease graded histologically as LGD had significantly prolonged 
overall survival compared to those with HGD and invasive adenocarcinoma 
respectively (median survival not reached [NR] vs. 58 months, 95%CI: 0.0 – 129.9 vs. 
34 months, 95%CI: 26.1–41.9 p <0.001) (Figure 5.4). When considering the ampullary 
adenocarcinoma group alone, endoscopic ampullectomy as definitive management 
achieved similar overall survival when compared to the cohort of patients who 
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underwent PD (n = 127, chapter 4) up to 36 months (49% versus 54% respectively) 
and there was no significant statistical difference in median survival (30 months, 
95%CI: 22.6 – 37.4 vs. 35 months, 95%CI: 17.8 – 52.2 p=0.152) (Figure 5.5).   
 
Figure 5.4 Kaplan Meier of overall survival following EA stratified by histological disease grade 
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Figure 5.5 Kaplan Meier of overall survival in patients undergoing EA v PD for AA 
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5.6 Discussion 
 Complete removal of ampullary lesions is mandatory due to their malignant 
potential.   There is no debate that EA has been established as a safe and effective 
alternative therapeutic modality to surgical resection in the management of non-
cancerous lesions of the ampulla with these data reaffirming this stance.   
Due to the focal nature of dysplastic change or malignant transformation it does not 
come as a surprise that random ampullary biopsies result in potentially high false-
negative rates of 11% to 60%(141, 153, 154, 156, 243).  The data from our series 
further confirms the inaccuracy of forceps biopsy with a change in histological 
diagnosis made in more than a third of patients and 28.8% of patients having an 
upstaged lesion.  An upgraded disease stage, particularly to invasive malignancy, will 
obviously have a major influence on management strategy.  Therefore these data 
support the concept EA must be performed in all patients with endoscopically 
resectable lesions containing as a crucial staging tool to permit a larger specimen to 
refine diagnosis and guide the most appropriate definitive management. 
EUS will also play a role in as a staging tool in assessing the lesion and determining 
the potential depth of invasion or the presence of intraductal extension. The method 
has an excellent tumour detection rate in excess of 90%(87) and can accurately 
identify and sample locoregional lymph nodes(102) for evidence of metastatic 
disease making this modality particularly complementary to EA. 
The complication rate following EA in our series was 28.1% with a mortality rate of 
1.3%. These figures are higher than those recognised for conventional ERCP although 
were comparable to those from other published series (9.7% to 35%)(146, 147, 183, 
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186, 241, 244-246) and from a literature review by Laleman et al that reported a 
mean complication rate of 27.9%(152).  The increase in complications, most notably 
acute pancreatitis and bleeding, compared to ERCP is likely to be related to the 
relative increase in tissue trauma required to excise the ampulla. 
 LGD lesions of the ampulla are adequately managed with EA and surveillance with 
excellent outcomes, as evidenced from our cohort where no patients disease 
progressed.  The only deviation from this plan is the presence of a lesion with a large 
intraductal component that is incompletely excised. In this rare situation it is difficult 
to be certain no focal malignancy exists and a PD may be warranted.  
The optimal treatment strategy of HGD lesions remains heterogeneous with no clear 
consensus.  Kim et al reported a high recurrence rate in patients with HGD and 
therefore should all undergo radical surgical resection unless their general fitness 
precluded this(247); however this data showed a trend to question this as disease 
progression was only seen in a single patient with positive EA margins in our small 
cohort of 10 patients.  The remaining patients were successfully managed with 
surveillance endoscopy with no recurrence.  
Therefore, complete resection of an HGD lesion by EA is an acceptable curative 
management alternative to major surgical resection according to these data.  The 
literature further supports this view as several studies report EA as a credible 
curative option(17, 248-250) furthermore Lee et al found that resected HGD surgical 
specimens demonstrated no lymph node or lymphovascular invasion(243).  
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Our cohort of 10 patients with resected T1 tumours following PD all demonstrated 
no lymph node involvement; perineural, lymphatic or venous invasion.  Despite 
previous reports of T1 tumours possessing lymphovascular invasion in 11% to 
56%(242, 243) our data disputes this and raises the possibility of EA being a suitable 
alternative to PD in early tumours that have been completely resected 
endoscopically, particularly in those with borderline fitness for PD, although further 
studies with larger patient numbers are needed to clarify this hypothesis .   When 
considering our endoscopically managed adenocarcinoma group of 22 patients 
further, 3 patients had normal surveillance biopsies and no evidence of recurrence at 
35, 40 and 41 months respectively which highlights that carefully selected patients 
with early invasive disease can have excellent outcomes from endoscopic 
management. 
When considering adenocarcinoma, at 36 months following initiation of definitive 
management both unmatched EA and PD cohorts had similar survival with 49% and 
54% of patients respectively remaining alive.  However, there was a significant 
worsening of outcome from this point onward for the EA group compared to the 
surgically managed cohort (Figure 5.5).  When considering median survival, again 
there was no significant statistical difference with 30 months in the EA group and 35 
in the PD group.  This displays that short to medium term outcomes are comparable 
for both treatment modalities and although EA is perhaps less likely to achieve long-
term cure, it is possible to achieve excellent survival with regular endoscopic 
therapy.  This makes EA an attractive option for elderly or frail patients and those 
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who have significant comorbidity and surgical characteristics that would make PD 
particularly high risk.  
The integration of comorbidity scoring systems and tools that evaluate a patients 
overall wellbeing to aid in this decision making process prior to the implementation 
of management may identify those patients who are likely to die with their 
ampullary disease rather than from it.  These include the ASA physical status 
classification system that assesses fitness prior to surgery and Charleson index which 
predicts one-year mortality for a patient with a range of comorbidities. 
From this data analysis and experience an algorithm for the management of all 
ampullary lesions has been developed as a proposed guideline for clinical use (Figure 
5.6).  Completely excised dysplastic lesions and partially excised LGD should undergo 
initial 3 monthly surveillance and then at 6-monthly intervals for a minimum of 3 
years. There have been reports of late recurrence even after 5 years(148, 251) and 
therefore long-term and even indefinite surveillance is warranted in select patients.   
For those select patients undergoing endoscopic management of HGD or T1 tumours 
with clear resection margins an early first follow-up endoscopy should be performed 
after 6 weeks to verify complete resection and no residual disease is present.  This is 
key as residual disease in certain cases would change management to the surgical 
pathway immediately and initial complete resection has seen to be the most 
significant factor affecting endoscopic success(252). 
 
 
 140 
 
 
Figure 5.6 Proposed algorithm for the management of ampullary lesions 
 
EA = endoscopic ampullectomy; LGD = low grade dysplasia; HGD = high grade dysplasia; Ca = invasive malignancy; CiS = carcinoma in situ; PD = pancreaticoduodenectomy; APC = argon 
plasma coagulation
5.7 Conclusion 
EA is a safe and effective method of curative resection for dysplastic adenomata 
when complete excision is achieved whilst also being an important staging tool in 
the initial assessment of ampullary lesions as it allows for more meticulous 
histological analysis. In this regard, all patients with an endoscopically resectable 
lesion should undergo EA.  Patients with incomplete resection of HGD or invasive 
disease should still undergo PD as definitive management where possible. The same 
is true of completely excised adenocarcinomas although our data suggests that a 
select cohort of T1 tumours may be adequately treated endoscopically, avoiding the 
risks of major surgical intervention.  However, in view of the limited data available, a 
large prospective trial is needed to confirm outcomes following EA and produce 
quality evidence for the development of global guidelines.  
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Chapter 6 
Immunohistochemical markers influencing survival and 
prognosis in Ampullary Adenocarcinoma 
6.1 Introduction 
As discussed in the previous chapters, the clinicopathological factors of resected 
specimens following PD help to characterise the behaviour of ampullary 
adenocarcinoma and predict prognosis for patients with the disease(19, 33, 83, 140, 
177, 211).  A detailed review of these factors are reported on within the meta-
analysis presented in section 3.3.3.  Unfortunately, these routinely assessed 
histological factors do not entirely explain the marked variability in outcome 
regularly observed in patients with AA patients following surgical resection.  As a 
result, there is a requirement for superior prognostic markers to be identified to 
potentially enhance management of AA and provide insight into the underlying 
biology. 
In recent years there have been new factors identified that are implemented in 
prognostication which are not routinely included with the AJCC 7th edition TNM 
classification of ampullary cancers.  These include the ability to categorise ampullary 
tumours into histological subtypes that allows for identification of two 
heterogeneous groups with marked variation in survival as demonstrated within our 
127 patient cohort (121 months for Intestinal vs. 21 months for pancreaticobiliary).  
This development has been augmented by the identification of cytokeratin and 
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mucin molecular markers, namely CK7, CK20, MUC1, MUC2 and CDX2 that have 
been implemented in enhancing the characterization of the subtypes and survival 
outcomes (34, 59, 61, 63).  With these markers being closely correlated to subtype 
the validity of their independent impact on survival must be carefully considered. 
There have been a number of key molecular aspects involved in the progression of 
PDAC identified over recent years with subsequent targeted pharmacological 
treatments in evolution; however, this area has mostly remained unexplored in AA.  
It is of interest to ascertain how the expression of different protein markers vary in 
AA particularly in the context of intestinal and pancreaticobiliary subtype tumours.  
As previously described, both subtypes have marked heterogeneous behavioural 
traits and so is of interest to establish how the underlying biomarker pathways that 
produce overall clinical and survival differences were affected.  
The aim of this chapter was to further elucidate the prognostic ability of molecular 
markers involved in signaling pathways found within AA with a view to 
implementation in the clinical setting.  Each investigated marker was grouped 
according to its biological function to aid in presentation; senescence, apoptosis, 
angiogenesis, invasion and metastases, insensitivity to growth inhibition and self-
sufficiency to growth signals.  
The primary aim was to evaluate each candidate biomarker and assess its 
relationship to clinicopathological factors and overall survival within a large post 
radical surgical resection AA cohort using IHC.  
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6.2 Methods 
6.2.1 Patient cohort 
All patients who were included in the immunohistochemical analysis underwent 
surgical resection with curative intent by either classical PD or PPPD in the West of 
Scotland Pancreatic Unit, GRI, over a 22-year period. The surgical procedure was 
performed by one of four surgeons and all were for an ampullary adenocarcinoma 
subsequently confirmed by histopathological analysis.  A detailed description of the 
operative procedure pathological assessment has been detailed in sections 4.4 and 
4.5.   No other biliary tract malignancies or surgical interventions were included in 
the study.  The decision to perform radical surgical resection with curative intent was 
made at the multi-disciplinary team meeting.  There was no standardised adjuvant 
therapy following PD, in part due to the negative studies and RCTs evaluating 
chemotherapy benefit post-operatively(47, 164, 166, 168, 169, 253).   Follow-up 
comprised of a standardised protocol of regular out-patient review and CT imaging 
was only performed when recurrence or complications were suspected.  From the 
127 patients reviewed earlier in chapter 4, it was able to perform IHC marker 
staining on the specimens for 81 resections. 
 
6.2.2 Statistical Analysis of Data 
Categorical variables were compared using the Mantel –Haenszel (χ2) test.  The 
Mann-Whitney U test was used to compare continuous variables following 
confirmation of a normal distribution of values.  The principal outcome measure was 
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length of survival as measured from the time of the original surgery.  Length of 
survival following surgery and cause of death were obtained from our prospectively 
maintained database and validated using the NHS Scotland Information Services 
Department (http://www.isdscotland.org).  Kaplan-Meier survival analysis was used 
to analyze the overall survival from the time of surgery.  Patients alive at the time of 
follow-up were censored.  The last follow-up period for patients still alive was June 
2014. To compare the length of survival between curves, a log-rank test was 
performed.  A Cox proportional hazards model was used for multivariate analysis to 
adjust for competing risk factors, and the hazard ratio (HR) with 95% confidence 
intervals (CIs) was reported as an estimate of the risk of disease-specific death. 
Variables that were found to be significant on univariate analysis at P < 0.10 were 
included in multivariate analysis in a backwards stepwise fashion.  The statistical 
significance for a test was set at a P ≤ 0.05.  All statistical analyses were performed 
using SPSS version 22.0 (IBM Corporation, NY, USA). 
 
6.2.3 TMA construction 
Previously, more conventional IHC required the use of whole tissue sections and was 
therefore highly reagent and sample intensive.  This technology has evolved over the 
years to create a platform enabled for high volume assessment of DNA, RNA and 
protein expression allowing gene validation and correlation of targets with the 
tumours themselves and clinicopathological data.  Creation of the TMA’s for this IHC 
analysis was carried out by highly trained scientists within the pathology laboratory 
to ensure high quality specimens for analysis. 
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 The selected H&E stained sections were reviewed and then multiple defined areas 
of invasive disease as well as normal ampullary tissue, pancreas, duodenum and bile 
duct were marked on the slides.  It was decided six cores should be obtained to gain 
a true representation of the tumour due to the heterogeneous nature of AA.  The 
criteria for selection was as follows: 
 1) High tumour content (minimal contaminants e.g. stromal tissue) 
 2) Definitive invasive ampullary adenocarcinoma (not HGD) 
3) Tumour size (volume enough for 18 x 0.6mm cores (leaving residual tissue 
for further work should it be required) 
 
6.2.4 Array design and construction 
Conventionally, it is standard practice to construct array outlines in an asymmetrical 
format to allow easy sample identification and cores should be randomised 
throughout the block.  The array was designed to include 6 tumour cores, 2 normal 
cores and control tissue with the ability to differentiate between each TMA and was 
constructed in a block of Paraplast using a manual tissue arrayer.  A wax core was 
removed at least 5.7mm from the recipient block edges using a hollow needle and 
then a core of tumour was removed from the first donor block using the matching 
marked H&E slide as a reference.  The specimen core obtained was then placed into 
the recipient block.  The position of the recipient block was changed each time and 
the process was repeated, positioning, a total of 1290 cores (6 x 0.6mm core x 215) 
across 7 different arrays.  There was a minimum distance of 0.8mm kept between 
each core.  The control tissues were arrayed in duplicate in each array and each 
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array with specimen tissue was incubated at 40c for 15 minutes and then allowed 
to cool prior to sectioning.  A prior test TMA was created with a number of practice 
tissue core lines for antibody optimization. 
6.2.4.1 Sectioning 
The tissue blocks were first cooled to -10c (Tissue Tec© cooler) and then sectioned 
using a tape-transfer system and a Leitz 1512 microtome.  A window of adhesive 
tape was applied to the array surface and the microtome blade was positioned 
under one edge to allow cutting of 5m sections.  The section was then fixed to an 
adhesive slide by 35 seconds of UV curing, TPC solvent released the adherent tape 
window and the slides were subsequently baked for 5 minutes at 80c and then 
stored at 4c. 
6.2.4.2 Haematoxylin & Eosin (H&E) staining 
The wax from the sections was removed in Histoclear and then washed in graded 
alcohol.  The sections were then immersed in haematoxylin for 4 minutes, rinsed 
under water, briefly immersed in acid alcohol and placed in Scott’s tap water for 1 
minute.  The sections were rinsed once more then placed in eosin Y for 30 seconds.  
A period of section dehydration was then undertaken using graded alcohol and 
Histoclear. 
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6.2.5 Immunohistochemisty (IHC) 
For the IHC protocol FFPE sections were dewaxed in xylene for 20 minutes and 
rehydrated through intermediate alcohols. Protocols were first optimised using FFPE 
sections then applied to the test TMAs and then the final ampullary TMA sections.  
To prepare for IHC evaluation the sections were stained using a DAKO Autostainer.  
This process began by incubating the sections in goat serum blocker for an initial 20 
minutes and then the primary antibody for a further 30 minutes. They were then 
rinsed in TBS, submerged in 0.3% hydrogen peroxidase for 5 minutes to block 
endogenous peroxidases and then again washed with TBS.  Envision ChemMate was 
used for antibody detection and 3,3-diaminobenzidine for visualization with copper 
sulphate used as an enhancing agent.  An antibody diluent was used on the negative 
controls.   
A combination of 0.1% trypsin and 0.1% calcium chloride within a Tris buffer was 
used when pretreatment enzyme digestion was required.  This was undertaken for 
25 minutes at a temperature of 37c.  Similarly, when microwave pressure cooker 
treatment was required slides were submerged in dH2O containing 0.55g EDTA and 
0.87% Tri base and then heated at full pressure for 5 minutes. 
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6.2.5.1 Antibodies 
Twelve antibodies were used in this study. There were: 
1. B-catenin (Monoclonal Mouse Anti-Human; clone catenin) Dako Ltd (Ely, UK) 
2. P53  (Monoclonal Mouse Anti-Human; clone DO-7)  Dako Ltd (Ely, UK) 
3. P21  (Monoclonal Mouse Anti-Human; clone SX118)  Dako Ltd (Ely, UK) 
4. SMAD4 (Monoclonal Mouse Anti-Human; clone B-8)  Santa Cruz (Ca, USA) 
5. CDX2  (Polyclonal Rabbit Anti-Human)   Santa Cruz (Ca, USA) 
6. LkB1  (Polyclonal Rabbit Anti-Human; clone ab58786)  Abcam (UK) 
7. mTOR  (Polyclonal Rabbit Anti-Human; 2971)   Cell Signalling (Ma, USA) 
8. GSK3  (Polyclonal Rabbit Anti-Human; 9331)   Cell Signalling (Ma, USA) 
9. Cyclin D1 (Monoclonal Rabbit Anti-Human; clone SP4)  Lab-Vision Neomarkers (Ca, USA) 
10. SRC  (Monoclonal Rabbit Anti-Human; 2109)  Cell Signalling (Ma, USA) 
11. MUC1 (Monoclonal Rabbit Anti-Human; 14161)  Cell Signalling (Ma, USA)  
12. CDX2  (Monoclonal Rabbit Anti-Human; 12306  Cell Signalling (Ma, USA) 
 
The selection of these antibodies was made for several reasons. Following an 
extensive review of the current literature of IHC markers in ampullary cancer (Table 
1.1) there were few candidate biomarker proteins identified for use in this cohort 
due to the paucity of published data. The markers MUC1 and CDX2 have previously 
been extensively investigated in their role in the assessment of histological 
phenotyping of pancreaticobiliary and intestinal subtypes(35, 42, 254) and using 
these would allow validation within our cohort and confirm previous findings.   
The antibodies used were also readily available in our lab for use in IHC evaluation 
and had previously been used on TMA’s for our PDAC cohort with interesting 
findings; in particular the LKB1-p21 axis where LKB1 suppression may serve as an 
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alternative to p53 suppression and drive pancreatic cancer evolution(189).  Similarly, 
the markers COX2, -catenin and GSK3 have been shown to be associated with 
clinicopathologcal status and overall survival following resection in PDAC(255) and 
SMAD4 inactivation has been associated with a poorer prognosis(256, 257).  
The progression from a histologically normal epithelium to LGD to HGD to invasive 
carcinoma appears to be associated with the build up multiple genetic mutations 
with each of these protein markers being involved in different steps of the cell cycle 
pathway including senescence, invasion and metastases; angiogenesis, self 
sufficiency and growth; and insensitivity to growth inhbition. 
6.2.5.2 Tissue microarray and image capture archiving 
The slides were digitally captures, stored and archived by CO once staining of the 
TMA sections was completed.  The Slidepath Digital Image Hub 
(http://ld.dih.slidepath.com/login.php) was used as a digital microscope to allow 
visualization and scoring of the TMAs.  These scores were linked to the tumour 
specimen with a unique identifier to allow integration of into the patient cohort 
database with the SPSS program. 
 
 
 
6.2.5.3 TMA assay quantification – modified histoscore 
This is the routine scoring method used in this insititution and has been used in this 
manner several times before(255, 258). It is a semi-quantitative ordinal scoring 
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system and is the default method pathologists are familiar with in the analysis of 
TMAs. This method considers three key factors: 
 1) Percentage of positive stained cells 
 2) Intensity of positive staining 
3) Percentage of tumour within core specimen 
 
The main issue with this method of visual analysis is its semi-quantitative nature 
which reduces data output from absolute values to an ordinal scale.  Each of the 
markers within this thesis were scored using a weighted histoscore.  When scoring 
each core, the proportion of cells staining was multiplied by the intensity of staining 
to achieve an overall score out of 300.  This was done for each cell compartment – 
nucleus, cytoplasm and membrane.  The digital microscope allowed for accurate 
scoring at multiple magnifications. 
The quantity of cells staining was given as a percentage and the intensity of staining 
was characterised in a 4 tier system; nil, weak, moderate and strong staining with a 
score of 0 to 3 given to each respectively. The overall score out of 300 was achieved 
by calculating the % cells with weak staining (x1) + % cells with moderate staining 
(x2) + % cells with strong staining (x3).  
For example, in a slide with 25% weak staining, 25% moderate staining and 50% 
strong staining the histoscore would be: (25 x 1) + (25 x 2) + (50 x 3) = 225 
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All of the proposed prognostic markers were scored by CRF and double scored by a 
consultant pathologist alongside other trained members within the research team 
(NBJ).  If there was any marked variance in overall histoscore between team 
members then reassessment of the core was undertaken simultaneously and a score 
agreed upon. 
6.2.5.4 IHC evaluation 
A semi-quantitative analysis of protein expression for the panel of proposed 
prognostic markers was undertaken using the Histoscore method.  The association 
between combinations of the studied markers; including CDX2, MUC1, B-catenin, 
Cyclin D1, LKB1, p53, SRC, GSK3, mTOR, SMAD4, P21 and COX were evaluated using 
Spearman’s Correlation Coefficient analysis. The identification of correlation 
between the putative markers and clinicopathological factors were obtained. 
6.2.5.5 Cutoff point determination for survival analysis 
For each proposed prognostic marker the cohort was dichotomised into low and 
high groups according to the histoscore obtained.  The point of separation was 
determined at the median point of scores and when this would split equal scores the 
two groups were created at the closest score that was not the median, either higher 
or lower.   This subsequently allowed for Kaplan Meier survival analysis and Cox 
proportional hazards modeling to be performed on the cohorts. 
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6.3 Results 
From the 127 patients who underwent a PD for ampullary cancer between January 
1990 and May 2013, it was able to perform IHC marker staining on the specimens of 
for 81 cases, all of which were included in the study.  The following markers were 
analysed: MUC1, CDX2, B-catenin, Cyclin D1, LKB1, p53, SRC, GSK3, SMAD4, mTOR, 
p21 and COX2. The weighted histoscore method was used as discussed in section 
6.2.5.2.  The histoscore median and range for each proposed marker used to 
determine cut-off values for high and low scoring used for subsequent survival 
analysis are displayed in Table 6.1. 
The number of specimens for each protein marker was variable and ranged from 47 
to 81.  This was because an additional array of 30 patients allowed for a total of 81 
specimens for some markers but only 50 patients had the broader range of markers 
evaluated. 
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Table 6.1 Marker median histoscores and ranges 
Protein No. of 
specimens 
Median 
Histoscore 
Interquartile  
Range 
Histoscore 
Range 
CDX2 81 5.00 87.5 0.0 – 300 
MUC1 81 0.00 1.00 0.0 – 4.00 
B-Catenin 52 0.00 15 0.0 – 225 
Cyclin D1 
Cyclin D1 Nuclear 
52 
52 
78.75 
2.00 
105.6 
1.5 
3.0 – 237.5 
0.0 – 3.00 
LKB1 52 165.00 133.75 0.0 – 300 
p53 
p53 Nuclear 
52 
52 
28.75 
1.00 
165 
2.5 
0.0 – 300 
0.0 – 3.00 
SRC 49 100.00 100 0.0 – 300 
GSK3 47 0.00 15 0.0 – 225 
SMAD4 Nuclear 
SMAD4 Cytoplasmic 
52 
52 
20.00 
60.00 
80 
143.75 
0.0 – 270 
0.0 – 300 
mTOR 39 230.00 100 100 – 300 
P21 
P21 Nuclear 
52 
52 
25.00 
1.00 
51.8 
1.00 
0.0 – 162.5 
0.0 – 3.00 
COX2 Nuclear 
COX2 Cytoplasmic 
COX2 Membranous 
50 
50 
50 
70.00 
195.00 
28.75 
86.38 
93.13 
65 
10 – 220 
17.5 – 300 
0.0- 300 
 
6.3.1 Protein Expression and Survival 
To assess whether levels of protein expression were associated with poorer survival 
in ampullary cancer, survival analysis was undertaken and graphs created for 
patients expressing low levels (below cut off) and high levels (above cut off) of 
molecular proteins.  The survival data for protein expression was compared using 
the log rank test with Table 6.2 demonstrating overall survival for each marker 
dependant on level of staining. 
From initial analysis, 6 protein markers demonstrated strong statistical significance 
all with p < 0.05, namely CDX2, MUC1, SRC, LKB1, COX2 and P21. While expression of 
B-catenin, Cyclin D1, p53, GSK3, SMAD4 and mTOR all failed to correlate with 
 157 
outcome. Table 6.2 and Figure 6.1 demonstrates Kaplan Meier graphs of the 
statistically significant markers.  
Figure 6.1 Kaplan Meier graphs demonstrating biomarkers that influence survival 
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Table 6.2 Survival following resection for Ampullary adenocarcinoma stratified by protein expression  
Marker Number of patients (%) Mean OS 
(months) 
Median OS 
(months) 
 
P value 
(Logrank) 
CDX-2     
   Low 41 (50.6) 47.8 29  
   High 40 (49.4) 136.4 55 0.001 
MUC-1     
    Low 46 (56.7) 99.1 92.0  
    High 35 (43.3) 43.0 21.0 0.003 
B-Catenin     
   Low 30 (57.7) 70.1 26.0  
   High 22 (42.3) 83.8 55.0 0.271 
Cyclin D1     
    Low 26 (50.0) 56.4 24.0  
    High 26 (50.0) 93.4 48.0 0.113 
Cyclin D1 Nuclear     
    Low 22 (42.3) 69.6 30.0  
    High 30 (57.7) 84.5 27.0 0.616 
LKB-1      
    Low 26 (50.0) 49.5 26.0  
    High 26 (50.0) 107.1 121.0 0.017 
P53      
   Low 27 (51.9) 61.7 26.0  
   High 25 (48.1) 90.4 48.0 0.336 
P53 Nuclear     
   Low 31 (59.6) 72.9 30.0  
   High 21 (40.4) 77.7 27.0 0.828 
SRC     
    Low 17 (34.7) 39.2 12.0  
    High 32 (65.3) 109.3 ---- 0.001 
GSK3B     
    Low 26 (55.3) 70.2 20.0  
    High 21 (44.7) 87.8 55.0 0.192 
SMAD4 Nuclear     
    Low 27 (51.9) 56.7 24.0  
    High 25 (48.1) 99.7 48.0 0.109 
SMAD4 Cytoplasmic     
    Low 26 (50.0) 49.0 24.0  
    High 26 (50.0) 108.7 ---- 0.021 
P21      
     Low 25 (48.1%) 50.0 17.6  
     High 27 (51.9%) 99.1 55.0 0.036 
P21 Nuclear     
     Low 33 (63.5%) 60.4 26.0  
     High 19 (36.5%) 103.1 55.0 0.121 
COX2 Nuclear     
     Low 24 (48%) 61.0 20.0  
     High 26 (52%) 96.1 55.0 0.194 
COX2 Cytoplasmic     
     Low 25 (50%) 54.6 26.0  
     High 25 (50%) 102.8 121.0 0.090 
COX2 Membranous     
     Low 25 (50%) 60.3 24.0  
     High 25 (50%) 101.9 55.0 0.147 
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6.3.2 Senescence markers prognostic influence 
There is evidence to suggest that aberrant expression of p21 and p53 can provide 
prognostic information in patients with PDAC partly due to their well-established 
roles in pathogenesis.  Unfortunately, the same cannot be said for AA with three 
studies from the past 15 years failing to demonstrate any correlation with survival 
(29, 55, 57). To date there has been no investigation of the role of LKB1 in ampullary 
cancer although low expression in PDAC has been associated with reduced overall 
survival (Morton et al 200x). 
6.3.2.1 LKB1 correlation with clinicopathological Features 
The expression of LKB1 was not associated with T stage, lymph node status or ratio, 
grade or tumour size. However; perineural, lymphatic and venous invasion were all 
significantly associated with lower median LKB1 expression (all p< 0.02) as was 
positive resection margin status  (p = 0.046)(Figure 6.2).  
In univariate analysis, low LKB1 expression was associated with significantly reduced 
overall median survival compared with high expression following resection (26 
months versus 121 months, p = 0.017)(Figure 6.1, Table 6.2). 
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Figure 6.2 Box plots of LKB1 expression according to pathological features 
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6.3.2.2 p21 correlation with clinicopathological Features 
The expression of p21 did not show any correlation with T stage, grade or tumour 
size, resection margin status, histological subtype, perineural invasion, lymphatic 
invasion or the lymph node ratio.   Interestingly, low p21 expression did show a 
significant association with N stage (p=0.031), number of positive nodes (p=0.026) 
and venous invasion (p=0.008) (Figure 6.3).  
In univariate survival analysis, low p21 expression was associated with significantly 
reduced overall median survival compared with high expression following resection 
(17.6 months versus 55 months, p = 0.036)(Figure 6.1, Table 6.2). 
Figure 6.3 Box plots of p21 correlation to clinicopathological features 
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6.3.2.3 p53 correlation with clinicopathological Features 
There were no significant correlation between p53 and any clinicopathological 
factors evaluated including survival following resection. 
6.3.2.4 Relationship between LKB1, p21 and p53 
Within the AA specimens, LKB1 showed a significant direct correlation to both p21 
(Spearman’s rho correlation coefficient = 0.40; p = 0.003) and p53 (Spearman’s rho 
correlation coefficient = 0.35; p = 0.012); however, no association was evident 
between p21 and p53 (Figure 6.4). 
Figure 6.4 Scatter plot demonstrating correlation between LKB1 and both p21 & p53 
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6.3.3 Invasion & metastases markers prognostic influence 
B-catenin and GSK3 have both been implicated in PDAC as markers that are both 
strongly linked to overall outcome and survival.  A single paper by Sung et al(58) 
identified in the earlier protein marker review proposed over expression of B-catenin 
correlates to cell grade, increased TNM stage and both lymphatic and perineural 
invasion.  There were no papers identified on the investigation of GSK3 and 
therefore both markers were reviewed on the AA TMAs. 
 
6.3.3.1 B-Catenin correlation with clinicopathological features 
The expression of B-catenin did not show any correlation towards T stage, tumour 
grade or tumour size; positive resection margins, histological subtype, perineural 
invasion, lymphatic invasion, venous invasion or recurrence.  There was a significant 
association with nodal disease, in particular a significant correlation between 
increased N stage (p < 0.001), number of positive nodes (p = 0.002) and the LNR (p = 
0.005) and reduced expression of B-catenin(Figure 6.5).  
In univariate survival analysis, while the  overall median survival was reduced for 
those patients with reduced  B-catenin expression seen within the AA TMA cohort 
this difference was not significant (26 months low expression versus 55 months high 
expression, p = 0.271)(Table 6.2). 
 
 
 164 
Figure 6.5 Box plots of B-catenin correlation to clinicopathological features 
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6.3.3.2 GSK3 correlation with clinicopathological features 
The expression of GSK3 showed an unsurprising similarity to B-catenin in terms of 
correlation to clinicopathological features.  Its loss showed the same affinity for N 
stage (p < 0.0001), number of positive nodes (p < 0.001) and the LNR (p < 
0.001)(Figure 6.6). However, there was weak correlation with resection margin 
involvement  (p = 0.048); however, did not show any correlation towards T stage, 
tumour grade or tumour size, subtype, perineural invasion, lymphatic invasion or 
venous invasion.  While there was a trend towards reduced survival in patients who 
had low expression, this did not translate into a significant association  with overall 
median survival seen within the cohort (20 months low expression versus 55 months 
high expression, p = 0.192)(Table 6.2). 
Figure 6.6 Box plots of GSK3 correlation to clinicopathological factors 
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6.3.4 Angiogenesis markers prognostic influence 
There were two identified papers from the performed literature search that 
reported on COX2 expression and its effects in ampullary cancer, predominantly 
improved survival with over expression.  Having said this, there is strong laboratory 
and experimental evidence to suggest that COX2 plays a role in the evolution of 
gastrointestinal malignancies, having been identified as a prognostic marker in 
PDAC(259).  We chose to further interrogate the prognostic role of COX2 in AA 
within the TMA cohort. 
6.3.4.1 COX2 correlation with clinicopathological factors 
 COX2 staining was predominantly seen within the cytoplasm of epithelial cells 
rather than the nucleus or membrane (median histoscore 195 versus 70 versus 
28.75). The expression of COX2 did not show any correlation towards T stage, 
tumour grade or tumour size; positive resection margins, subtype, lymphatic 
invasion and lymph node ratio.  It did show a significant correlation with N stage (p = 
0.019), perineural invasion (p < 0.001), venous invasion (p = 0.020), and number of 
positive nodes (p = 0.035)(Figure 6.7).  There was a marked difference in median 
overall survival with low and high expression of COX2 (26 months versus 121 
months); however, this did not translate into a statistical overall median survival 
advantage (p =0.090)(Table 6.2). 
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Figure 6.7 Box plots of COX2 correlation to clinicopathological features 
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6.3.5 Markers of self-sufficiency for growth prognostic influence 
The prognostic value of the protein markers SRC and cyclin D1 were evaluated in this 
section. There was one previous report on the prognostic value of cyclin D1 in the 
literature by Guo et al(57) that found that low expression correlated with overall 
survival. 
6.3.5.1 Cyclin D1 correlation with clinicopathological factors 
The expression of cyclin D1 demonstrated affinity towards T stage only (p = 0.007) 
(Figure 6.8).  The histoscore was low in T1 disease (3-30), maximum expression was 
seen in T2 and then lost with advancing T stage thereafter.  There was no correlation 
towards tumour grade or size; positive resection margins, subtype, lymphatic 
invasion, perineural invasion, venous invasion, recurrence or any LN evaluation. 
There was also no significant difference in median overall survival with expression 
loss of cyclin D1 (24 months versus 48 months; p = 0.113)(Table 6.2). 
Figure 6.8 Box plot of cyclin D1 correlation to T stage 
 
 169 
6.3.5.2 SRC correlation with clinicopathological factors 
SRC staining was only seen within the membrane of epithelial cells rather than the 
nucleus or cytoplasm.  The expression of SRC only showed strong correlation with 
venous invasion (p = 0.045) and tumour recurrence (p = 0.022) with the former only 
just reaching statistical significance (Figure 6.9).  All of the other clinicopathological 
features reviewed showed no relationship to the SRC protein.  Perhaps surprisingly, 
in view of the limited associated to clinicopathology there was a significant effect 
towards a poorer overall survival with low expression of SRC (12 months versus 
median survival not reached [NR] months; p < 0.001 (Table 6.2, Figure 6.1). 
Figure 6.9 Box plot of SRC correlation to clinicopathological features 
 
 
6.3.5.3 Relationship between cyclin D1 and SRC 
From the AA specimens included in the TMAs, there was no direct correlation 
between cyclin D1 and SRC proteins (Spearman’s rho correlation coefficient = 0.096; 
p = 0.510). 
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6.3.6 Insensitivity to growth inhibition markers prognostic influence 
SMAD4, which is part of the TGFβ pathway, is inactivated in approximately 50% of 
pancreatic cancers, either by allele mutation or by homozygous loss of both alleles. 
When the PDAC cohort was evaluated there was a significant reduction in overall 
survival associated with loss of SMAD4 in the cytoplasm (DATA NOT SHOWN).  The 
prognostic influence of this protein was therefore assessed in the AA TMA cohort.  
 
6.3.6.1 SMAD4 correlation with clinicopathological factors 
SMAD4 expression was seen within both the cytoplasm and nucleus of the ampullary 
tumour epithelium however loss was not correlated with clinicopathological 
features(Figure 6.10).  While there was no survival impact associated with loss of 
nuclear SMAD4 expression, there was a significant overall poorer survival associated 
with low expression within the cytoplasm of 24 months compared to median survival 
not reached [NR](p = 0.021)(Table 6.2, Figure 6.1). 
Figure 6.10 SMAD4 correlation to tumour recurrence 
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6.3.7 MUC1 and CDX2 markers prognostic influence 
MUC1 and CDX2 have been the most extensively researched markers in the context 
of ampullary cancer with the majority of studies reporting that they are key markers 
in the delineation of histological subtype (high MUC1 and low CDX2) in 
pancreaticobiliary subtype and the converse seen in the intestinal subtype tumours) 
with subsequent survival implications as a result(31, 34, 59, 63). These markers were 
evaluated in the TMAs to revalidate this data within our cohort. 
6.3.7.1 MUC1 correlation with clinicopathological factors 
MUC1 expression was seen to correlate with clinicopathological features, namely 
tumour grade (p = 0.002), venous invasion (p = 0.011), number of positive nodes (p = 
0.038) and tumour recurrence (p = 0.011)(Figure 6.11).  There was no association 
with any other evaluated factors and surprisingly, although there was a trend 
towards subtype it did not reach statistical significance (p = 0.095). There was a 
significant overall survival benefit with low expression of MUC1 (67 months versus 
20 months; p = 0.003)(Table 6.2, Figure 6.1). 
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Figure 6.11 Box plots of MUC1 correlation to clinicopathological features 
 
 
 
6.3.7.2 CDX2 correlation with clinicopathological factors 
CDX2 expression was seen to have a strong association with tumour subtype (p < 
0.001), and grade (p = 0.003)(Figure 6.12).  There was a no relationship between the 
other clinicopathological features. High CDX2 expression was associated with a 
prolonged  overall median survival when compared to tumours with low CDX2 
expression (26 months versus median survival not reached [NR](p < 0.001)(Table 6.2, 
Figure 6.1). 
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Figure 6.12 Box plots of CDX2 correlation to clinicopathological features 
 
 
6.3.7.3 Relationship between MUC1 and CDX2 
There was no direct correlation between the MUC1 and CDX2 markers; however, 
when patients were stratified into those who had either a tumour with high MUC1 
expression and low CDX2 (pancreaticobiliary phenotype) or one with low MUC1 and 
high CDX2 expression (intestinal phenotype) marked heterogeneity was seen in 
overall survival (20 months 95%CI: 10.4-29.5, versus median survival not reached 
[NR]; p < 0.0001) implying the presence of two different disease and prognosis 
(Figure 6.13). 
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Figure 6.13 Kaplan Meier of effects of MUC1 & CDX2 on survival 
 
 
6.3.8 Metastatic phenotype 
From the evaluated protein markers, B-catenin and GSK3 were the two most 
strongly correlated (p <0.001) with the presence of lymph node metastases followed 
by p21 (p = 0.031). When considering venous and perineural invasion, LKB1 was 
identified as having the strongest correlation (all p < 0.02).  The relationship of these 
markers together with regards to local invasion was addressed to establish their 
prognostic value and potential to reveal a metastatic phenotype.  As GSK3 and B-
catenin are implicated in the same biological process only the latter was included in 
the analysis.  
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There were 11 of 52 (21.2%) patients who were found to have high expression of 
LKB1 and B-catenin and 15 of 52 (28.8%) patients had low expression of both.  The 
remaining 26 patients (50%) were in a group where one marked demonstrated high 
expression and the other low.  In those with high expression 7 patients (63.6%) had 
no evidence of LN or microscopic metastases.  There were 2 patients with N1 
disease, 1 patient with perineural invasion and 1 with lymphatic invasion.  This 
contrasts to the low expression group where 13 of 15 (86.7%) patients had evidence 
of nodal disease and microscopic invasion.  Of the 12 patients with N1 status 11 
(91.7%) had simultaneous microscopic invasion and a single patient had microscopic 
invasion only.  8 of 12 patients (66%) had invasion at more than a one site with 
venous being most common (8/12; 66%) followed by lymphatic and perineural (both 
5/12; 41.6%).  The median overall survival of patients stratified by LKB1 and B-
catenin expression showed significantly poorer survival with loss of expression of 
both markers compared to the mixed and high expression groups (13 months, 
95%CI: 0.0-38.0 versus 30 months, 95%CI: 15.0-44.2 versus median survival not 
reached [NR]; p = 0.022)(Figure 6.14).   
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Figure 6.14 Kaplan Meier graph of effect of LKB1/B-catenin expression on survival 
 
 
With the addition of p21 to the combination of LKB1 and B-catenin the markers were 
re-evaluated in an effort to obtain greater prognostic power.  There were 8 of 52 
(15.4%) patients who were found to have high expression of all 3-protein markers 
and a further 9 of 52 (17.3%) with low expression.  The remaining 35 (67.3%) had a 
mixture of low and high expression of the three markers.  In the high expression 
group 5 patients (62.5%) had no nodal or microscopic invasive disease and the 
remaining three each had one of N1 disease, lymphatic invasion or perineural 
invasion.  Of the 9 patients in the low expression group, 8 (88.9%) patients had 
evidence of nodal metastases and 7 (77.8%) had signs of microscopic invasion, all of 
which were at multiple sites (3/7, 42.9% perineural and 6/7, 85.7% both venous and 
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lymphatic).  In the patients with N1 staged disease, 87.5% had evidence of 
concurrent microscopic invasive disease. 
Following survival analysis there was a significant overall median survival 
disadvantage with the loss of all three markers compared to the mixed group and 
the high expression group (10 months, 95%CI: 8.6-11.0 versus 27 months, 95%CI: 
14.5-39.5 versus median survival not reached [NR]; p = 0.001).  When the mixed 
group was further stratified into single and double marker loss the overall survival 
difference remained statistically significant (10 months, 95%CI: 8.6-11.0 versus 30 
months, 95%CI: 0.0-65.3 versus 24 months, 95%CI: 14.8-33.1 versus median survival 
not reached [NR]; p = 0.007)(Figure 6.15). 
Figure 6.15 Kaplan Meier graphs of effect of LKB1/B-catenin/P21 on survival 
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6.4 Discussion 
IHC remains at the forefront of biological molecular assessment of malignant 
tumours.  It is multi-faceted in the information it provides; allowing description of 
protein marker expression in relation to the histopathological appearance of the 
tumour(260) whilst also allowing determination of the location and intensity of 
expression.  There are multiple roles for IHC in laboratory diagnostics today and is 
routinely employed for breast cancer (oestrogen/progesterone receptor staining), 
cytokeratin staining for tumour delineation and the identification of lymphoma to 
name but a few.  In AA, IHC has been used to evaluate cytokeratins, namely CK7 and 
CK20, to aide accurate determination of subtype(34, 59, 61, 62) and more recently 
Chang et al were able to demonstrate the use MUC1 and CDX2 in three distinct 
cohorts to further classify AA into histomolecular phenotypes(31). As there is wide 
variation seen in survival of patients following PD for AA, often greatly prolonged 
compared to PDAC, the identification of patients with molecularly identified 
aggressive disease can impact management.  
An issue with the markers mentioned above is their limited clinical value other than 
subtype identification. From the comprehensive review of IHC prognostic markers 
following AA resection presented in Table 1.1 little headway has been made in 
identifying any relevant markers that can be applied to the clinical setting with the 
majority of data coming from single studies.  When considering ampullectomy 
specimens, the identification of a molecular marker that possesses a strong 
correlation to lymph node or lymphovascular invasion, effectively predicting a 
metastatic phenotype, would potentially have great clinical impact in terms or 
 179 
management strategy by providing prognostic information at an earlier point in 
time. 
The data included in the current chapter is the first time that semi-quantitative 
assessment of multiple prognostic protein markers has been performed in AA.  The 
mirrored PDAC cohort from the same institution has underwent the same TMA 
evaluation, with the results from that cohort being consistent with the published 
literature(259).  
The evaluation of LKB1 expression in AA is particularly interesting.  While there has 
been previous work evaluating the role of LKB1 in PDAC this present work remains 
the first of its type in AA.  These data have demonstrated that LKB1 deficiency 
correlates most strongly with microscopic invasion.  It also correlates with loss of 
p21 expression with a significant overall poorer median survival, and that LKB1 
deficiency may act as an alternative to p53 mutation in ampullary adenocarcinoma 
tumour evolution. These results support the theory that LKB1 may act as a tumour 
suppressor gene in the periampullary region and that may function, at least in part, 
by prohibiting p21 expression.  As mentioned, low levels of p21 and LKB1 were 
correlated, data that is consistent with the previous findings from PDAC studies that 
loss of LKB1 expression prevents culture induced cellular senescence(261) and allows 
BRAF mutant melanoma cells to proliferate(262).  
p21 is a CDK inhibitor and prevents progression through the cell cycle mainly at S 
phase.  The literature review identified a single paper that had previously assessed 
its value in ampullary cancer with no prognostic value having been identified(57).  
These data found low p21 expression to correlate with N1 disease, increased lymph 
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node positivity and venous invasion that translated to an overall reduction of median 
overall survival suggesting that it does indeed have prognostic value.  There were 
however several tumours in this cohort that were found to have low p21 with high 
LKB1 expression suggesting that LKB1 is not the only factor implemented in this 
process and is likely multi-factorial.    
p53 is a tumour suppressor protein that acts to promote apoptosis or arrest the cell 
cycle in the presence of DNA damage and abnormal cells, and is frequently mutated 
in the development of ampullary adenomas to adenocarcinoma(263).  The fact that 
p53 is mutated, rather than deleted, suggests that mutant p53 provides some 
tumour cell growth advantage.  Despite over 40 studies assessing the prognostic 
impact of p53in PDAC(259) and a further 3 in AA(29, 55, 57) no significant correlation 
to clinicopathological factors or survival impact has been seen.  This is also true of 
the AA cohort reported in this thesis.  Interestingly, p53 correlated with LKB1 
expression, which suggests this may play a role in the initial dysregulation of LKB1.  
B-catenin and the associated E-cadherin are important proteins involved in the 
maintenance of cell to cell adhesion and in contributing to B-catenin activation(264).  
B-catenin also functions as a transcription factor(58) with dysfunction possibly 
contributing to the development of ampullary cancer(265).  This study demonstrated 
that loss of membrane B-catenin was not associated with a statistically significant 
reduction in median overall survival; however, did show a marked correlation 
towards the presence of lymph node metastases.  As a result, the prognostic 
relevance of loss of B-catenin expression highlights a cohort of patients at risk of 
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early local spread and the necessity for further investigation into early B-catenin 
targeted anti-metastatic therapies.   
The expression of nuclear B-catenin was not thought to be reproducible and 
therefore not formally assessed in this cohort and is not a common feature of 
ampullary cancers(266).  Certainly, nuclear localisation is regarded as a method by 
which B-catenin can alter gene expression and therefore future work is required to 
resolve the prognostic relevance of this.  The work provides the first evaluation of 
GSK3β expression related to AA and overall survival. These data suggest that 
reduced expression of GSK3β was also strongly associated with lymph node 
involvement and tumour recurrence following resection. This unfortunately does not 
support the theory that GSK3β plays a role in the inactivation of B-catenin. Therefore 
further interrogation of the interaction between GSK3β and B-catenin is required. 
There were two studies within the literature detailing the role COX-2 expression has 
in the prognosis of ampullary cancer, in particular the increased frequency of 
intestinal phenotype and improved survival with over expression.  The latter was 
also true from our cohort although statistical significance was not met (121 months 
versus 26 months; p=0.090).  The converse is true from previous evaluation in other 
GI malignancies, as COX-2 expression was associated with worse overall survival 
independent of stage and tumour histological grade in PDAC(267) and with poor 
prognosis, larger tumour size and nodal disease in colorectal cancer(268).  Loss of 
COX-2 expression had significant correlation to nodal involvement, perineural 
invasion and venous invasion which is in keeping with previously described COX-2 
expression having an established relationship with angiogenesis(269).  Due to the 
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paucity of published data on COX-2 in the context of ampullary cancer it is difficult to 
ascertain whether it is a plausible target for therapy compared to the multitude of 
evidence for COX-2 inhibition preventing colorectal cancer.  A previous study has 
reported that high COX-2 influences promoted Lkb1 expression in polyps of Peutz-
Jeghers syndrome patients(270) which is also true within the AA patients within this 
study (Spearman’s rho correlation coefficient = 0.60; p < 0.001). This finding is in 
keeping with previous studies that suggest COX-2 may inactivate tumour suppressor 
genes including LKB1.  Having said this, as the relationship possesses a positive 
correlation within the AA cohort, the effect on LKB1 must be indirect in nature. 
This data confirms the previously published work by Chang et al on the utility of 
MUC1 and CDX2 by Chang et al(31) who state that these markers allow for the most 
accurate classification of AA into two distinct histomolecular phenotypes.  Despite, 
only CDX2 having a statistically significant correlation to subtype in this cohort when 
both markers were combined two distinct homogenous groups were identified with 
marked variability in median overall survival between the two.  This has clinical 
significance as high MUC1/low CDX2 pancreaticobiliary subtype tumours behave in a 
similar manner to true PDACs and suggests they should possibly be treated as such 
with consideration of neoadjuvant therapies prior to definitive surgery. 
The work within this chapter was the first of its kind for the majority of the markers 
included.  A potential subsequent step is investigating the prognostic utility of these 
markers in preoperatively collected EA specimens. A completely novel aspect of this 
thesis has been the attempt to identify a metastatic phenotype in ampullary cancer 
by grouping protein markers by the strength of their correlation to lymph node 
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metastases and microscopic invasion.  It was possible to stratify patients into 
subgroups where when p21, LKB1 and B-catenin were all lost the likelihood of having 
local disease spread out with primary tumour was nearly 90%.  This has clinical 
significance as if this were applied to EA specimens, patients prospectively planned 
for definitive endoscopic management due to borderline fitness would ultimately be 
better managed by high-risk radical surgical intervention with this marker profile.  
Clearly, due to the small number of patient data, further, larger studies in a 
validation group are required before definite conclusions can be made in this regard. 
However, this work has provided evidence that such protein markers and their 
expression can be utilised as adjuncts to traditional tumour staging and to influence 
management strategies by redefining outcomes. 
 
6.5 Limitations 
The value of IHC protein marker evaluation has increased with the introduction of 
TMA technology by providing the ability to perform assessment of large numbers of 
specimens simultaneously(271) making test conditions standardised and hence 
reducing multi-test error. Having said this, variations will still exist in the 
experimental procedures themselves such as antigen retrieval, scoring inconsistency 
and marker cut-off point selection variability all of which can influence the 
prognostic value of the proposed protein marker in question. The introduction of 
automated scoring techniques may allow for standardisation of these areas and 
overall time reduction.  Furthermore tumour heterogeneity also limits the 
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applicability of results generated from TMA analysis highlighting the importance of 
multicentre validation cohorts as well as full section histological analysis.  
This current chapter included 47 to 81 patients depending on which protein marker 
being evaluated.  TMA analysis requires multiple numbers of cores and tumour 
samples to provide meaningful output due to its semi-quantitative nature and 
therefore further larger cohorts are required to test this profiling method.  Despite 
use of a semi- quantitative scoring method, which provided a continuous score for 
protein marker expression, there was still the potential for bias associated with the 
subjective categorical assessment undertaken by the examiner.  The proposed 
prognostic protein markers evaluated in this chapter are not an inclusive set and 
systematic review of the literature suggests that markers such as S100A4, hENT and 
EGFR may possess prognostic capability.  To increase the strength of these data 
findings, a complete data set of protein markers could be achieved by undertaking 
further IHC work and creating extra TMAs so that data is available on all 127 patients 
recorded. A further validation cohort would also like to have been tested to assess 
the validity of the findings current chapter of work.  
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7.0 CONCLUSIONS 
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Chapter 7 Conclusions 
7.1 Thesis Summary 
This thesis evaluates several different methods for the improvement of the 
prediction of survival and outcome in patients undergoing management of 
Ampullary adenocarcinoma.  Initially, the conventional clinicopathological features 
reported in the literature were interrogated and tested in chapter 3 to obtain a 
general understanding of the prognostic value of traditional clinicopathological 
features.  Prior to the assessment of biomarker for prognostication, a large cohort of 
patients undergoing resection at a single institution with detailed and complete 
clinicopathological data available were assessed and compared with the literature in 
chapter 4.  This focused on subtype variability and the prognostic role of lymph node 
involvement and notably highlighted a particularly high rate of margin involvement 
in AA compared to other documented series.  The first novel conclusion made was 
that pancreaticobiliary subtype tumours behave in a remarkably similar way to true 
PDAC tumours and should perhaps be treated as such with consideration of 
neoadjuvant therapy regimens that are now being increasingly utilized in the 
management of PDAC.  Chapter 5 then focused on the evolving role of endoscopic 
ampullectomy in the management of ampullary tumours. Certainly these data 
suggest that ampullectomy will upgrade lesions from LGD to HGD or HGD to 
adenocarcinoma in 28.8%. Furthermore long-term survival can be achieved with 
endoscopic resection alone in those patients for who are unsuitable for PD due to 
frailty or significant comorbidity. IHC molecular evaluation of proposed prognostic 
protein biomarkers were performed in chapter 6 with interesting outcomes seen for 
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a number of candidate markers.  From this, an attempt to develop a metastatic 
phenotype was undertaken by combining the markers with prognostic correlation 
towards metastatic disease.  Potentially the implementation of IHC assessment of a 
selection of markers in EA specimens could provide the clinician with a more 
detailed information into the biology of tumour and enable a more precise 
management algorithm particularly for those patients who possess a tumour with 
favourable prognosis according to histological and molecular characterisation and 
should be subjected to a highly morbid PD. 
 
7.2 Overall Conclusions 
Ampullary adenocarcinoma is a rare disease with the incidence having been 
estimated to be 6 per million persons per year(272)  The gold standard of therapy 
remains  PD and as patients typically manifest symptoms earlier in the course of the 
disease, a relatively high resection rate of up to 80% is seen within the 
literature(193).  While overall prognosis is generally better than for PDAC, there is 
significant heterogeneity as to the clinical behaviour of ampullary adenocarcinoma 
following PD, with 5-year survival rates ranging between 37% to 68%(19, 140, 211). 
Therefore, it is important that we attempt to establish the clinicopathological and 
molecular features of AA that can help more precisely predict outcome and guide 
therapeutic strategies most effectively. Particularly, as PD remains a high-risk 
operative procedure with a 30-day mortality of up to 5% and morbidity seen in up to 
50% of patients(112) and therefore caution must be exercised when selecting 
operative candidates. 
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When considering conventional cancer reporting using the AJCC cancer staging 7th 
edition TNM criteria, the clinicopathological factors influencing survival in AA from 
the literature were in keeping with other biliary and GI tract malignancies. This 
system has adapted very little over the years and while it accurately predicts 
prognosis for some patients with what is an extremely heterogonous disease it fails 
to discriminate between two distinct histological subtypes(173).   
Chapter 3 highlighted the variability in pathological reporting within the literature. 
Employing a meta-analysis, that is the first of its kind in ampullary adenocarcinoma it 
was possible to capture the features indicative of a poorer prognosis in ampullary 
cancer following radical surgical resection following.  The vast majority of patients 
achieved an R0 resection (median 96.8%) which raises two points; if accurate, as so 
few patients undergo a margin positive resection, margin status is not a major 
contributing factor influencing survival; it questions the adequacy of pathological 
reporting in the literature.  Our resected AA R1 rate was much higher than seen in 
the literature at 31.5% using a SP reporting method although median overall survival 
figures for the entire cohorts were comparable.  This was also true within the PDAC 
cohort(220)and therefore is thought to reflect high-quality reporting rather than 
poor surgical technique compared to other centres.  The presence of lymph node 
involvement was an independent predictor of outcome in 19 of the 30 included 
studies and increasing burden demonstrated the strongest association with survival. 
A pancreaticobiliary subtype tumour is associated with a significantly reduced overall 
survival mortality rate when compared to the intestinal subtype.  This appears to be 
true in all other periampullary adenocarcinomas(33, 59, 222) and questions whether 
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‘periampullary cancers’ should be classified by subtype over anatomical location 
whilst emphasises the importance of this features inclusion in standardised 
histopathological reporting guidelines(173).  Our patient cohort data indicate that 
more valuable prognostic information is obtained from morphological subtyping 
than provided by tumour stage or tumour grade. 
Related to the reviewed clinicopathological features in the literature, chapter 4 
allowed analysis and comparison of the AA patient cohort undergoing resection 
within this institution to previously published work.  Nodal involvement once again 
significantly reduced overall survival from a 5yr survival of 66% to 22% although did 
not stratify patients in a homogenous manner.  No T1 tumours displayed evidence of 
lymph node or microscopic invasion, which has important implications for EA and 
raises the question to it being a valid alternative treatment option in early stage 
disease. Intestinal and pancreaticobiliary subtypes shows marked heterogenicity 
with marked variance in prognosis.  The AA pancreaticobiliary subtype behaved 
similarity to PDAC with no significant difference in survival observed.  This questions 
whether AA is in fact two distinct disease processes and as the pancreaticobiliary 
subtype mirrors PDAC raises the possibility of whether it should be treated as such 
and potentially considered for neoadjuvant chemotherapy as is currently being 
considered in PDAC(273).  Clearly considerable further clinical and molecular 
research will be required before this strategy could be sanctioned. However, 
potentially this strategy could appropriately avoid resection in those patients who 
experience early recurrence as a result of micro-metastatic disease.   Again, the 
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marked variance in survival also questions whether subtype and not origin is a more 
important classification tool for pancreaticobiliary cancers. 
With the relatively recent introduction of EA, chapter 5 assessed its increasing role in 
the diagnosis and management of patients with an ampullary lesion. These data 
support the need for mandatory EA in all patients with an ampullary adenoma in an 
effort to more accurately determine nature of the lesion (LGD versus HGD). The 
frequency of upstaging suggests that endoscopic biopsy alone is perhaps inadequate 
prior to decision making for the management of patients with ampullary lesions 
particularly.  For patients with adenocarcinoma resected by EA, survival was seen to 
mirror the surgical resection cohort up to 30 months demonstrating that EA provides 
excellent medium term outcomes and, although perhaps not curative, makes 
definitive endoscopic management an attractive option for elderly patients and 
those with significant comorbidity that make PD high risk. A proposed treatment 
guideline has been developed from our early experience and evaluated data which 
will require prospective validation.  
A review of the literature pertaining to prognostic protein markers in AA was 
performed prior to chapter 6 with a paucity of data available compared to that seen 
in PDAC(259).  The lack of useful markers may be related to the rarity of the disease 
process resulting in small numbers for evaluation.  A number of protein markers 
prognostic value was assessed in the TMA cohort, individually, based on functional 
groups and then by correlations with clinicopathological features.  The cohort 
demonstrated that low expression of SMAD4, p21, SRC and LKB1 were all 
significantly associated with poor overall survival.  A novel undertaking was the 
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attempt to identify a metastatic phenotype; markers with the strongest correlation 
to nodal disease or microscopic invasion were grouped with LKB1, p21 and B-catenin 
being associated with a very poor survival.  This has implications to the clinical 
setting as evaluation of these markers in EA specimens would identify patients with 
a highly invasive tumour, reinforcing the need for the patient to undergo PD as the 
only curative option even in the face of borderline fitness.   
The implementation of these evaluated biomarkers alongside the previous work by 
Chang et al(31), who demonstrated that MUC1 and CDX2 expression were 
determinates of differing histomolecular phenotypes in AA, will allow for the further 
stratification of the disease, in both ampullectomy and resection specimens, and 
assessment of biomarker specific therapeutic responsiveness with the potential for 
use of focused chemotherapy regimes.  
As previously discussed, recent genomic research has further interrogated ampullary 
tumour evolution and has identified that some ampullary tumours display 
characteristics of intestinal tumours such as microsatellite instability, inactivation of 
the tumour suppressor gene ELF3 by a high frequency of mutations and disruption of 
the WNT signaling pathway(43, 274).  This was not homogenous for tumour type or 
subtype; however with the implementation of further subtyping by extensive 
biomarker assessment it may be possible to identify which tumours exhibit these 
characteristics and therefore adopt a custom treatment plans and pave the way for 
genomic WNT targeted therapies alongside tailored chemoradiotherapy regimes. 
 
 192 
In conclusion, this work consists of one of the largest ampullary adenocarcinoma 
cohorts studied to date which has demonstrated marked heterogeneity in outcome 
when considering standard clinicopathological factors and has went some way to 
suggest ways of improving tumour classification by identifying new biochemical 
markers that allow for a much more homogenous analysis of outcomes.  These 
markers have also allowed for the identification of ‘high risk’ tumours, particularly 
those at significant risk of metastatic dissemination, and when applied to current 
practice with further work will enable the clinician to identify tumours that are 
appropriate for less aggressive intervention compared to current standards(21). 
Leading on from this piece of work, the next step would be to obtain further 
specimen samples and perform more immunohistochemistry to first obtain a patient 
cohort with a complete protein marker dataset.  This will allow for further evaluation 
in greater numbers, improving the results and providing more robust findings. It 
would also be appropriate to seek a similar cohort of patients from another 
institution and apply the same experiements we have here to validate our findings. 
As we are aware, pancreatic cancer research has progressed greatly in the past five 
to ten years with the introduction of genomic profiling to identify specific gene 
alterations within PDACs that may make tumour cells susceptible to specific 
chemotherapy regimes with some progress having been made in this field from an 
ampullary perspective as mentioned earlier(43).  It would seem that the next step in 
the interrogation of ampullary carcinoma from this work is to adopt precision 
medicine and look to identify markers both as predictors of survival (similar to the 
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metastatic phenotype identified in this work) and those targetable for patient 
tailored adjuvant and neoadjuvant therapies. 
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